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Chapter 1
General introduction and outline of the investigations

General introduction
1.1 General introduction
Nutritional depletion is associated with the development of infectious 
complications and impaired convalescence following illness or surgery. Total 
parenteral - i.e. intravenously administered - nutrition (TPN) is therefore frequently 
used in clinical practice to improve the nutritional status of patients with impaired 
nutrient uptake by the digestive tract.
Lipid emulsions are part of TPN regimens as a source of fuel calories and 
(essential) fatty acids. However, clinical studies suggest that immune-modulating 
effects of lipid emulsions contribute to the increased infectious complication rate that 
is associated with the use of TPN. Furthermore, the type of infections suggests that 
especially the function of the non-specific phagocyte immune system, and more 
specifically of the neutrophilic granulocyte, is compromised. Unfortunately, so far 
studies that addressed the effects of lipid emulsions on the function of neutrophils and 
other immune competent cells have yielded conflicting results. Possible explanations 
are numerous and include the use of non-physiological lipid concentrations, distinct 
lipid effects on different components of the immune system, and differences in 
emulsion content of constituents, such as lipid source, emulsifier, fatty acids and anti­
oxidants. Also, since a number of emulsions have only recently been introduced, such 
as emulsions based on structured lipids and olive- or fish oil, the number of studies 
evaluating their effect on the immune system remains limited so far.
1.2 Outline of investigations
The aim of the studies presented in this thesis was to test the hypothesis that 
structurally different lipid emulsions distinctly modulate the function of the human 
immune system. Therefore, various aspects of the function of the non-specific 
immune system, represented by the neutrophilic granulocyte, and the specific 
immune system, represented by the mononuclear leukocytes, were evaluated under 
the influence of lipid emulsions.
The emulsions under investigation were structurally different and contained either 
long-chain triglycerides, a physical mixture of long- and medium-chain triglycerides 
or synthetic structured lipids. Emulsions were tested within the physiological 
triglyceride concentration range that is reached in patients when lipids are 
administered intravenously. Both in vitro studies, evaluating cell functions after lipid 
exposure in the test tube, and in vivo studies, following intravenous lipid 
administration in healthy volunteers, were performed.
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In the final chapters, studies are presented in which possible mechanisms 
underlying the observed lipid effects were investigated. Here, two more recently 
developed emulsions, based on olive oil and fish oil, were included.
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Aspects of human neutrophil function: clinical relevance and assessment

Neutrophil functions
2.1 Introduction
2.1.1 The immune system
The defense of the human body against invasion by microbial pathogens is 
established by a complex interplay of components and mediators of the non-specific 
(innate) and the specific (adaptive) immune system [1]. The non-specific branch 
comprises soluble (humoral) and cellular components, such as the complement 
system and various types of phagocytes (granulocytes, macrophages) and cytotoxic 
natural killer (NK) lymphocytes. The specific immune response is established by 
mononuclear cells (B- and T-lymphocytes and monocytes) and involves the 
production of humoral signaling and effector substances such as cytokines and 
immunoglobulins (mainly by various T- and B-lymphocyte populations, 
respectively), as well as microbial phagocytosis, killing and antigen presentation (by 
monocytes, macrophages and dendritic cells) [2]. Monocytes and macrophages 
constitute the reticulo-endothelial system (RES), or mononuclear phagocyte system 
(MPS). Macrophages develop from monocytes in various tissues after leaving the 
vascular compartment. Dendritic cells are bone-marrow-derived cells of the myeloid 
lineage that are present in lymph nodes, spleen and thymus.
2.1.2 Neutrophils
Polymorphonuclear granulocytes, also called neutrophilic granulocytes or neutrophils, 
constitute the first line of defense against invading bacterial and fungal pathogens in man 
[3,4]. Neutrophils are produced in large numbers (~ 1.3 x 1011 cells per 80-kg person per 
day) in the bone marrow, were they evolve from pluripotent stem cells through several 
myeloid cell precursor stages (Fig. 1). In healthy individuals about 90 percent of the 
neutrophil pool is present in the bone marrow, 2 to 3 percent in the circulation and the 
remainder in the tissues. The blood pool comprises two compartments: the marginated 
pool, containing cells adherent to the endothelium, and the free circulating pool. The 
availability of neutrophils is regulated by mediators, such as granulocyte colony- 
stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor 
(GM-CSF), which increase the release of leukocytes from the bone marrow into the 
blood stream and change their immune-modulating functions [5,6]. The half-life time in 
the circulation of neutrophils is 6 to 7 hours, while their half-life time in tissues 
approximates 3 days [7].
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Figure 1. Neutrophil life span and stages o f maturation.
Tissues 
(pool size 
unknown)
360
The ordinate shows the flux through each compartment and the abscissa shows the time in each 
compartment. The area o f each o f the compartments gives the number of cells in each compartment. 
The stepwise increase in cell numbers through the first three compartments represents serial 
divisions o f the cells in these compartments. Note that no divisions occur after the myelocyte stage. 
(Adapted from Bainton DF: The cells o f inflammation: a general view (1980). In W eissman G (ed.) 
The Cell Biology o f Inflammation, vol 2, pp 1-25. Amsterdam: Elsevier/North-Holland.)
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2.1.3 Neutrophil counts: clinical implications and regulation o f cell trafficking
Granulocyte defects leading to an increased susceptibility to infections comprise two 
major categories, i.e. quantitative and qualitative or functional defects. Numerical 
defects are the result of defective maturation and differentiation, and occur much more 
frequently than specific granulocyte dysfunction of clinical significance [4]. The normal 
neutrophil number in peripheral blood is 2.5 to 7 x 109 cells/L, while any peripheral 
white blood cell count over 10 x 109 cells/L indicates leukocytosis [8]. However, 
absolute neutrophil counts vary widely in healthy individuals and the relative proportion 
of neutrophils and lymphocytes in the blood is also age dependent. A characteristic 70% 
predominance of neutrophils in adulthood is attained at puberty [9].
Neutropenia means that the absolute number of circulating neutrophils is 
decreased. This condition appears to be associated with an increased risk for bacterial 
infection when the cell count falls below 1000 per microliter. Causes of neutropenia 
extrinsic to bone marrow myeloid cells include infections, drug- and immune-induced 
neutropenia, reticulo-endothelial sequestration as in hypersplenism, bone-marrow 
replacement as in malignancy, radiation and chemo-therapy, or ineffective 
granulopoiesis as in malnutrition. Patients with severe neutropenia (less than 500 
cells per microliter) are likely to develop life-threatening illness, especially from 
bacterial cutaneous infections, pneumonia and septicemia [7,9]. However, 
neutropenia per se does not seem to increase the susceptibility to parasitic, viral or 
fungal infections or bacterial meningitis.
Neutropenia is the hallmark of a number of intrinsic disorders, such as cyclic 
neutropenia, congenital neutropenia or Kostmann syndrome, chronic idiopathic 
neutropenia, Shwachman’s syndrome, cartilage-hair hypoplasia and dyskeratosis 
congenita [9]. Importantly, when fewer than 200 cells per microliter are present, the 
inflammatory process remains absent despite infection [7].
Arterial and venous blood leukocyte counts differ widely, even intra-individually, 
depending on the anatomical site of sampling. On the other hand, the number of 
various leukocyte types present in peripheral blood is kept within normal ranges by 
homeostatic mechanisms that govern cell production, release and elimination [8]. 
Cell trafficking, including neutrophil emigration from the marrow into the blood, 
demargination from blood vessel walls, and (prevention of) imigration into tissues, is 
also closely regulated. The molecular model for the recruitment of neutrophils from 
the bloodstream into inflamed tissue involves selectins, integrins, chemokines and 
proteases (see below) [10,11]. Many microbial products or components, such as 
endotoxins, exotoxins and formylpeptides, have also been shown to induce 
leukocytosis [12].
The interleukin 1P (IL-1P) has both direct and indirect effects on leukocyte counts 
after intravenous administration. IL-1P induces immediate leukopenia within 30 min 
and a return to normal levels by 5 h [13,14]. IL-1P can regulate reversible rolling or 
irreversible adherence to endothelia (margination) by increasing the expression of
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adhesion molecules on leukocytes and endothelia, as well as by inducing secretion of 
soluble integrins, chemokines and proteases and the induction of granulocyte- 
macrophage colony-stimulating factor (GM-CSF) [13,15]. Colony-stimulating 
factors, such as granulocyte colony-stimulating factor (G-CSF) and GM-CSF both 
affect peripheral leukocyte counts by an immediate leukocytosis, which is 
independent of cell proliferation, followed by a late, proliferation-dependent 
leukocytosis after three days [16]. Interleukin-8 (IL-8), in contrast to IL-1P, induces 
leukopenia within 5 minutes, followed by a profound granulocytosis after 30 min and 
a return to normal within 8 hours [17,18].
Evidence is emerging now that proteases, belonging mainly to the families of the 
trypsin-like serine proteases and of the matrix metalloproteases (MMPs), are involved 
in the regulation of circulating leukocyte counts [8]. The complexity of this 
regulatory system is exemplified by the fact that many of these proteases act in 
cascades and that their activity may be regulated at at least five different levels: gene 
transcription by cytokines (e.g. IL-8, TNF-a); secretion of granule-stored enzymes; 
proteolytic activation (e.g. plasmin); specific inhibitors that are transcriptionally 
controlled by cytokine (e.g. IL-6); and glycosylation [19-25].
2.1.4 Neutrophil phenotype
Resting neutrophils are spherical cells, with a volume of about 300 jim and a 
diameter that approximates 12 im  [26-28]. The most distinctive morphological 
characteristics of neutrophils are a multilobular nucleus and a cytoplasm that is filled 
with different types of granule and vesicle. Both of these are exocytosable organelles 
that develop at various stages of cell maturation. Primary or azurophilic granules are 
peroxidase-positive and appear during the promyelocyte cell stage.
Besides myeloperoxidase (MPO), they contain acid hydrolases, cathepsins G, B 
and D, defensins, bactericidal permeability-increasing protein, cationic proteins and 
lysozyme [3,29]. Next, during the myelocyte cell stage, the more numerous specific 
or secondary granules are formed. These peroxidase-negative granules contain 
lysozyme, lactoferrin, vitamin B 12-binding protein, alkaline phosphatase, NADPH 
oxidase components, collagenase and histaminase [3,7,29]. A third category of 
cytoplasmic inclusions are the secretory vesicles, which contain endocytosed plasma 
proteins and are the major reservoir of complement receptor type 1 (CD35) and 
FcyRIII (CD16) [29,30]. Granule species and vesicles can be distinguished by means 
of membrane-incorporated protein markers, which are designated according to the 
international workshops on leukocyte antigens as CD11b, CD11c, CD16, CD18, 
CD35, CD63 and CD66b [31-35]. All of these markers are also present on the 
neutrophil plasma membrane, together with non-granule markers, such as CD 11a, 
CD32 and CD62L. Functions of CD11a, CD11b, CD11c, CD16, CD18 and CD62L 
are discussed below. The function of granulophysin (CD63), which is specific for 
azurophilic granules, and CD66b, a receptor for uptake of non-opsonized bacteria 
present on specific granules and secretory vesicles, remains largely unknown [36-40].
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The expression of some markers (CD16 and CD62L) is regulated through proteolytic 
shedding, e.g. upon neutrophil activation [41].
2.2 Neutrophil functions
In the section below, the cascade of neutrophil effector functions that is initiated by 
cell activation will be discussed. The invasion of the body by pathogens, usually 
following disruption of the skin or mucous membranes, induces the release of 
chemoattractant substances from the inflamed tissue, and thereby activates the 
underlying vascular endothelium [42]. These chemoattractants form a group of 
inflammatory mediators, such as formylated peptides (fMLP), complement-derived 
C5a, leukotriene B4 (LTB4), interleukin (IL)-8, and platelet-activating factor (PAF) 
[43]. Also, the bacterial endotoxin lipopolysaccharide (LPS), which is present at sites 
of infection, promotes the release of inflammatory cytokines such as tumor necrosis 
factor-a (TNF-a) and IL-ip, which will in turn enhance IL-8 synthesis in an 
autocrine or paracrine manner [42].
Next to the activation of endothelium a cascade of events is triggered that results in 
the activation of neutrophils and their adhesion, in a stepwise manner, to the activated 
vascular lining. This is followed by transendothelial migration of the leukocytes, or 
diapedesis, into the tissue and migration towards the site of inflammation. The 
process ends with the ingestion (phagocytosis) of invading microbes. This means that 
the latter are ingested, through engulfment by the neutrophil plasma membrane. The 
so-formed intracellular compartments are called phagosomes. Our knowledge of the 
biochemistry within the phagosome is limited due to its inaccessibility to standard 
detectors and scavengers [44]. However, it has been shown that antibacterial contents 
of cytoplasmic granules, vesicles and lysosomes are released into the 
phago(lyso)some and that, under normal conditions, the ingested pathogens are 
ultimately killed by means of these oxidative and non-oxidative cytotoxic compounds 
[10,45,46].
The immune response that results in the killing and clearance of microbial 
pathogens is locally or systemically accompanied by signs and symptoms of 
inflammation due to the release of vaso-active or toxic intermediates, such as 
eicosanoid mediators and oxygen radicals. Indeed, great effort has been made to 
develop new therapeutic strategies for life-threatening conditions like shock and 
sepsis, in which neutrophil recruitment and activation are believed to be responsible 
for deleterious tissue damage, clinically seen as adult respiratory distress syndrome 
(ARDS). Given the clinical repercussions, the need for interventions that modulate 
various aspects of neutrophil function seems obvious. Examples of such strategies are 
the inhibition of chemoattractants through influencing the lipoxygenase pathway, 
neutralization of cytokines through TNF-a binding by anti-TNF antibodies, inhibition
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of receptor binding of activating substances through PAF-receptor antagonists, and 
the modulation of inflammatory mediators by IL-10 application [6,42,47-49].
In the section below, various aspects of neutrophil function are described in more 
detail. Because significant defects in effector functions provide insight in the 
particular contribution to neutrophil performance, and because of their relevance for 
clinical practice, a number of associated clinical conditions will be discussed as well.
2.2.1 Cellular signaling, adhesion and migration
2.2.1.1 Signaling (see also Fig. 2)
Cellular signaling induced by mediators that bind to neutrophils through a G- 
protein-coupled cell surface receptor involves various isoforms of protein kinase C 
(PKC) [43]. The membrane receptor for the bacterial chemotactic peptide fMLP for 
instance is coupled to a pertussis toxin-sensitive G-protein and the signal cascade 
from the occupied receptor comprises activation of phospholipase C, formation of 
inositol phosphates and diacylglycerol, activation of PKC and calcium mobilization 
[50-52]. Additional signaling pathways in neutrophils require the activity of kinases, 
phosphatases and small guanosine triphosphate-(GTP) binding proteins (small 
GTPases) of the Ras family (see also Fig. 2a). Ras-like small GTPases activate a 
cascade of protein kinases that phosphorylate and activate mitogen-activated protein 
kinases (MAPKs). Activation of the Ras/MAPK family will lead to activation of the 
nicotinamide adenine dinucleotide phosphate-(NADPH) oxidase enzyme complex, 
the activity of which is pivotal for the production of toxic oxygen products to 
eliminate pathogens (see below) [53]. CD14, an important lipopolysaccharide (LPS) 
receptor on leukocytes, is also responsible for neutrophil activation and exists both as 
a soluble molecule (sCD14) and in a membrane-bound CD14 isoform [54].
As mentioned above, signaling in many cells requires an increase in the 
intracellular concentration of free calcium ions to initiate effector functions. 
Incubation of neutrophils with chemoattractants induces a biphasic response, 
consisting of a first peak caused by liberation of calcium from intracellular stores, 
followed by a second peak due to influx of calcium from outside the cells [55]. This 
second phase is caused by the production of an intercellular messenger, most likely 
platelet-activating factor (PAF) [56]. Neutrophil activation with opsonized particles 
also involves hydrolysis of phosphatidylinositolbisphosphate (PIP2) with the
subsequent production of inositol-(1,4,5)trisphophate (IP3), which induces
2+intracellular Ca release, and diacylglycerol (DAG), which activates protein kinase C 
[57-59].
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2.2.1.2 Adhesion molecules
Interactions between cells and adherence to the extra-cellular matrix are mediated 
through various families of adhesion molecules. Especially important for cell-cell and 
cell-matrix interactions in almost any human cell type is a family of hetero-dimeric 
glycoprotein adhesion molecules, the integrins [60]. Several integrin subfamilies can 
be distinguished by a specific P subunit, that can dimerize non-covalently with one of 
multiple a  subunits.
Figure 2. Leukocyte signaling
Chemokine receptor
C3b¡ receptor Fc receptor
GDP
ITAM
>• InsP3 + DAG
I
[Ca2+],i
O2
Respiratory burst
O Actin polymerization 
Chemotaxis
Leukocytes possess all four known surface-receptor-activated PI 3-Ks. The Py subunits o f trimeric 
G proteins activate PI 3-Ky (the only class IB PI 3-K known is associated with p101) and PLCp2/3, 
while complement receptors (e.g. the C3bi receptor, MAC-1, CD11b/CD18) and Fc receptors 
mediate the activation o f PTKs (e.g. Syk). PTKs then stimulate p85-associated PI 3-Ks (class IA PI 
3-Ks) by phosphorylation o f ITAM motifs (e.g. on the y chain o f FcyRI), which in turn function as 
SH2 docking sites. PTKs and the product o f PI 3-Ks, PtdIns(3,4,5)P3, co-activate VAV, a GEF for 
small GTPases (smg) such as RAC or CDC42. RAC is involved in fibroblast ruffling, and is part of 
the assembled granulocyte NADPH-oxidase, which comprises a mebrane situated b-type 
cytochrome (p22phox/p91phox) and additional cytosolic factors (p40phox,p47 phox, p67 phox). O f these 
p67 phox is most likely to interact with the predominant form o f RAC in granulocytes, RAC2. 
PtsIns(3,4,5)P3 can also trigger the activation o f o f protein kinases, for example recruit and activate 
PKB, with the involvement o f PDK or act on PKCÔ and Downstream signaling by PI 3-Ks is 
generally considered to be mediated by molecules with a pleckstrin homology (PH) domain, which 
functions as a binding domain for poly-phosphorylated phosphoinositides. P K C a and P are
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activated by elevated Ca2+ levels and DAG, and are involved in the respiratory burst, but not the 
chemotactic process. Processes linking PKCs, PKB, RAC, PTKs and others with the respiratory 
burst, actin polymerization and secretion are emerging, but are poorly characterized in hematopoetic 
cells. Dd indicates a connection of PKB and chemotaxis in Dictostelium discoideum  (Reprinted 
with permission from W ymann et al.: Lipids on the move, in: Immunology Today, 2000; 6:260-4).
The members of the p2 integrin subfamily are only expressed on leukocytes and 
share a common p2 subunit (CD18) [60,61]. The a  subunits of each p2 integrin family 
member, lymphocyte-function-associated antigen-1 (LFA-1), macrophage antigen-1 
(Mac-1, or complement receptor type 3 (CR3)) and p150,95, are designated CD11a 
(aL), CD11b (aM) and CD11c (aX), respectively [10]. Recently, a fourth member, 
CD11d (aD) has been identified [62].
The CD11a/CD18 subtype is constitutively expressed on granulocytes, whereas 
Cd11b/CD18 and CD11c/CD18 integrins are stored in granules and vesicles and are 
rapidly upregulated on the cell surface upon stimulation by various agents [63]. 
While CD11a/CD18 and CD11b/CD18 mediate neutrophil adhesion to vascular 
endothelium, the function of CD11c/CD18 is less clear [64]. A ligand for 
CD11b/CD18 is iC3b, which is an opsonic fragment of the third component of the 
complement system fixed to the surface of microorganisms during complement 
fixation. CD11b/CD18 thus acts as an iC3b receptor and is therefore also called 
complement receptor type 3 (CR3). It has been shown to act synergistically with 
receptors for the Fc portion of IgG to enhance the adherence and phagocytosis of 
opsonized microorganisms [7].
Integrins mediate cell adhesion by binding to a wide array of ligands, including 
extracellular matrix proteins like collagen, plasma proteins such as fibrinogen and 
transmembrane glycoproteins such as the intercellular adhesion molecules or ICAMs 
[2]. ICAM-1 (CD54) and ICAM-2 (CD102), are ligands for CD11a/CD18 and 
CD11b/CD18. Both ICAMs belong to a second family of adhesion receptors, the 
immunoglobulin superfamily. ICAM-2 is constitutively expressed on endothelial 
cells, while endothelial ICAM-1 expression is increased following exposure to 
stimulating agents such as bacterial endotoxin or inflammatory cytokines. In inflamed 
tissue the CD11b/CD18 and CD11c/CD18 interaction with ICAM-1 seems to be 
responsible for increased granulocyte adhesion [42].
A common feature of integrins is that they require a physiological temperature, the
2+ 2+presence of extracellular Ca and/or Mg and an intact cytoskeleton to bind ligand 
[65]. Importantly also, integrins have to be activated to become functionally active 
[2]. The current concept is that adhesion molecules are important for a broad range of 
adherence-related functions and do not merely mediate adherence to specific ligands. 
The importance of an intact p2 integrin-mediated adhesion response of neutrophils is 
best illustrated in patients sufferering from the leukocyte adhesion deficiency (LAD) 
syndrome (see below).
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2.2.1.3 Neutrophil adhesion to activated endothelium and extravascular migration
The neutrophil extravascular migration process is established stepwise and comprises 
rolling, activation, firm adhesion to activated endothelium, and finally transendothelial, 
extravascular migration or diapedesis (see also Fig. 3) [10,11,42, 45].
Circulating non-activated leukocytes do not adhere to the vascular endothelium 
and do not leave the circulation, probably due to the fast flow in the circulation. 
However, many leukocytes move at a reduced speed along the endothelal cells, 
especially in areas with a slower flow rate, like postcapillary venules or sites with 
vessel dilatation due to inflammation [2]. ‘Tethering’, refers to a loose and somewhat 
transient adhesion between leukocytes and the epithelium that is mediated by the 
interaction of adhesion molecules on both leukocytes (L-selectin, CD62L) and 
endothelial cells (E- and P-selectin) [5,66,67]. ‘Tethering’, in combination with the 
shearforces in the bloodstream, results in the ‘rolling’ of leukocytes along the 
endothelium. As mentioned before, inflammatory mediators activate the underlying 
endothelium at a site of inflammation. This causes local upregulation of adhesion 
molecules and the production of substances such as interleukin-8 (IL-8) and platelet- 
activating factor (PAF) [68]. These molecules remain attached to the endothelial cell
Figure 2a. Rho-like GTPases.
Rho-like GTPases act as molecular switches (by Dr. P. Hordijk, Central Laboratory o f the 
Netherlands Blood Transfusion Service (CLB), Amsterdam, The Netherlands, reprinted with 
permission).
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surface and establish a haptotactic gradient, i.e. a surface-attached concentration 
gradient of chemoattractants [69,70].
Tethering is important because it allows a short-term cell contact that activates the 
next step in the adhesion cascade, the increased adhesion. During this step, 
leukocytes respond to ligands on the endothelial surface by intracellular signaling [2]. 
The objective of this triggering is to turn on the adhesive function of the (not yet 
functionally active) integrins. Activation of rolling neutrophils occurs through cross­
linking of the ligands of P- and E-selectin on the neutrophils, through ligand-induced 
cross-linking of L-selectin, and through the neutrophil receptors for PAF and IL-8. 
Thus, a further decrease in the rolling velocity is induced, with increased adhesion. 
Finally, and within seconds, firm attachment to endothelial cells is established by 
means of the activated adhesion molecules. From these sites, the neutrophils leave the 
intravascular compartment by squeezing between the endothelial cells (diapedesis) 
and subsequently move towards the inflammatory site along local gradients of 
chemoattractants. In this way, infection induces local activation of the nearby 
endothelium and a local immune response. Firm adhesion, diapedesis, tissue 
migration and phagocytosis are all p2 integrin mediated.
Reversible p2 integrin activation is essential for neutrophil movement. The cell 
needs substratum for its movement: at the leading edge, the p2 integrins bind to the 
substratum, then the cell moves over this fixed point of contact, and establishes a new 
point of contact and finally, the original binding point is left by deactivation (locally) 
of the p2 integrins. Migration in all motile cells also involves shape changes in 
response to external stimuli [71]. This process is established in neutrophils through 
cyclic actin polymerization-depolymerization rearrangements, which result in 
extrusion and retraction of small, veil-like membrane ruffles or lamellipods [72-74]. 
Multiple cycles of small-scale shape changes ultimately result in net cell translocation 
[73]. Neutrophils undergo a shape change upon stimulation with chemotactic agonists 
or after making contact with a substratum [75-77]. This shape change is essential for 
cellular migration and consists of two super-imposed events: the development of a 
cellular protrusion, the pseudopod, which renders the cell a polar shape, and the 
formation of lamellipods, which are superimposed on the pseudopod 
[27,75,76,78,79]. Lamellipods develop earlier after stimulation than pseudopods, 
while the cell body is still spherical [27,76]. Cell stimulation also leads to changes in 
the neutrophil content of filamentous actin, or F-actin, which is the major cytoskeletal 
component. Periodic fluctuations in cell body size, with a period of approximately 8 
seconds at 37°C, arise from lamellipod extension and retraction cycles. These shape
16
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oscillations, which are probably based on cyclic actin polymerization, are thought to 
be a fundamental feature of neutrophil migration [75].
Figure 3. Stages o f leucocyte transmigration and involved adhesion molecules.
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(by Dr. P. Hordijk, Central Laboratory o f the Netherlands Blood Transfusion Service (CLB), 
Amsterdam, The Netherlands, reprinted with permission).
Overall, neutrophil migration involves a cellular driving motor; the transmission of 
driving forces to the cell periphery; and the traction of the cell periphery on the 
substratum, where reversible adhesive interactions between lamellipods and the 
substratum occur. The formed adhesive interactions are reversed at a later stage, 
when the cell body has followed the leading pseudopod [72,80]. In the absence of a 
chemotactic gradient, neutrophils extend pseudopods in random directions, and the 
cells show undirected motility with a constant frequency of cellular turns. 
Chemoattractants decrease the angle between the direction of pseudopod extension 
and the chemotactic gradient, which rapidly results in accurate orientation of the cell 
along the gradient [81-83]. Changes as small as 2% in concentration over one single 
cell length can be detected by the neutrophil. This orientation accuracy results from 
senses in the change in receptor occupancy, which occurs upon displacement along 
the cell [81].
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2.2.2 Phagocytosis and killing
Phagocytic killing is the primary mechanism through which the immune system 
eliminates gram-positive and gram-negative organisms and pathogenic fungi. This is 
a complex process that requires coordination of a variety of signaling reactions [84]. 
Deficiencies in phagocyte function therefore may result in life-threatening infections 
with microorganisms that otherwise display relatively low virulence or invasive 
tendency.
Neutrophils, as well as mononuclear phagocytes, express a variety of phagocytic 
receptors, including the mannose receptor, scavenger receptors, receptors for 
complement fragments and receptors for the Fc region of IgG (FcyRI-III) [85-87]. 
Phagocytosis proceeds by the extension of actin-based pseudopods around a 
circumferentially opsonized target [88-90]. The pseudopods appear tightly opposed to 
the target, the result of ligation of the phagocyte FcyR with the IgG on the target 
surface. Fusion of the pseudopods entraps the target in a phagosome, where it is 
eventually degraded. These observations form the basis of the ‘zipper hypothesis’ for 
IgG-mediated phagocytosis [89]. The phagocytic signal transduction cascade can be 
divided into three stages: (i) target-binding to the phagocyte surface with subsequent 
FcyR cross-linking, (ii) proximal signaling events including tyrosine phosphorylation 
of the FcyR and activation of low-molecular-weight GTPases and (iii) more distal 
events involving activation of protein kinase C and phospholipases [91-95].
2.2.2.1 Phagocytosis
Once arrived at the site of infection, neutrophils release enzymes such as 
collagenase and elastase, which help to establish abscess cavities, while lysozyme 
and acid proteases help digest cell debris [7]. The release of these and other enzymes, 
by means of exocytosis (degranulation) of neutrophil granules and vesicles, is 
preceded by the contact between the selectins on activated endothelium and their 
counterparts P-selectin glycoprotein ligand-1 (PSGL-1), L-selectin and sialated 
glycoproteins on neutrophils. These ligands are placed like sensors on neutrophil 
microvilli and transduce signals that mobilize secretory vesicles, but not granules. 
Vesicle mobilization enriches the plasma membrane with p2 inte grins and various 
receptors for chemotactic factors, without liberating potentially harmful granule 
products. This enhanced adhesive and signaling potential may be essential for 
diapedesis [29]. Specific and azurophilic granules are mobilized during phagocytosis 
and fuse with the plasma membrane, thereby releasing their contents into the 
phagosome and into the surrounding medium and exposing their markers on the cell 
membrane. Also, the NADPH-oxidase membrane component cytochrome b558, which 
is mainly localized in specific granules and secretory vesicles in resting neutrophils 
(see below), is upregulated in this way in the phagosomal membrane [29].
Neutrophils carry receptors recognizing IgG molecules and activated complement 
factors, like C3b, localized on the surface of properly coated (opsonized) bacteria 
[42]. These ligands promote the attachment of pathogens and debris to the neutrophil,
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followed by phagocytosis (see also Fig. 4). The CD11b/CD18 integrin has an 
important function in binding complement-opsonised particles [64]. Fibronectin and 
the tetrapeptide tuftsin also facilitate the phagocytic process. In neutrophils Fcy 
receptors mediate the phagocytosis of immunoglobulin G (IgG)-coated particles. Two 
types of receptor for the Fc part of IgG are expressed in mature neutrophils. Fcy 
receptor II (Fcy RIIa, CD32) is a transmembrane protein, while FcyRIIIb (CD16) on 
neutrophils lacks a cytoplasmic tail, but is linked to the membrane through a 
glycosyl-phosphatidyl-inositol (GPI) anchor [41,96,97]. The high-affinity receptor 
for IgG (FcyRI, CD64) is progressively lost during neutrophil maturation, but mature 
neutrophils may express CD64 upon exposure to certain cytokines, such as interferon 
Y [98,99]. Phagocytosis is established when the neutrophil makes tight contact with 
its target and the plasma membrane flows around the surface until the bacterium is 
completely enclosed [100]. Thus, the amount of extracellular fluid entering the 
phagosome with the bacterium is minimized. The phagosomes then fuse with 
lysosomes to form phagolysosomes, where the killing and digestion of 
microorganisms take place [101].
The phagolysosome is initially a very small space in which granule contents 
released within seconds of ingestion constitute a significant proportion of the 
phagosome volume [102,103]. The release of degranulation products into a small 
volume causes the initial protein concentration to be high, with an estimated 30-40% 
protein content. The osmotic pressure further increases with the formation of large 
amounts of small-molecular protein degradation products. With time this osmotic 
pressure decreases due to the influx of water. Also, sequential release of the contents 
of different types of granule provides a succession of different phagosomal 
environments [31,104]. This necessitates a tight control of the pH in the phagosome. 
While oxidation of NADPH to NADP+ and H+, and transfer of reducing equivalents 
across the membrane to phagosomal oxygen result in acidification of the cytoplasm, 
dismutation of the superoxide anion renders the phagosome alkaline [105]. Strong 
proton pumping from the cytoplasm into the phagosome restricts this increase within 
an hour from an initial pH of 8.0 to 6.0 after phagosome formation [106,107].
2.2.2.2 Killing and the role of reactive oxygen intermediates
While respiration in resting neutrophils is largely non-mitochondrial and 
anaerobic, these cells produce reactive oxygen metabolites, such as superoxide and 
hydrogen peroxide, in response to the phagocytosis of particulate stimuli or high 
concentrations of chemoattractants [108-112]. These reactive oxygen intermediates 
are released into phagosomes and into the extracellular surroundings in response to a 
variety of soluble and particulate stimuli [113-117]. An NADPH oxidase complex 
that assembles at the phagosomal membrane mediates the oxygen radical production. 
As a result, phagocytosis is accompanied by a burst of oxygen consumption, the so- 
called ‘respiratory’ or ‘metabolic burst’ [116,118]. The radical species that are
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formed from oxygen during this burst and the enzymes that mediate their conversion 
are described in Fig. 5 (based on [44]).
The NADPH oxidase complex consists of several subunits, two of which, gp91- 
phox and p22-phox, form the membrane-bound cytochrome b558, while the three 
cytosolic components, p47-phox, p67-phox and p40-phox, translocate to the 
membrane upon activation (see also Fig. 6). This translocation involves several low- 
molecular-weight GTP-binding proteins. Binding of the cytosolic NADPH oxidase 
components to cytochrome b558 leads to a conformational change in gp91-phox, 
which renders this protein accessible to NADPH on the cytoplasmic side. Electrons 
are then transferred from cytoplasmic NADPH to molecular oxygen on the 
phagosomal side of the membrane, generating first superoxide. Most of the 
superoxide is subsequently reduced to hydrogen peroxide [119-121]. Next, the 
hydrogen peroxide is converted into hydroxyl radicals and hypochlorous acid.
Many studies have addressed the question which intermediates of the respiratory 
burst are responsible for the microbial killing capacity of neutrophils [122-126]. The 
non-radical hypochlorous acid (HOCl) is the most bactericidal oxidant that is 
produced by the neutrophil [116,127-132]. Bacterial targets for HOCl include 
membrane transport systems and DNA synthesis [133-136]. Evidence for a role of 
superoxide also exists, as microbial killing has been shown to be impeded when the 
superoxide scavenger SOD was introduced into phagosomes simultaneously with 
bacteria [137,138]. The importance of the oxidative burst in microbial killing is best 
shown by the susceptibility to infections of individuals with chronic granulomatous 
disease (CGD), a genetic disease in which NADPH oxidase is inactive (see below) 
[139-141].
2.2.2.3 The role of myeloperoxidase in killing
The mechanism for oxidative microbial killing involves MPO, which consumes most 
of the hydrogen peroxide generated by neutrophils [117,142]. MPO, a major constituent 
of the azurophilic granules, uses hydrogen peroxide to oxidize a variety of aromatic 
compounds, thus generating substrate radicals [143-147]. However, although many 
species of bacteria are killed readily by a MPO/hydrogen peroxide/chloride system in 
vitro, the exact role of MPO remains uncertain. This is exemplified by the fact that MPO 
deficiency in clinical practice is not associated with severely compromised host defenses 
[148].
2.2.2.4 Oxidative and non-oxidative mechanisms in killing
Apart from oxidative strategies also non-oxidative mechanisms contribute to the 
microbicidal capacity of neutrophils, in the form of strongly cationic granule proteins 
and small peptides known as ‘defensins’ that are released into the phagosome [149-151]. 
The mechanism (oxidative versus non-oxidative) that predominates is dependent on 
microbial species, metabolic state and prevailing surrounding conditions [135].
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However, optimal killing of most species of bacteria seems to require products from the 
oxidative burst, as exemplified in CGD (see below) [139,140].
Figure 4. Neutrophil activation.
Outside
Plasm a membrane
Inside IgG-Fc and
complement
receptors
Granules
Neutrophil □ □ ÖQ
Contact o f opsonized microorganisms with neutrophil surface receptors (IgG-Fc and complement 
receptors) starts phagocytosis, NADPH oxidase activation and degranulation. W ithin the 
phagosome, oxidative products may interact with granule proteins for effective killing o f ingested 
microorganisms (Reproduced with permission from Roos D (1991) The respiratory burst of 
phagocytic leukocytes. Drug Investigations 3: 48-53).
The strains of bacteria that are killed poorly in vitro by CGD neutrophils are also 
responsible for the infections that are characteristic of CGD [140]. Moreover, normal 
neutrophils tested under anaerobic conditions, or in the presence of the NADPH 
oxidase inhibitor diphenylene iodonium, are also impaired in their ability to kill these 
bacteria [46,152-154]. Other species are killed normally, either because they are 
catalase-negative and able to supply an alternative source of hydrogen peroxide, or 
because they can be disposed of effectively by non-oxidative mechanisms [155,156].
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Figure 5. Possible oxidant generating reactions in stimulated neutrophils (adapted from [44]).
2.2.3 Cellular membrane fluidity and lipid rafts
Membrane fluidity is a complex feature of the physicochemical nature of the 
cellular membrane involving mobility and “order” of membrane components as well 
as membrane permeability properties, with an important role in regulating cellular 
functions through membrane-bound enzyme- and receptor functions [157-160]. 
Changes in cellular membrane fluidity are implicated in the pathophysiology of such 
diverse clinical conditions as rheumatoid arthritis, diabetes mellitus, hepatitis B 
infection and muscle dystrophy [161-165]. Furthermore, modulation of the function 
of immune-competent cells by nutritional formulations may result from alterations in 
membrane fluidity, due to the incorporation of fatty acids [163,166-169]. Finally, 
decreased neutrophil membrane fluidity has been demonstrated after incubation with 
oxidized low-density lipoprotein (LDL) particles [170].
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Figure 6. Translocation o f NADPH oxidase components.
Activation o f the NADPH oxidase. The membrane-bound NADPH-oxidase components gp91-phox 
and p22-phox and the small GTPase Rap1A are located in resting neutrophils in the membranes of 
specific granules and secretory vesicles. During cell activation (e.g. after binding o f opsonized 
microorganisms to surface receptors on the neutrophils), these organelles fuse with the plasma 
membrane, thus leading to upregulation o f the expression o f these components on the neutrophil 
surface, especially in plasma membrane areas surrounding the phagocytosed material 
(phagosomes). Concomitantly, the cytosolic NADPH-oxidase components p40-phox , p47-phox and 
p67-phox translocate to the cytochrome b558 subunits (gp91 -phox and p22-phox) and induce a 
confirmational change in p91-phox that allows NADPH to bind to gp91-phox and donate its 
electrons to the FAD moiety in this subunit. The cytosolic small GTPase Rac (Rac1 in macrophages 
and Rac2 in neutrophils) regulate the translocation process by binding to the plasma membrane and 
to p67-phox, and perhaps also to gp91 -phox (reprinted with permission from ‘Chronic 
Granulomatous Disease’, by Roos D and Curnutte JT, in: Primary Immunodeficiency Diseases, 
Ochs HD, Smith CIE, Puck JM  (eds.), Oxford University Press, New York, 2002).
Besides PKC-mediated reactions (directly induced by phorbol-myristate or 
indirectly by the tripeptide fMLP), modulation of membrane fluidity (e.g. by 
detergents or fatty acids) can result in neutrophil activation [171-173]. Thus, the 
detergent sodium dodecyl sulphate (SDS) has been shown to activate neutrophil 
NADPH oxidase in a PKC-independent manner [174]. On the other hand, neutrophil 
activation by various mediators is also accompanied by an increase in fluidity of the 
cellular membrane [166,175].
Apart from membrane fluidity, the induction of signaling pathways by the plasma 
membrane in immune competent cells is also coordinated by compartmentalization
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into so-called lipid rafts, i.e. micro-domains characterized by a unique lipid 
environment, leading to their insolubility in nonionic detergents. Many receptors (e.g. 
for Interleukin-2) are constitutively or inducibly localized in such lipid rafts 
[167,177]. Apart from a role in signal transduction, lipid rafts also serve as entry and 
exit sites for microbial pathogens and toxins, such as influenza and measles viruses, 
HIV and cholera toxin [178].
2.3. Clinical conditions associated with decreased neutrophil functions
2.3.1 Defective adhesion or migration
Mild neutrophil dysfunction in most cases remains without clinical significance, 
probably because the other parts of the immune system remain intact [3,9,179,180]. 
On the other hand, significant defects in neutrophil adhesion and migratory abilities 
are associated with an increased incidence of infectious complications.
2.3.1.1 Leukocyte adhesion deficiency
The importance of adhesion and migration for neutrophil function is clearly shown 
in two genetic disorders, leukocyte adhesion deficiency (LAD) type 1 and type 2. 
These disorders also exemplify the importance of P2 integrins and selectins in 
neutrophil migration, respectively. Sialyl-Lewis X (sLex) is a fucosylated sugar 
moiety on the carbohydrate ligands for selectins [181]. Patients with LAD type 2 lack 
these sLex carbohydrate groups [182-184]. Patients with LAD type 1 fail to express 
the common p2 chain of the p2 integrins [185-187]. Neutrophil extravascular 
migration is severely impaired in both diseases. Whereas neutrophils from patients 
with LAD type 2 do not roll but can become firmly attached and do migrate, 
neutrophils from patients with LAD type 1 roll normally, but fail to adhere and 
migrate. Recurrent life-threatening bacterial and fungal infections are common in 
patients with either form of LAD [3,185-187]. Congenital abnormalities in neutrophil 
chemotaxis are also present in the hyper-immunoglobulin-E-recurrent infection 
(Job’s) syndrome and Chediak-Higashi syndrome [188-193].
Apart from congenital disorders, defective cell adhesion and migration may be 
drug-induced, for instance by the use of non-steroidal anti-inflammatory drugs, as 
well as by colchicine, glucocorticoids and alcohol. Acquired adhesional defects are 
known to occur in hemodialysis treatment, while migration is affected by thermal in­
juries, malignancy, autoimmune disease, viral infections and malnutrition [7].
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2.3.2 Impaired microbial phagocytosis and killing
2.3.2.1 Chronic granulomatous disease
Chronic granulomatous disease (CGD) is a rare disorder affecting about 1 in
250,000 individuals. It is an important model of defective oxidative metabolism, 
caused by the phagocytes’ inability to produce sufficient reactive oxygen metabolites 
[194]. The gp91-phox protein is encoded on the X-chromosome and p22-phox, p47- 
phox and p67-phox are encoded on different autosomal chromosomes. A defect in 
any of these components leads to CGD. Most often CGD is inherited as an X-linked 
recessive pattern, while in about 35% of patients an autosomal recessive pattern is 
reported. Patients with CGD characteristically present at a young age with recurrent 
infections with catalase-positive microorganisms and extensive inflammatory 
reactions. Neutrophil apoptosis, which is stimulated by hydrogen peroxide, is 
believed to be impaired in patients with CGD, in contrast with MPO deficiency, 
resulting in incomplete neutrophil clearance and formation of granulomas in CGD 
patients [44,195].
2.3.2.2 Specific granule deficiency
The importance of neutrophil specific granules in the inflammatory response is 
best shown in specific granule deficiency, a very rare autosomal recessive disorder in 
which specific granules are absent [3]. Neutrophils that are deficient in specific 
granules fail to increase the surface expression of CR3, fMLP receptors and 
components of the NADPH oxidase system after stimulation, as normal neutrophils 
do [196-198]. Patients with this disorder suffer from recurrent severe bacterial 
infections of the skin and deep tissues as a result of impaired chemotaxis and 
microbicidal activity.
2.3.2.3 Myeloperoxidase deficiency
MPO deficiency is the most common neutrophil defect, which is inherited as an 
autosomal recessive trait and may have an incidence of about 1 in 4000 persons 
[140]. Neutrophils isolated from the blood of MPO-deficient individuals poorly kill a 
variety of microorganisms [199-201]. Moreover, inhibitors of MPO such as azide and 
cyanide impair killing by normal cells [138,200,202,203]. However, isolated MPO 
deficiency is not associated with severely compromised anti-microbial defenses and 
doubts have even been raised as to whether MPO has any role in bacterial killing
[204]. Acquired MPO deficiency occurs in various forms of leukemia and these 
diseases are associated with an increased risk for fungal infections.
Neutrophils from patients with Chediak-Higashi syndrome show abnormal rates of 
microbial killing due to slow fusion of the granules with phagosomes. Drug-induced 
abnormalities of microbial killing occur with the use of glucocorticoids, 
cyclophosphamide and colchicine, and with leukemia, thermal injury, sepsis, diabetes 
mellitus, and malnutrition.
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2.4. Methods to evaluate neutrophil functions
Over the past decades numerous assays have been designed to evaluate specific 
aspects of neutrophil function, such as adhesion, migration, oxygen metabolite 
production, phagocytosis and the capacity to kill bacterial or fungal pathogens such 
as Staphyoloccus aureus and Candida albicans, respectively.
2.4.1 Cell isolation
To avoid the effects of spontaneous apoptosis, neutrophil functions should be 
assessed as soon as possible, and at least within 24-36 hours after collection of blood 
in polypropylene tubes with citrate or EDTA as anti-coagulant. Storage should take 
place at room temperature (20-25°C) [4]. With the exception of flow cytometric 
assays, in which various leukocyte species can be distinguished by morphology (size, 
volume) and immunophenotype (binding of fluorescent monoclonal antibodies), the 
tests are usually performed on highly purified neutrophils. These cells can be isolated 
from whole blood by means of colloidal density gradient centrifugation and 
subsequent isotonic lysis of erythrocytes [205-207]. Importantly, these isolation 
procedures induce changes in the expression of surface proteins and lead to cell loss 
and pre-activation (priming), in which centrifugation on the density gradient seems to 
be the crucial step [4,205].
2.4.2 Neutrophil stimulation and signaling
Neutrophil stimulation, which is necessary to elicit most previously described 
effector functions, can be mediated by several agents in a distinctive manner. The 
most frequently used agents in investigations assessing neutrophil functions are listed 
below.
Serum-treated zymosan (STZ), i.e. yeast particles opsonized with both IgG and C3 
complement fragments, comprises a particulate stimulus that binds to membrane 
complement receptors (CR1 and CR3) and Fcy receptors (FcyRIIa and FcyRIIIb) on 
neutrophils. After binding to these receptors, the STZ particles are ingested, thereby 
concomitantly inducing the respiratory burst and degranulation.
The STZ-induced respiratory burst in human neutrophils is moderately influenced 
by priming [208]. Priming refers to the phenomenon that an agent that by itself does 
not activate a certain response enhances the response induced by a subsequent activator. 
It is known that during the isolation of neutrophils, these cells often become primed
[205].
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N-formyl-methionyl-leucyl-phenylalanine (fMLP), a formylated peptide of three 
amino acids, is a soluble receptor-mediated neutrophil stimulus, which requires 
priming to activate the respiratory burst [209]. Priming of the fMLP-induced 
respiratory burst can be mediated by various agents, e.g. LPS, which is the major 
constituent of the outer part of the outer membrane of Gram-negative bacteria. 
Bacterial outer membrane proteins often start with the fMLP sequence. FMLP binds 
to a specific fMLP-receptor with a seven-transmembrane-domain structure, 
characteristic of the G-protein-coupled receptor superfamily [210,211]. For
respiratory burst activation, about 10-100 times higher concentrations of fMLP are2+
required than for activation of chemotaxis and Ca signaling.
The phorbol ester phorbol-myristate acetate (PMA) crosses the cellular membrane 
and binds directly to and activates protein kinase C in a diacylglycerol-like manner. 
This results in phosphorylation and translocation of the cytosolic NADPH-oxidase 
components, which in turn mediates activation of the respiratory burst. The PMA- 
induced respiratory burst is receptor-independent and not absolutely dependent on 
priming, although priming results in an enhanced rate of oxygen consumption in 
neutrophils [212].
Proper calcium signaling in neutrophils can be evaluated with spectrofluorometry 
or flowcytometry by measuring the concentration of intracellular free calcium ions 
after loading the cells with a calcium chelator dye, which becomes fluorescent after 
binding calcium. Changes in the actin network of neutrophils can be investigated with 
flowcytometry by measuring the amount of polymerized or filamentous actin. 
GTPase (e.g. Ral, Rap, Ras and Rac) activation can also be measured, in addition to 
quantification of receptors (e.g. Fc- and chemoattractant receptors) and adhesion 
molecules (see below) by means of flowcytometry [43,213]. The presence and 
activity of various tyrosine and serine-threonine kinases can be investigated by 
Western blot.
2.4.3 Adherence and degranulation
The expression of adhesion and degranulation markers on the outer cell membrane 
can be quantified by flowcytometric analysis after staining of cells with fluorescent- 
conjugated monoclonal antibodies [214]. Due to their distinctive fluorescence 
scattering patterns, flowcytometric analysis of various leukocyte species does not per 
se require isolation of these cells from whole blood. This may be advantageous in the 
light of the previously mentioned phenotypical changes induced by isolation 
procedures. Markers for various neutrophil granules and vesicles comprise CD63, 
MPO and elastase for azurophilic granules, CD11b, CD66, lactoferrin and vitamin 
B12-binding protein for specific granules, CD10, CD11b, CD35 for secretory 
vesicles, and FcyRIIa and FcyRIIIb for plasma membrane, respectively [4]. When 
studying degranulation, it is important to realize that PMA and fMLP induce only the 
fusion of specific granules with the plasma membrane, whereas fMLP in combination 
with cytochalasin B induces the fusion of both specific and azurophilic granules with
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the plasma membrane [205]. Recently an assay has been developed in which the 
function of adhesion molecules can be evaluated, by measuring the binding capacity 
of leukocytes for latex beads coated with specific ligands, for instance ICAM-1 
(CD54) in the case of LFA-1 (CD11a/CD18) or Mac-1 (CD11b/CD18) [215]. This 
method also works with neutrophils [216].
2.4.4 Migration
Migration of neutrophils is usually assessed with the Boyden chamber [217-219]. 
This instrument consists of a lower compartment containing the chemo-attractant 
substance, and an upper compartment in which the cells are placed, separated by a 
filter. By diffusion of the chemotactic agent, a concentration gradient is established 
through the pores of the filter. This induces a chemotactic response of the cells, 
resulting in movement across the filter. The percentage of cells is measured that, after 
a defined period, has passed from the upper compartment through the 5-8-^m pore­
sized polycarbonate filter, towards the lower compartment. Filter passage is evaluated 
both in the presence (chemotaxis) and absence (random migration) of chemotactic 
facors, such as zymosan-activated serum (C5a), IL-8, PAF, LTB4 or fMLP.
Besides counting the number of cells that have passed the filter after a defined 
period, methods have also been developed to evaluate only the cells that move the 
fastest through the filter. This is done by stopping the assay before the cells have 
traversed the filter and measuring (by microscope) the distance that has been traveled 
by the fastest cells, the so-called ‘leading front’ method. Recently, more sophisticated 
and elaborate methods employing computerized confocal microscopy have been 
developed to measure the number of cells at different positions in the filter, giving an 
impression of the chemotactic abilities of the complete neutrophil population under 
investigation [4].
2.4.5 Microbial phagocytosis and killing
Colony counting remains the ‘golden standard’ to assay phagocytic killing, 
although the method is cumbersome and requires considerable expertise to be 
reproducible [220,221]. More recently a test has been developed where the vital 
fluorescent marker bis-carboxyethyl-carboxy-fluorescein (BCECF) is used, instead of 
differential staining with a conventional dye [220]. Briefly, cells of the yeast- 
pathogen Candida albicans are labelled by incubation in broth containing bis- 
carboxyethyl-carboxyfluorescein penta-acetoxymethylester (BCECF-AM), which 
diffuses into the cells and is cleaved by cytoplasmic esterases to yield the fluorescent, 
membrane-impermeable product BCECF, that remains trapped within the cells. To 
assay phagocytosis, phagocytes are labeled with a monoclonal antibody and 
incubations with the yeast cells are terminated by pipetting aliqouts into 
paraformaldehyde solutions. Flowcytometric analysis then yields information on the 
association (both ingestion and adherence) of yeast particles with the phagocytes,
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thus replacing time-consuming microscopic analysis. To assay for killing, BCECF- 
labeled yeast cells are incubated with phagocytes. The latter are subsequently lysed 
with DOC to liberate the yeast cells, which fall into the following two populations 
that are also quantified by use of a flowcytometer: (i) fluorescent and viable and (ii) 
non-fluorescent and non-viable. Importantly, the use of flowcytometry enables the 
use of total leukocyte suspensions, because other cell populations can be gated out 
from the scatter diagram.
2.4.5.1 Production rates of reactive oxygen intermediates
The production of reactive oxygen intermediates in the respiratory burst can be 
evaluated in several ways. Firstly, the stimulus-induced production of oxygen 
metabolites can be measured indirectly as the maximum rate of oxygen uptake by 
neutrophils, as described by Weening et al. [222]. In a radical-specific manner, 
superoxide production can be determined spectrometrically as the stimulus-induced 
superoxide dismutase-inhibitable reduction of ferricytochrome c. Similarly, hydrogen 
peroxide production can be determined as the peroxidase-dependent oxidation of 
homovanillic acid to a fluorescent dimer catalyzed by an added peroxidase [223].
Finally, oxygen radical production can be measured in a non-radical-specific semi­
quantitative manner by means of the luminol-enhanced chemiluminescence technique 
[224-226]. The amplifying molecule luminol (5-amino-2,3,dihydro-1,4-phtalazinedione) 
reacts with the oxygen species generated by the neutrophils to produce an excited 
intermediate that emits light (chemiluminescence) upon relaxation to the ground state. 
The luminol molecule can cross biological membranes, and the detection system thus 
measures reactive oxygen species released from cells as well as oxygen species 
generated within a phagosome [224]. Compared to the cytochrome c reduction 
technique, the chemiluminescence technique has the advantage that it is more sensitive, 
though not quatitative, and it allows both intra- and extracellular NADPH oxidase 
activity to be measured [226]. Furthermore, the chemiluminesence technique, due to its 
high sensitivity, can easily be performed on diluted whole blood [227].
2.4.6 Neutrophil membrane fluidity
Membrane fluidity of neutrophils can be assessed after labeling of cells with 
fluorescent probes such as 1,6-diphenyl-1,3,5-hexatriene (DPH) or the more polar 
trimethyl-ammonium (TMA)-DPH). These probes have been widely used to measure 
membrane fluidity, as they characterize the complete cell membrane apparatus by 
penetrating both the plasma- and intracellular membranes [228]. Fluorescence 
polarization can be measured using spectrofluorophotometry by calculating 
fluorescence anisotropy, the reciprocal of membrane fluidity [161,162,229-231].
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The mobility of membrane receptors for neutrophil stimuli such as fMLP, the Fc- 
part of IgG and C3 can also be studied using fluorescence recovery after 
photobleaching (FRAP) [173,232,233]. In FRAP, membrane fluorescence is sampled 
microscopically at short time intervals (0.05 sec) to assess whether a rapidly diffusing 
component, such as lipid, is present [234]. The fractional recovery or mobile fraction 
of receptors corresponds to the number of mobile receptors in the membrane, whereas 
the immobile fraction probably reflects receptors anchored to the cytoskeleton or 
trapped in membrane domains smaller than the bleach spot [160,235-237].
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Lipid emulsions and the immune system: a review

Lipids and the immune system
3.1 Lipid emulsions: applications, composition and metabolic effects
3.1.1 Total parenteral nutrition
Total parenteral nutrition (TPN) implies that all nutritional requirements are met by 
means of a sterile aqueous solution that is administered intravenously. This thera­
peutic strategy is frequently used in patients with gastrointestinal diseases that result 
in inadequate nutrient and fluid uptake. Thus, TPN is applied on a large scale in 
clinical practice in the treatment of postoperative patients and on Intensive Care units. 
On a more permanent basis, home TPN is given in a number of patients with 
longstanding malabsorbtion, short bowel syndrome or motility problems of the small 
intestine.
3.1.2 Lipid emulsions
Lipids, or triglycerides, consisting of fatty acids (FA) attached to a glycerol 
molecule, are one of three macronutrients, besides proteins and carbohydrates. In a 
water-soluble form, as an emulsion, they establish an integral part of TPN 
formulations as a non-insulin-dependent, non-protein energy source and (essential) 
fatty acid (EFA) supply [1]. Another application for lipid emulsions in clinical 
practice is that of carrier substance for the deliverance of fat-soluble anaesthetic 
agents, antibiotics and vitamins [2-4].
Since the introduction of TPN a number of structurally different emulsions have 
been developed. Differences exist with respect to the content and composition of 
several components of the emulsion, such as lipid source, emulsifier and anti­
oxidants. For an overview of characteristics of emulsions applied in the studies in this 
thesis (see Table 1).
3.1.3 Lipid sources in structurally different lipid emulsions
Over the last three decades, long-chain triglycerides (LCT) such as Intralipid®, 
Lipofundin-S® or Emulsan®, with a fatty acid carbonchain-length of 14 to 24 atoms, 
have been the most widely used lipid sources in fat emulsions [5]. The hydrocarbon 
chain of the fatty acids of LCT can be saturated (no double bonds) or unsaturated 
(one or more double bonds). Polyunsaturated FA (PUFA) can be further divided into 
four major families according to the location of the first double bond from the 
terminal methyl end of the carbon chain. These are the w-3, w-6, w-7, and w-9 FA. 
The w-3 and w-6 classes are not inter-convertible in animals, and are essential FA in 
man. The lipids that are derived from fractionated soybean or safflower oil have a 
high content of the essential w-6 PUFA a-linoleic acid (C18:2w-6), the parent FA of 
the w-6 family and a precursor of arachidonic acid (20:4w- 6). As much as 25% of 
the FA in plasma membranes of immune cells is arachidonic acid. The major w-3 FA 
in plants is the parent FA of the w-3 family, a-linolenic acid (C18:3w-3).
Eicosanoids are 20-carbon endogenous biochemical mediators derived from both 
the w-3 and w-6 FA families. The w-6 parent linoleic acid gives rise to the dienoic or
2-series of prostanoids (prostaglandins, prostacyclins and thromboxanes) and
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leukotrienes of the 4-series. These are all known inducers of inflammation or immune 
suppression. In contrast, w-3 FA in the eicosanoid cascade give rise to the trienoic or
3-series of prostanoids and leukotrienes of the 5-series, which are less inflammatory 
and immune suppressive [6]. Absorbed PUFA interact with FA-binding proteins 
within cell membranes and cytoplasm and are processed in the endoplasmic reticulum 
(desaturation-elongation reactions, lipid synthesis, eicosanoid and epoxide 
production) and in peroxisomes (P-oxidation, synthesis, oxidation products). PUFA 
interact with receptors, ion channels, and nuclear elements, resulting in modulation of 
gene expression, as well as local and systemic inflammatory disease activity [7].
Some ten years after the introduction of TPN another emulsion type became 
available that is based on a physical mixture of 50% long- and 50% medium-chain 
triglycerides (LCT/MCT, such as Lipofundin® or Vasolipid®). Because pure MCT 
emulsions contain no EFA, LCT/MCT emulsions contain less w-6 PUFA compared 
with pure LCT. The MCT component, containing saturated FA with a carbonchain- 
length of 6 to 12 atoms is derived from palm kernel or coconut oil. A new LCT/MCT 
formulation (Lipofundin E®), enriched with a-tocopherol (a vitamin E isoform) has 
replaced the original Lipofundin formulation in The Netherlands in 1998.
Structured lipids (SL), i.e. synthetic lipids made by random enzymatic 
transesterification of the FA in the 1,3 position of the triglyceride, represent a new 
generation of fat emulsions that may be clinically advantageous compared to 
conventional LCT emulsions, and to LCT/MCT [8-11]. The most used structured 
lipid emulsion, Structolipid®, contains 63% long-chain fatty acids (LCFA) and 37% 
MCFA .
A number of novel emulsions with supposed beneficial effects on the incidence of 
cardiovascular and auto-immune diseases, based on fish-oil (such as Omegaven®, 
rich in w-3 PUFA eicosapentanoic (EPA, C20:5w-3) and docosahexanoic acid (DHA, 
C22:6w-3)) and olive oil (such as Clinoleic®, a 80:20 mixture of olive oil and 
soybean oil, rich in the w-9 mono-unsaturated FA (MUFA) oleic acid (C18:1w-9)), are 
currently becoming available for clinical practice [12-17].
3.1.4 Emulsifiers and anti-oxidants in lipid emulsions
Lipids have to be made water-soluble to be transported in the blood after intra­
venous administration. This is established by means of an emulsifier that is usually 
derived from egg-yolk (Lipofundin®, Intralipid®, Emulsan®, Endolipid®) or soybean 
phospholipids (Lipofundin-S®). The type of emulsifier in LCT emulsions 
(Lipofundin-S® compared with Intralipid® and Emulsan®) has been shown not to 
influence human neutrophil function [18].
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The content of several antioxidants in lipid emulsions, especially various 
tocopherol isoforms, is highly variable and sensitive to storage conditions [19]. 
Concerns have been raised that the content of a-tocopherol in LCT emulsions may be 
inadequate to meet patients’ requirements, when compared with LCT/MCT (See also 
Table 1) [20,21].
3.1.5 Metabolic effects and - complications o f intravenous lipid emulsions
LCT-emulsions have been extensively used in clinical practice since the 
introduction of TPN, over three decades ago, and have been shown to be safe and 
well tolerated [22-25]. However, concerns have also been raised. LCT administration 
potentiates endotoxin-induced coagulation activation, suggesting that the emulsion 
might induce thrombotic complications in patients with infections [26]. Furthermore, 
infusion of LCT emulsions results in accumulation of EFA, such as a-linoleic acid, 
reduction of w-6 and w-3 long-chain FA in membranes, as well as anti-oxidant (a- 
tocopherol) depletion [16]. The use of LCT has also been associated with the 
development of acute respiratory events, possibly due to fat overload [27]. In this 
respect it is interesting to note that LCT agglutinate with lipoproteins: an interaction 
that may be relevant in the pathogenesis of fat embolism [28]. Finally, LCT 
emulsions induce endothelial damage and platelet adherence, which may eventually 
result in atherosclerosis [29].
MCT have since long been advocated as a superior substrate for parenteral use 
compared to LCT because of special physicochemical properties, such as low 
molecular weight and increased solubility in biological fluids. As a result, the 
metabolic pathways of MCT are simpler and more rapid when compared with LCT 
[30]. Also, because their metabolism is carnitine-independent, MCT appear to be a 
superior energy source in clinical situations where carnitine is in the subnormal 
range.
However, despite the supposed advantages, pure MCT are less well tolerated than 
LCT in clinical practice. This is mainly because the metabolic breakdown of MCT 
generates more ketone bodies, thus carrying the risk for the development of acidosis. 
It also has to be considered that EFA, which are all LCT, are not provided by pure 
MCT. Therefore, only physical mixtures of LCT and MCT (LCT/MCT) can be used 
in humans [1,31,32].
In accordance with the metabolic concepts described above, LCT/MCT has been 
shown to be cleared and deliver energy more rapidly, to induce less hyperlipidemia, 
and to interfere less with linoleic acid metabolism than pure LCT [5,33-37]. Also, 
LCT/MCT seemingly does not impair liver or pulmonary function [38]. The safety of 
and tolerance to LCT/MCT have been demonstrated in severely ill, malnourished 
patients [39-42]. The same authors also evaluated LCT/MCT and LCT in 
malnourished patients on long-term TPN, and found no adverse clinical effects with
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any emulsion [43]. In studies comparing LCT/MCT and LCT in critically ill patients, 
neither emulsion induced coagulation disorders [44,45].
Advantages of LCT/MCT over LCT have been reported in surgical patients, with 
improved protein metabolism, reduced weight loss and less fatty infiltration and 
enlargement of the liver [46-48]. However, other authors could not confirm these 
findings, and disadvantages of LCT/MCT over LCT (induction of higher insulin 
concentrations and increased plasma fatty acids concentrations) have also been 
reported [41,49-51].
In line with the original metabolic and biochemical concept, structured lipids 
revealed no side effects, were cleared rapidly from the plasma compartment, were 
rapidly oxidized without hyperlipidemia or ketosis, and increased whole body fat 
oxidation in stressed postoperative patients when compared to LCT [8,9,11]. A study 
on the biodistribution of radioactively labeled emulsions showed that emulsions with 
MCFA in the 1,3 position were removed slower from the blood circulation than those 
with LCFA in the 1,3-position [10]. This implies that the type of core material 
influences the in vivo circulation time of fat emulsions. Positive effects of SL- 
containing TPN have been observed in studies regarding liver morphology where 
livers of structured lipid and LCT fed rats showed less steatosis than those of lipid­
free and MCT groups [52,53].
The rationale for supplementation of w-3 FA-containing fish oil (FO) lies in the 
anti-inflammatory effects of these lipid compounds. First evidence for the importance 
of dietary intake of FO has been derived from an observation of the low incidence of 
inflammatory bowel disease in Eskimos [54]. Also, FO has been shown to reduce 
plasma triglyceride concentrations and to prevent the hyperlipidemia and fatty 
infiltration of the liver seen during sepsis [55,56]. Positive effects of FO 
supplementation on the clinical course in patients with various auto-immune diseases 
have been confirmed and probably result from altered eicosanoid synthesis and 
chemotactic responsiveness of neutrophils through inhibited signal transduction [57­
59]. This might explain the finding that administration of parenteral FO in guinea 
pigs improved survival to endotoxin [60]. Also, a favorable course with respect to 
metabolic complications has been observed in FO-treated animals in response to 
bacterial endotoxin when compared with LCT [61]. Finally, reported inhibitory 
effects on colon tumor growth of FO need confirmation [62].
Positive effects of structured lipids synthesized from FO and MCT over pure LCT 
have been demonstrated in rat cancer and burn models in the form of inhibited tumor 
growth and improved maintenance of body weight and nitrogen balance, indicating 
that dietary fat composition can influence tumor protein kinetics [63-65].
Olive oil (OO) emulsions appears to be another safe and well tolerated lipid source 
that maintains normal EFA status, and may prevent lipid peroxidation better than a 
soybean emulsion despite a slower elimination [66,67].
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3.1.6 Lipid peroxidation
Lipid emulsions used in TPN are prone to peroxidation, which is a feature of 
oxygen-associated tissue damage. Incubation of LCT with hydrogen peroxide and 
FeCl2 increased lipid peroxidation, measurable as increased production of pentane 
and malondialdehyde. In line with this evidence, LCT has been shown to increase 
pentane production in expired breath in pre-term infants, partly due to pentane 
dissolved in LCT as a result of lipid peroxidation during storage. This indicates that 
LCT undergoes peroxidation, thus causing free-radical-dependent damage to human 
cells [68]. When LCT, LCT/MCT and SL were compared in the presence of 
stimulated neutrophils, lipid peroxidation increased with all emulsions. Furthermore, 
a-tocopherol prevented this phenomenon in a concentration-dependent manner [69].
3.1.7 Effects o f parenteral admixtures and lipid emulsions on microbial growth
Because of the apparent risk for infectious complications, lipid emulsions have 
been evaluated for their potential to support microbial growth [70-75]. The fungal 
pathogen Candida albicans as well as Gram-negative and -positive microorganisms 
have been shown to multiply in LCT at room temperature [75]. Soybean and 
safflower oil LCT emulsions have displayed no differences in growth patterns of 
Gram-negative, Gram-positive, and yeast pathogens due to the nature of the oil or its 
concentration [73]. However, other investigators found that only C. albicans 
demonstrated significant growth regardless of fat content [71].
Microbial growth rates in TPN admixtures, which are hypertonic and more acidic, 
would be expected to be lower than those in lipid emulsions, which are isotonic and 
have a neutral pH [71]. Indeed, while many organisms seem to grow well in a lipid 
emulsion, they often die or grow only minimally in lipid-free or lipid-containing TPN 
formulation [72]. Only C. albicans appears to grow in all formulations. At an initial 
inoculum of 10 CFU/ml, approximating touch contamination, growth of Candida in 
lipid-free and combined formulations has been shown to be less than 1 log after 24 
hr. In contrast, 10% LCT displayed a growth greater than 2 log at 24 hrs. This 
indicates that a 24-hr infusion period is safe for the evaluated combined TPN 
formulation [72].
3.2. Lipid emulsions and infectious complications: clinical studies
The use of TPN has since long been associated with an increased risk for infectious 
complications. Apart from catheter-related problems this has been attributed to 
immune suppressive effects of the applied lipid emulsion, which in most studies was 
the LCT emulsion Intralipid [76,77]. Especially the incidence of infections related to 
dysfunction of the phagocyte system, such as pneumonia and wound infections, 
appeared to be increased.
Several studies yielded additional evidence for the existence of a relation between 
infectious complications and the use of lipid emulsions. In critically ill infants,
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Staphylococcal bacteremia occurred nearly six times more often when compared to 
controls in case intravenous lipids (LCT) were administered [78,79]. Nearly 60% of 
all cases of bacteremia could be attributed to lipid administration. Interestingly, the 
average induction time for bacteremia after lipid administration was less than one 
day, compared to over 5 days for bacteremia associated with central-venous catheter 
use. Prolonged LCT administration has also been shown to be a risk factor for the 
development of fungal (mostly Candida) colonization in very low birth weight infants 
[80]. A retrospective study revealed that of all patients receiving TPN, 5.2% 
developed candidemia, with a mortality rate of 34% [81]. A rare complication of 
lipid-based TPN administration is fungemia with Malassezia furfur. This lipid- 
dependent organism requires high lipid concentrations to proliferate and causes 
pulmonary infections and thrombopenia [82,83].
The evaluation of the effects of various lipid emulsions on complication rates is 
extremely complex due to the large number of variables that may influence study 
outcomes, such as patient category, the type of surgery that is performed, pre- and/or 
post-operative feeding, period of feeding etc. When the effect of peri-operative 
LCT/MCT-based TPN in addition to an oral diet in cancer patients was compared to 
an oral diet alone, a decreased morbidity and infectious complication rate was 
observed [84]. In contrast, a placebo-controlled trial using preoperative LCT- 
containing TPN in malnourished surgical patients showed no different infection rates 
[85]. The question whether the emulsion type affects the infectious complication rate 
has been addressed in a study comparing LCT to LCT/MCT in critically ill patients 
who were in need of TPN. Neither toxic nor infectious or metabolic complications 
were encountered in either group, nor was there evidence for an advantageous effect 
of LCT/MCT over MCT [86].
When glucose- and LCT-based TPN, administered after bone-marrow 
transplantation, were compared, the incidence of graft-versus-host disease was 
lowered in the lipid group, indicating immune suppression. However, survival also 
tended to be higher in the lipid group, while rates of infectious complications were 
not different [87]. Another study in bone-marrow transplant recipients, comprising 
more than five hundred patients with an observation period up to 2 months, compared 
6-8% (low dose) to 25-30% (standard dose) of total daily energy given as a 20% LCT 
emulsion. No differences in incidence of bacteremia, fungemia or time to first 
infection were observed, suggesting that moderate amounts of lipid are not associated 
with an increased infection risk in this patient category [88]. Malnourished AIDS 
patients receiving lipid-based TPN gained weight and showed an improved activity 
level and immune status as indicated by lymphocyte mitogen responses [89]. In 
surgical cancer patients, FO/MCT-derived structured lipids have been shown to 
reduce the number of infectious complications, possibly due to an altered eicosanoid 
production by PBMC [90].
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3.3 Lipid emulsions and immune system function: in vitro and in vivo studies
3.3.1 Effects o f lipid emulsions on neutrophil effector functions
3.3.1.1 Adhesion
Only a few studies are available that evaluate the effects of lipids on leukocyte 
adhesion. In TPN patients, the expression of adhesion molecules L-selectin (CD62L) 
and ß2 integrins (CD11a/CD18, CD11b/CD18 and CD11c/CD18) has been shown not 
to be influenced by 24-h administration of LCT [91]. This is supported by findings in 
an animal study evaluating macrophage expression of adhesion molecules under 
influence of orally administered emulsions rich in w-6 or w-3 PUFA [92]. On the 
other hand, increased neutrophil adherence induced by the w-3 PUFA DHA and EPA 
has been shown in vitro [93]. Here, flowcytometric analysis revealed up-regulation of 
the complement C3bi receptor (CD11b), while saturated fatty acids of the same chain 
length were without effect.
Studies regarding the effects of structurally different emulsions, such as LCT/MCT 
and SL, on leukocyte adhesion are lacking. The same applies for the evaluation of 
actual neutrophil adhesion rather than the expression of adhesion molecules on the 
cellular membrane, under the influence of lipids.
3.3.1.2 Migration
Although numerous studies have focused on the influence of lipid exposure on 
leukocyte migration, the overall picture remains unclear (See Table 2) [22,85,94­
111]. Possible explanations for the conflicting outcomes of various studies are 
multiple, such as differences in lipid formulations and concentrations, as well as 
different techniques to assess leukocyte migration and the inclusion of human 
volunteers versus patients or animals.
Lipid effects may also differ in investigations with an in vivo design, in which 
lipids are administered intravenously with subsequent evaluation of the migration of 
isolated leukocytes, compared to in vitro studies in which leukocytes are isolated 
from whole blood before lipid incubation.
In human studies, LCT has been shown to have detrimental effects on neutrophil 
migration in some but not all in vitro studies [94,96, 97, 99,102,104,106]. This 
controversy remains after several in vivo studies [22,85,94,95,100,101,103, 105]. In 
contrast, increased neutrophil migration after LCT administration has also been 
reported in neonates, both in the in vivo and the in vitro setting [98,99].
That lipid effects on cellular motility may depend on the leukocyte type under 
investigation has been shown in a study in which LCT increased monocyte migration, 
whereas neutrophil chemotaxis decreased [94]. Others found that soybean- and 
safflower-derived LCT emulsions both decrease neutrophil migration. However,
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when the emulsions were dialyzed against a physiological saline solution these 
effects were abolished, suggesting that the inhibiting factor is either dialyzable or 
neutralized by saline [97].
Structurally different lipids display distinct effects on cell migration, as was 
exemplified in an in vitro study where LCT/MCT and MCT, contrary to LCT, 
significantly decreased random neutrophil migration and chemotaxis [109]. In 
contrast, others observed no effects of LCT/MCT in vivo [112]. Decreased migration 
in vitro and unaffected mobility in vivo have also been reported for LCT/MCT in 
animal studies [110,111].
Underlying diseases and the nutritional status in a patient population are additional 
factors that may cause conflicting results. It has been demonstrated that LCT 
administration in patients with Crohn’s disease did not alter neutrophil migration, 
whereas in volunteers increased migration was observed [100]. In cancer patients 
neutrophil migration also appeared not to be inhibited by LCT [103]. In malnourished 
cancer patients after 48h-infusion of lipid-based TPN containing LCT or LCT/MCT, 
no changes in migration of neutrophils and monocytes were observed, compared to 
lipid-free TPN [108].
Conflicting results have not been limited to human studies. Intravenous 
administration of LCT in septic and non-septic rats depressed neutrophil and 
monocyte chemotaxis in both categories in one study, whereas others found that LCT 
had no effect. In contrast, MCT clearly inhibited chemotaxis [107,110]. To make 
matters even more complicated, parenteral administration of either emulsion left 
neutrophil motility unaffected in a study in rats [110,111].
3.3.1.3 Phagocytosis
The discussion on the numerous variables that may contribute to the conflicting 
results described in the previous section on migration also applies for neutrophil 
phagocytosis and reticulo-endothelial system (RES) function (See Tables 3 and 5) 
[94, 97,101,106,108, 110,111,113-120].
With respect to lipid effects on neutrophil phagocytosis, a somewhat more uniform 
picture emerges, as the phagocytotic capacity in most human and animal studies 
appears to be decreased in vitro by LCT, whereas in vivo no effects were observed 
[94,97,101, 108,110,111,113,116]. An inhibitory effect of LCT on bacterial 
clearance, with increased bacterial virulence, has been reported, suggesting that LCT 
might enhance the risk of bacterial sepsis [106]. Also, depressed phagocytosis, 
oxygen radical production and Fc-receptor expression have been observed after 
exposure of neutrophils to LCT [115]. However, when LCT was added at the start of 
the assays, microbial ingestion increased, indicating that LCT might act as a 
particulate stimulus that eventually exhausts cellular metabolism and effector 
functions.
When LCT/MCT was compared with LCT in vivo in cancer patients, phagocytosis 
remained unaffected with either emulsion, whereas in vitro the MCT emulsion
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displayed a detrimental effect [108,114]. In contrast, these investigators have found 
rat leukocyte phagocytosis with LCT to be decreased in vivo, when compared with 
LCT/MCT [119].
3.3.1.4 Microbial killing capacity and oxygen radical production
For an overview of studies regarding neutrophil microbial killing capacity and 
oxygen radical production under influence of lipid emulsions see Table 4 [69, 94,96­
101,108,110,113,114,121 122]. Neutrophil oxygen radical production has been 
shown to be dose-dependently and equally decreased by LCT, LCT/MCT and SL in 
vitro [69]. LCT also depresses LPS-induced radical production and degranulation of 
neutrophils, indicating that LCT might substitute for plasma HDL, a known inhibitor 
of LPS effects in Gram-negative infections [121,125]. As mentioned previously, most 
in vitro human studies regarding LCT effects on killing and oxygen radical 
production indicate inhibited neutrophil functions [97,113,121]. However, others did 
not establish such in vitro LCT effects [96,99,114,123].
In vivo LCT effects in humans vary from inhibition to increased function and absence 
of any effect [96,100,101.108,113,123].
That MCT activate neutrophils was suggested in a study in which LCT/MCT and 
MCT, compared with LCT, increased oxygen radical production, while after lipid 
removal decreased responses and decreased microbial killing were observed [114]. 
An in vitro study in rats, by the same investigators, demonstrated that MCT inhibited 
bacterial killing, in contrast with LCT. However, parenteral administration of both 
lipids in rats did not affect bacterial killing [110]. LCT/MCT has been shown to 
induce faster stimulus-induced production of oxygen radicals by isolated human 
neutrophils, also resulting in an increase in maximum rate of radical production, 
compared with long-chain or structured triglycerides [126]. In cancer patients a 
moderate effect of LCT on neutrophil bacterial killing has been observed, while 
LCT/MCT showed no effects [108].
When the effect of various emulsions on oxygen radical production of human 
neutrophils was compared in vitro, both FO and LCT suppressed radical production, 
while LCT/MCT increased the respiratory burst. The influence of lipids and FA on 
this neutrophil function appeared to be more pronounced with increasing carbon 
chain length and increasing numbers of double bonds [15,127].
3.3.2 Effects on mononuclear cells and reticulo-endothelial system function
Table 5 provides an overview of studies regarding mononuclear cell functions 
under the influence of parenteral lipid emulsions [13,85,87,105,124,128-155].
3.3.2.1 Lymphocyte functions
Lymphocyte functions can be investigated by measuring the production of humoral 
immune mediators (immunoglobulins for B-lymphocytes and cytokines for T- 
lymphocytes, respectively), as well as by evaluating cell proliferation in response to
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stimuli (mitogens), which mostly are plant lectins, such as pokeweed, Concanavalin 
A (Con-A) or phytohaemagglutinin (PHA). Regarding lymphocyte proliferation 
under the influence of LCT emulsions, the studies that reported detrimental effects 
outnumber those that found no, or even positive effects [85,87,105,124,129,130, 132­
137,139,140,142,145,149,150,153]. That the mitogen with which lymphocyte 
proliferation is evaluated is of importance has been suggested in a study in which 
pokeweed-induced responses were diminished in the presence of LCT, while PHA-, 
and Con-A-induced responses remained unaltered [156].
With respect to cytokine production, especially œ-6 PUFA in pure LCT emulsions 
have been associated with depressed lymphocyte functions due to altered eicosanoid 
metabolism (increased production of prostaglandins of the 2-series and leukotrienes 
of the 4-series) [157]. In surgical cancer patients, LCT has been shown to increase 
postoperative anti-inflammatory cytokine (IL-6) levels while decreasing lymphocyte 
proliferation rates, suggesting an amplified stress response and immune suppression 
[141]. Others found that LCT also dose-dependently inhibited human LPS-induced 
pro-inflammatory cytokine (TNF-a) production, whereas a murine in vitro study 
suggested that LCT might interfere with antiviral immunity because of decreased 
cellular cytotoxicity and Fc-receptor expression [134,153]. Furthermore, LCT 
inhibited the production of IL-2 and abolished the responsive capacity of an IL-2- 
dependent cell line, suggesting interference with receptor binding [132]. With regard 
to B-cell function, LCT has been shown to decrease immunoglobulin production at a 
physiological triglyceride concentration [150].
Emulsion effects may depend on triglyceride structure, with altered lymphocyte 
proliferation and cytokine production depending on lipid concentration, degree of 
unsaturation and carbonchain-length [158]. A decreased ratio of helper to suppressor 
T-lymphocytes in response to LCT, but not LCT/MCT administration has been 
observed in volunteers and patients [145]. In AIDS patients, LCT, when compared 
with LCT/MCT, induced abnormalities in lymphocyte function [142]. In another 
study, LCT, LCT/MCT and MCT emulsions all inhibited human lymphocyte 
proliferation in a dose-dependent manner. Here, LCT, but not LCT/MCT, inhibited 
the generation of LAK cells [129]. On the other hand, other investigators found that 
MCT inhibit LAK cell function more strongly than LCT [148]. With respect to 
cytotoxic effects against tumor cells, in a human study MCT showed more effects 
than LCT, whereas in animals MCT, but not LCT, increased metastatic disease [159].
Many investigators have not observed inhibitory effects of lipids on PBMC 
function. For instance, intravenous LCT administration in humans did not influence 
some inflammatory responses (fever, TNF-a release, leukocytosis), and even 
potentiated others (IL-6 and -8 release, neutrophil degranulation) [4,153]. Similarly, 
in malnourished surgical patients LCT left immunoglobulin levels and PBMC 
populations normal, while lymphocyte counts and mitogenic responses were and
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remained depressed [85]. In a rat study, LCT did not alter lymphocyte proliferation or 
cytokine (IFN-y, IL-2, IL-4) production [139,160]. LCT displayed similar effects on 
T-lymphocyte subsets as lipid-free TPN or LCT/MCT in surgical cancer patients 
[149]. Also in cancer patients, LCT and LCT/MCT did not evoke alterations in 
immunoglobulins, lymphocyte proliferation or cytokine (IL-1, IL-6, TNF-a) levels 
compared to placebo [84,161].
When OO and LCT were compared for immune modulating effects, LCT 
decreased lymphocyte responses and cytokine (IL-2) production, whereas OO 
showed no inhibitory effect. All emulsions tended to inhibit to a similar extent the 
release of pro-inflammatory cytokines (TNF-a and IL-1P), suggesting that OO 
maintain protective immunity while reducing the inflammatory response [13]. OO 
thus may offer an immune-neutral alternative to soybean oil for use in parenteral lipid 
emulsions [162]. When compared with LCT, OO has also been shown to increase the 
expression of the IL-2 receptor a-chain (CD25) [12]. In this study the differences in 
PUFA, especially linoleic acid (OO emulsion 18% versus 52% in LCT) were held 
responsible for the effects on lymphocytes.
With respect to the effects of FO, the œ-3 PUFA a-linolenic acid (18:3œ-3) has 
been shown to suppress lymphocyte and NK cell functions [163]. Accordingly, 
enteral FO (œ-3) supplementation has been shown to reduce pro-inflammatory 
cytokine production in cancer patients [154,164]. Effects of intravenous FO 
administration on mononuclear cell functions also indicate immune suppression, 
resulting in prolonged graft survival after organ transplantation [133,138,146,147]. It 
appears that FO and LCT both are immune-suppressive when applied as the main FA 
source. However, the more balanced the œ-3 to œ-6 ratios, the less 
immunosuppressive the fat emulsion, with no effect at a œ-3/œ-6 ratio of 1:2.1 
[138,165-167].
3.3.2.2 Monocyte and reticulo-endothelial system functions
Monocyte oxygen radical production has been shown to be increased by LCT in 
vivo in man and pig [94,124]. In pigs, LCT also increases oxygen radical production 
by PBMC and alveolar macrophages (MP) [124]. In this respect, it is interesting to 
note that the formation of lung granulomas, indicating cell activation, has been 
reported in pigs on TPN [168]. Direct effects on PBMC and alveolar MP and altered 
membrane function, due to a-linoleic acid enrichment, were considered tentative 
explanations for the raised cell responses. MP have been shown to ingest lipid 
droplets after in vitro incubation with LCT and after central venous administration 
[169]. Typically, intravascular lipid accumulation took place in lungs and liver, were 
MP increased in size and number. Lipid uptake might activate MP and thereby play a 
role in lung tissue inflammation seen in response to lipid-based TPN in pigs. Similar 
findings have been reported in rats, where lipids recruited pulmonary MP, indicating 
a stimulatory effect on the RES [170].
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In contrast with the findings above, others reported in human and animal studies 
that LCT suppressed monocyte chemotaxis [105,107]. The mechanism behind the 
observation that subcutaneous injection of heparin prevented this effect remains 
unclear so far. In animal studies, LCT has been shown to inhibit MP phagocytosis 
and peritoneal microbial clearance, together with increased bacterial dissemination 
[117,119,171].
RES dysfunction, reflected by increased microbial accumulation in lungs and 
spleen following intravenous administration of LCT has been demonstrated in rabbits 
[118]. When the effects of SL and LCT/MCT were compared in rats, SL relatively 
improved RES function [120].
Intravenous treatment of human monocytes with LCT has been shown to result in 
increased TNF-a production compared with LCT/MCT, while LCT/MCT induced 
higher IL-6 release than LCT [152]. In malnourished patients receiving TPN, LCT 
increased monocyte TNF-synthesis, while no differences in the LCT/MCT group 
were detected. The latter is considered beneficial in seriously ill patients [144]. That 
LCT/MCT may better support RES function compared to LCT has been suggested in 
a study in which LCT increased the level of bacteremia and decreased sequestration of 
exogenous bacteria to the liver and the lung than with LCT/MCT [172]. In contrast with 
MCT, LCT seem to impair RES function due to decreased clearance and accumulation 
of LCT in the liver, while feeding MCT stimulated the lung uptake of Technetium 
Sulfur Colloid [173].
In a study in surgical patients comparing LCT/MCT and structured lipids, it 
appeared that both MCFA-containing emulsions did not suppress RES function as 
measured by Technetium-colloid clearance [174]. A study on the effects of structured 
lipids and LCT/MCT in rats revealed that structured lipids increased sequestration of 
bacteria in liver and spleen compared to LCT/MCT, indicating better RES function 
[120].
While information on parenteral supplementation is lacking, oral administration of 
FO to rats has been shown to alter MP membrane fluidity, diminish antigen 
presentation by dendritic cells and decrease TNF-binding affinity [175,176].
3.4 Conclusions
So far, despite the conflicting data described above, most authors agree that there is no 
justification for withholding intravenous lipids to patients, because they effectively 
provide essential fatty acids with a high caloric content when administered in the 
recommended dosage [177]. An improvement in the immune response capacity is noted 
along with an improved nutritional status. From comparative studies aimed at evaluating 
the effect of structurally different lipid emulsions on the components of the immune 
system, it is too early to say whether their use will lead to significant clinical
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repercussions [178]. Future studies are needed to define the adequate composition of 
lipid emulsions in different clinical situations.
Table 1. Composition and characteristics of lipid emulsions according to a manufacturer or b investigator 
[19]. NA = none added NIA = no information available
L C T
Intralipid
L C T /M C T  (-E)
Lipofundin (E) °
SL
Structolipid
M C T
Fractionated soy bean oil (g/l) 200 100 0 0
Medium-chain triacylglycerols (g/l) 
Fatty acid (% w/w o f total)
0 100 0 200
caproic acid (C6:0) - 0.5 0.1 < 2 %
caprylic acid (C8:0) - 28.5 23.4 50-63 %
capric acid (C10:0) - 20 10.4 36-47 %
lauric acid (C12:0) - 1 0.2 < 2 %
palmitic acid (C16:0) 9 6.5 7.5 -
stearic acid (C18:0) 5 2 3.2 -
oleic acid (C18:1) 25 11 16.2 -
linoleic acid (C18:2) 55 26 33.3 -
a-linolenic acid (C18:3) 8 4 4.2 -
arachidonic acid (C20:4) 1 0.5 - -
structured triacylglycerols (g/l) 0 0 200 0
mean molecular triglyceride weight 865 634 683 505
fractionated egg phospholipids (g/l) 12 12 12 12
glycerol (g/l) 22.5 25 22.5 20
tocopherol (mg/l): a 8.8 a 16.9b 50a (200) 21.8b NIAa NAa
P NIAa 4.3b NIAa NIAb NIAa NAa
8 43.1 a 119.8b NIAa 53.9b NIAa NAa
Y 84.4a 44.3b NIAa 27.9b NIAa NAa
pH 8.0 6.5-8.5 6.5 - 8.5 8.0
LCT: long-chain triglycerides
LCT/MCT: physical mixture o f long-chain and medium-chain triglycerides 
LCT/MCT-E: vitamin-E-enriched LCT/MCT 
SL: structured lipids
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Table 2: Effects o f lipids on leukocyte migration (cells other than neutrophils are indicated) 
p: patients; v: volunteers; T: increase; = no effect; ¿: decrease
Author [ref] Subjects Design Lipid (time) Outcome
W iernik [94] Human v in vivo LCT (2 h) monocyte T
in vitro neutrophil i
Nordenstrom [95] Human v in vivo LCT (2 h) i
in vitro after 22h: =
W heeler [96] Neonate + Adult in vitro LCT =
English [97] Human v in vitro LCT i
after dialysis: =
Usmani [98] Neonate in vivo LCT
Single dose (4 h) Single dose: =
Long-term (2-6 wk) Long-term: T
Usmani [99] Adult in vitro LCT (30 min) adult =
Neonate neonate T
Palmblad [100] Human v+p in vivo LCT (< 12 wk) volunteers T
Crohn pts: =
Rasmussen [101] Human v in vivo LCT =
Kohelet [102] Neonate in vitro LCT (30 min) =
Escudier [103] Human p in vivo LCT (6 h) =
Herson [22] Neonate + Adult in vivo LCT (16 h) =
in vitro
Ota [83] Human v in vivo LCT =
M archand [104] Human v in vitro LCT i
Fraser [105] Human v in vivo LCT monocyte i
Fisher [106] Human v in vitro LCT i
Chen [107] Rat in vivo LCT monocyte i
neutrophil i
W aitzberg [108] Human p in vivo LCT; LCT/MCT monocyte =
(48 h) neutrophil: =
Bellinati [109] Human p in vitro LCT, LCT/MCT LCT: =
(30 min) LCT/MCT: i
W aitzberg [110] Rat in vivo LCT; LCT/MCT in vivo: all =
in vitro in vitro: LCT =
LCT/MCT: i
W aitzberg [111] Rat in vivo LCT; LCT/MCT =
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Table 3. Effects o f lipids on phagocytosis and reticulo-endothelial system function 
(cells other than neutrophils are indicated) 
p: patients; v: volunteers; T: increase; = no effect; ¿: decrease
Author [ref] Subjects Design Lipid (time) Outcome
Jarstrand [113] Human p in vivo LCT RES function =
in vitro
W iernik [94] Human v in vitro LCT (30 min) monocyte T
neutrophil i
W aitzberg [108] Human p in vivo LCT; LCT/MCT monocyte =
(48 h) neutrophil =
Bellinati [114] Human v in vitro LCT; LCT/MCT LCT: =
LCT/MCT i
English [97] Human v in vitro LCT (30 min) i
normalized after dialysis
Rasmussen [101] Human v in vivo LCT =
Cleary [115] Human v in vitro LCT i
W aitzberg [110] Rat in vivo LCT; LCT/MCT in vivo: all =
in vitro in vitro: all i
Fisher [106] Mice in vivo LCT bacterial clearance i
W aitzberg [111] Rat in vivo LCT; LCT/MCT =
Nishiwaki [116] Rat in vivo LCT Kuppfer cells =
Nugent [117] Mice in vivo LCT Bacterial clearance i
in vitro macrophage i
Kelbel [118] Rabbit in vitro LCT RES function i
Cukier [119] Rat in vivo LCT; LCT/MCT LCT: monocyte i
macrophage i
Pscheidl [120] Rat in vivo LCT/MCT; SL RES function with
SL > LCT/MCT
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Table 4. Effects of lipids on microbial killing and oxygen radical production (ORP) by leukocytes 
(cells other than neutrophils are indicated)
p: patients; v: volunteers; T: increase; = no effect; decrease
Author [ref] Subjects Design Lipid (time) Outcome
Jarstrand [121] Human v in vitro LCT ORP i
Jarstrand [113] Human p in vivo LCT ORP, killing i
in vitro ORP, killing i
W iernik [94] Human v in vivo LCT (2h monocyte ORP T
W aitzberg [108] Human p in vivo LCT; LCT/MCT monocyte: ORP, killing =
neutrophil: ORP, killing i
Bellinati [114] Human v in vitro LCT ; LCT/MCT LCT: ORP =
LCT/MCT: ORP T
Hawley [122] Human v in vitro oleic acid killing =
palmitic acid killing i
Robin [123] Human p in vivo LCT (4 h) ORP i
p in vitro ORP =
v ORP =
W u [17] Human v in vitro LCT;LCT/MCT; all: ORP i
SL
English [97] Human v in vitro LCT (30 min) ORP i
normalized after dialysis
Palmblad [100] Human v in vivo LCT (< 12 wk) patients: killing, ORP =
Crohn p+v volunteers: ORP T
Rasmusen [101] Human v in vivo LCT killing, ORP =
Usmani [98] Neonate in vivo LCT (4 h) single dose: ORP =
(2-6 wk) longterm: ORP T
Usamani [99] Neonate in vitro LCT (30 min) ORP =
Adult
W heeler [96] Neonate in vivo LCT (24 h) ORP =
in vitro ORP =
Aksnes [124] Pigs in vivo LCT NBT monocyte, alv macr T
W aitzberg [110] Rat in vivo LCT in vivo: all: killing =
in vitro LCT/MCT in vitro: MCT: killing i
LCT =
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Table 5. Effects o f lipids on mononuclear cell activity (for abbreviations: see page 225) 
p: patients; v: volunteers; T: increase; = no effect; ¿: decrease
Author [ref] Subjects Design Lipid Outcome
Sedman [128] Human p in vivo LCT NK =, LAK i ,  IL-2 (T-lymph) T
LCT/MCT NK and LAK T
Sedman [129] Human v in vitro LCT LCT>LCT/MCT: L P i, LAK i
MCT, LCT/MCT IL-2-dependent cell growth i
Calder [130] in vitro 2 emulsions L P i
Aksnes [124] Pigs in vivo LCT PBMC and M P activity T, LP T
Ota [83] Human p in vivo LCT LP i  pre-TPN, not TPN-improved
Sirota [132] Neonate in vitro LCT IL-2 i  in preterms, not adults
Adult IL-2-responses abolished with LCT
Grimminger [133] Rat in vivo œ-3,œ-6 transplant survival T with w-3
Loo [134] Mice in vivo LCT ADCC i ;  Fc expression i
Ladisch [135] Human v LCT LP i
Monson [136] Human p in vivo LCT ADCC, T-lymphocytes, IL-2 T
Da Pont [137] Human v in vivo LCT ratio helper to suppressor T-cells =
Grimm [138] Rat in vivo œ-3,œ-6 allograft survival T (w-6/w-3 ratio)
Chen [139] Rat in vivo LCT LP =
Francis [140] Human p both LCT LP i
Fraser [105] Human p,v in vivo LCT LP =, monocyte chemotaxis i
Furukawa [141] Human p in vivo LCT IL-6 T, NK i
Gelas [142] Human p in vivo LCT; LCT/MCT LCT: L P i; LCT/MCT LP =
Gogos [143] Human p in vivo LCT; LCT/MCT TNF-a: LCT T, LCT/MCT =
Gogos [144] Human v in vivo LCT TNF-a: LCT T
Gogos [145] Human p,v both LCT; LCT/MCT Th/Ts i  with LCT; with LCT/MCT=
Grimm [146] Rat in vivo œ-3/œ-6 œ-3 and œ-6 immune suppressive
œ-3/œ-6 = 1/2 is immune neutral
Hayashi [147] Rat in vivo œ-3/œ-6 w-6 IL-6, IL-8, IL-10 T; w-3 =
Kimoto [148] Human v in vitro LCT; LCT/MCT LCT/MCT: LAK i
Muscaritoli [87] Human v in vivo w-6 Graft versus host disease i
Rodriguez [149] human p in vivo LCT; LCT/MCT T-lymphocyte subsets =
Salo [150] Human v in vitro LCT B-lymphocyte function i
Strunk [151] Guinea pig in vitro LCT MP function i
Tufano [152] Mice both LCT; LCT/MCT LCT: T N F-a T; LCT/MCT: IL6 T
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Table 5 (continued).
Author [ref] Subjects Design Lipid Outcome
Granato [13] Human v in vivo LCT; OO LCT: LP, IL-2 i ;  OO: LP, IL-2 =
Van der Poll [153] Human v both LCT in vitro: T N F-a i
in vivo: T N F-a =; IL-6, IL-8 T
Tashiro [154] Human v in vivo w-3, w-6 a>-3: T N F-a i ,  IL-10 i
Rat a>-6: T N F-a T, IL-6 T
DTH i  restored by w-3, not w-6
Yamashita [155] Human v both w-3 NK i
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Abstract
Background: The aim of this study was to evaluate immune modulating properties 
of lipid emulsions applied in parenteral nutrition by measuring neutrophil oxygen 
radical production (the ‘respiratory burst’) after lipid incubation.
Methods: Neutrophils, isolated from the blood of 10 healthy individuals, were 
incubated in medium or in lipid emulsions in a physiological concentration (2.5 
mmol/L) containing long-chain- (Intralipid (LCT)), mixed medium- and long-chain- 
(Lipofundin (LCT/MCT)) or structured triglycerides (SL). After washing and 
stimulation with phorbol 12-myristate 13-acetate (PMA) or serum-treated zymosan 
(STZ) particles, the respiratory burst was evaluated by measuring maximum oxygen 
uptake, superoxide and hydrogen peroxide production rates and chemiluminescence.
Results: Unlike LCT and SL, LCT/MCT increased PMA- and STZ-induced 
oxygen uptake rate by 45% and 31%, respectively (both P=0.006 compared to 
medium), as well as superoxide (+56%, P=0.006) and hydrogen peroxide (+14%, 
P=0.04) production, within 5 min after stimulation. Increased LCT/MCT-mediated 
early respiratory burst was confirmed by decreased PMA- (-65%) and STZ- 
stimulated (-54%) chemiluminescence peaktime (time after stimulation to peak) in 
combination with unchanged peakheight (maximum rate of radical production). Late 
respiratory burst (within 2 h) of LCT/MCT, indicated by overall luminescence 
(overall radical production), remained unchanged (PMA) or decreased (STZ, 
P=0.02). The addition of 2.5 mmol/L LCT/MCT or MCT emulsion to unstimulated 
neutrophils, in contrast to LCT and SL, resulted in significant luminescence.
Conclusions: Early neutrophil respiratory burst is accelerated by the LCT/MCT 
emulsion Lipofundin, whereas LCT (Intralipid) and structured lipid emulsions exert 
no effect. MCT containing emulsions, contrary to LCT and structured lipid 
emulsions, can induce oxygen radical production in unstimulated neutrophils.
Introduction
The use of total parenteral nutrition (TPN) is associated with an increased risk for 
infectious complications. This has been attributed to immunosuppressive effects of 
the applied lipid emulsions [1-3]. Intralipid, the most widely used formulation, is a 
long-chain triglyceride (LCT) emulsion that has shown detrimental effects on several 
aspects of neutrophil granulocyte function in some [4-7] but not all [8,9] in vitro 
studies. This controversy remains after several in vivo studies [10-13]. Another 
emulsion, Lipofundin, consists of a mixture of 50% medium-chain triglycerides 
(MCTs, with saturated fatty acids of 6-12 carbons) and 50% LCTs. Saturated 
medium-chain fatty acids stimulated in vitro neutrophil oxidative metabolism and 
superoxide production in a previous study [14], whereas others found that MCT- 
treated neutrophils showed depressed oxidative activity [15]. The latter investigators 
also observed decreased chemotaxis of LCT/MCT-treated neutrophils [9]. Studies 
regarding neutrophil function in relation to a more recently developed synthetic lipid 
emulsion with medium- and long-chain fatty acids randomly distributed within one 
triglyceride molecule (structured triglyciderides) are lacking. Research suggests that
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structured lipid emulsions may be clinically advantageous to LCT and LCT/MCT 
emulsions [16].
We conducted this study to investigate the effect of structurally different 
triglyceride emulsions in a ‘physiological’ concentration (i.e. reached with the 
administration of TPN) on cellular immune system function, as represented the 
capacity of neutrophil granulocytes to produce oxygen radicals upon stimulation: a 
process known as the ‘respiratory burst’.
Materials and Methods
Subjects: Ten healthy volunteers (five men, five women), with a mean age of 34 ± 
8  years (range 27-50), were included in the study. After an overnight fast, blood 
samples were drawn and processed as described. Serum triglyceride was determined 
colorimetrically on a Hitachi-747 analyser. Mean fasting serum triglyceride in 
volunteers was 0.94 ± 0.29 mmol/L- (range 0.55-1.56 mmol/L).
Materials: Reagents were from Sigma Chemicals (St Louis, MO, USA), unless 
stated otherwise. PMA was stored as a 0.1 mg /mL stock solution in dimethyl­
sulfoxide at -20°C. Serum-treated zymosan (STZ) was prepared as described [17]. 
Hank's balanced salt solution (HBSS) was from Life Technologies Ltd (Paisley, 
Scotland). Isotonic lysis solution contained 155 mmol/L NH4Q , 10 mmol/L KHCO3 
and 0.1 mmol/L EDTA (pH 7.4). Phosphate-buffered saline (PBS) contained Na+ 
163.9 mmol/L, Cl" 140.3 mmol/L, HPO42- 10.9 mmol/L and H2PO4- 1.8 mmol/L (pH 
7.4). Medium contained HBSS supplemented with 0.5% (wt/vol) human serum 
albumin (HSA; from Behring, Westwood, MA, USA). Percoll (density 1.129 g/ml at 
20°C) was from Pharmacia Biotech AB (Uppsala, Sweden). LCT emulsion (Intralipid 
20%) was from Kabi Pharmacia AB (Stockholm, Sweden). LCT/MCT emulsion 
(Lipofundin 20%) was from B. Braun Melsungen AG (Melsungen, Germany). 
Structured lipid emulsion (Fat Emulsion 73403) was from Kabi Pharmacia 
Parenterals (Stockholm, Sweden). For lipid emulsion characteristics see Table 1, 
Chapter 3.
Procedures and assays
Cell isolation: was performed as described previously [18]. Granulocytes were 
purified from blood anticoagulated with lithium-heparin. The blood, diluted 1:1 with 
PBS with 0.4% (wt/vol) trisodium citrate (pH 7.4), was placed on Percoll (specific 
density 1.076 g/mL) and centrifuged (700 x g, 18 min, 25°C). The pellet was 
suspended in 50 mL of ice-cold isotonic lysis solution for 10 min. After 
centrifugation (5 min, 400 x g) at 4°C, the remaining erythrocytes were lysed on ice 
in fresh lysis solution for another 5 min. Cells were then washed and resuspended to a 
final concentration of 2 x 106 /mL and kept at room temperature.
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Cytospin preparations showed > 97% granulocytes (May-Grünwald/Giemsa staining) 
and > 99% viable cells as determined by staining with trypan blue.
Lipid incubation: isolated neutrophils (final concentration 1 x 106 /mL) were 
incubated in a shaking waterbath at 37°C for 60 min in medium or 2.5 mmol/L- lipid 
emulsion (Intralipid 20%, Lipofundin 20%, Fat Emulsion 73403, at a triglyceride 
concentration of 2.5 mmol/L). Thereafter, cells were washed twice and counted in a 
Bürker chamber.
Maximum oxygen uptake rate: after preincubation of the neutrophil suspension 
(1x106 /mL) for 5 min at 37°C, PMA (100 ng /mL final concentration) or STZ (1 mg 
/mL final concentration) was added, and the maximum oxygen uptake rate was 
measured for 5 min with a Clark-type oxygen electrode as described previously, and 
expressed as nmol oxygen/min per 106 neutrophils [19].
Superoxide production: was determined at 37°C on a thermostatted Perkin-Elmer 
Lambda 12 spectrometer (Perkin-Elmer Corp., Norwalk, CT, USA) as the superoxide 
dismutase inhibitable reduction of ferricytochrome c, as described previously [20], 
and was expressed as the maximum rate of cytochrome c reduction in nmol/min 
per106 neutrophils at 550 nm, using 21.1 mmol/L.cm-1 for the extinction coefficient 
of (reduced-oxidized) cytochrome c [21].
Hydrogen peroxide production: was determined as the peroxide-dependent 
oxidation of homovanillic acid to a fluorescent dimer that is mediated by horseradish 
peroxidase, as described previously [22], and was expressed as nmol H20 2/20 min per 
105 neutrophils after PMA stimulation. In brief, after lipid incubation, 105 neutrophils 
were added to 650 ^L of medium and 250 ^L of a solution of 400 ^mol/L 
homovanillic acid containing 4 U of horseradish peroxidase per mL in medium. 
Stimulation of neutrophils with 1 ^L of PMA stock was performed (20 min, 37 °C) 
and the reaction was terminated by adding 125 jxL of 0.1 mol /L glycine-NaOH, pH 
12, containing 15 mmol/L EDTA. After centrifugation (2200 x g, 10 min) the 
fluorescent product of the supernatant was determined on a Shimadzu RF-5000 
spectrofluoro-photometer (Kyoto, Japan) with A,ex 314 nm and A,em 425 nm. Standards 
of hydrogen peroxide were used for calibration.
Luminol-enhanced chemiluminescence: (see also Fig. 1) was measured at 37°C for 
120 min in an automated BioOrbit 1251 Luminometer (BioOrbit Oy, Turku, Finland) 
in cuvettes containing 0.7 mL of Luminol solution, 0.2 mL of cell suspension (2x105 
neutrophils) and 0.1 mL of STZ (10 mg /mL) or 0.1 mL of medium + 1 ^L of PMA 
(0.1 mg /mL). Luminol stock solution (10" mol /L in DMSO) was diluted in medium 
to a final concentration of 2 x 10-5 mol /L. Means of peaktime (time until peak of 
light emission, in seconds), peakheight (in mV) and total luminescence, representing 
total light emission during 120 min (V/s) were calculated with Multi-Use software 
(BioOrbit Oy). For kinetic measurements in 96-well microplates, an automated 
LB96V Microlumat Plus luminometer (EG&G Berthold, Bad Wildberg, Germany) 
was used. Per well 20 ^L of a 1:20 dilution of Luminol stock in incubation medium 
was added to 150 ^L of neutrophil suspension (2 x 106 /mL) and 150 ^L of lipid
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emulsion (2.5 mmol/L final concentration). Luminescence was expressed as relative 
light units per second (RLU/s). Data were analysed with Winglow (EG&G Berthold, 
Bad Wildberg, Germany) software.
Figure 1: Luminol-enhanced chemiluminescence.
Peaktime
Statistical analysis: Wilcoxon’s signed rank test (two-tailed) was used for analysis 
of the results. The significance level was set at 0.05. Values are depicted as means ± 
standard deviation unless stated otherwise.
Results
To monitor the effect of lipid incubation on maximum oxygen radical production 
during the early fase of the respiratory burst, oxygen consumption and radical 
production rates were measured within five min after stimulation with a receptor- 
independent (PMA) or a receptor-dependent (STZ) stimulus, in the presence or 
absence of lipid emulsions. Maximum oxygen uptake rates compared with medium 
are shown in Table 2.
PMA- and STZ-induced oxygen uptake with LCT/MCT was also increased 
compared with LCTs and structured lipids (all P<0.01). PMA- and STZ-induced 
oxygen uptake with LCT or structured lipid was not significantly different.
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Table 2. Maximum oxygen uptake rates (in nmol/min per 106 cells) o f PMA- or STZ-stimulated 
neutrophils after incubation in 2.5 mmol/L lipid emulsion compared with medium (n=10).
95% CI % P 95% CI % P
PMA STZ
medium 6.2 ± 1.4 5.3 - 7.1 - - 9.5 ± 1.9 8.3 - 10.6 - -
LCT 6.6 ± 1.2 5.8 - 7.3 + 6 0.72 10.0 ± 1.4 9.1 - 10.8 + 5 0.26
LCT/MCT 9.0 ± 1.3 8.2 - 9.8 + 45 0.006 12.4 ± 1.6 11.4 - 13.4 + 31 0.006
SL 7.3 ± 0.8 6.8 - 7.8 + 18 0.02 9.5 ± 1.1 8.8 - 10.1 0 0.80
Superoxide production induced by PMA and measured in the presence of 
LCT/MCT was increased compared with medium (Table 3), LCT (P=0.006) and 
structured lipids (P=0.006), whereas LCT and structured lipids were not significantly 
different. Hydrogen peroxide production induced by PMA and measured in the 
presence of LCT/MCT, in contrast to LCT and structured lipids, was increased 
compared with medium (Table 4). Rates of LCT/MCT and LCT were not different 
(P=0.10), but compared with structured lipids, LCT/MCT increased hydrogen 
peroxide production (P=0.008).
Table 3. Superoxide production (in nmol/min per106 cells) o f PM A-stimulated neutrophils after 
incubation in 2.5 mmol/L lipid emulsions compared with medium (n=10).
95% CI % P
medium
PMA
7.5 ± 1.7 6.4 - 8.5
LCT 7.5 ± 2.2 6.1 - 8.8 0 0.95
LCT/MCT 11.7 ± 1.6 10.7 - 12.7 + 56 0.006
SL 6.9 ± 1.7 5.9 - 8.0 - 8 0.03
Table 4. Hydrogen peroxide production (in nmol/20 min per 105 cells) o f PMA-stimulated 
neutrophils after incubation in 2.5 mmol/L lipid emulsions compared with medium (n=10).
95% CI % P
medium
PMA
3.5 ± 1.9 2.6 - 4.3
LCT 3.5 ± 1.4 2.3 - 4.7 0 0.48
LCT/MCT 4.0 ± 1.6 2.8 - 5.1 +14 0.04
SL 3.4 ± 1.1 2.4 - 4.4 - 3 0.13
The chemiluminescence assay makes it possible to measure oxygen radical 
production for an extended period of time (up to hours) and may offer an impression 
of both maximal and overall radical production. PMA-induced peakheight (Table 5) 
showed no differences between categories. STZ stimulation was accompanied by 
increased peakheight in LCT/MCT compared with structured lipids (P=0.04) but not 
LCTs (P=0.29). Luminescence peaktime after PMA- as well as after STZ stimulation 
was reduced with LCT/MCT compared to medium (Table 6), LCT (P=0.02 and 0.01, 
respectively) and structured lipids (P=0.02 and 0.01, respectively). This confirms
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increased radical production in the early respiratory burst. Results of LCT and 
structured lipids were not different. With PMA, no differences in overall 
luminescence were observed (Table 7), but STZ stimulation resulted in decreased 
overall luminescence compared to medium (P=0.02), LCT (P=0.02) and structured 
lipids (P=0.02).
Table 5. Chemiluminescence peakheight (in mV) o f PMA- or STZ stimulated neutrophils after 
incubation in 2.5 mmol/L lipid emulsions compared with medium (n=10).
95% CI % P 95% CI % P
PMA STZ
Medium 152 ± 22 138-166 - - 188 ± 33 167-208 - -
LCT 158 ± 26 142-174 +4 0.73 183 ± 22 169-197 - 3 0.67
LCT/MCT 153 ± 30 134-171 +1 0.94 196 ± 29 178-214 +4 0.62
SL 149 ± 26 133-165 - 2 0.94 171 ± 20 158-183 - 9 0.11
Table 6. Chemiluminescence peaktime (in s) o f PMA- or STZ-stimulated neutrophils after 
incubation in 2.5 mmol/L lipid emulsions compared with medium (n=10).
___________________ 95% CI % P_______________ 95% CI % P
PMA STZ
medium 486 ± 60 449 - 523 - - 549 ± 120 475 - 624 - -
LCT 486 ± 60 449 - 523 0 1.0 655 ± 108 588 - 722 + 19 0.06
LCTMCT 169 ± 90 58 - 281 - 65 0.02 254 ± 90 198 - 309 - 54 0.02
SL 465 ± 78 416 - 513 - 4 0.35 592 ± 128 512 - 671 + 7 0.2
Table 7. Overall chemiluminescence (in mV/s) o f PMA- or STZ-stimulated neutrophils after 
incubation in 2.5 mmol/L lipid emulsions compared to medium (n=10).
___________________ 95% CI % P______________95% CI % P
PMA STZ
medium 277 ± 58 241-313 - - 345 ± 49 315-376 - -
LCT 289 ± 45 262-318 +4 0.47 346 ± 25 331-361 +1 0.96
LCT/MCT 252 ± 43 225-278 -9 0.31 270 ± 48 240-300 -22 0.02
SL_________273 ± 38 249-297 -2 0.77 330 ± 44 302-357 -4 0.38
Because of the stimulatory effect of the LCT/MCT emulsion described above, we 
investigated whether addition of 2.5 mmol/L LCT/MCT emulsion to unstimulated 
neutrophils would result in activation of the neutrophils. Indeed, contrary to addition of 
LCT or structured lipids, significant luminescence could be measured (see Figure 2). 
The addition of 2.5-mmol/L pure MCT emulsion resulted in an even more pronounced 
luminescence signal. The LCT/MCT-induced neutrophil stimulation was shown to be 
triglyceride-concentration dependent in a range of physiological triglyceride 
concentrations, with a maximum at a concentration of 12.5 mmol/L- (see Fig. 3).
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Discussion
In this study, we addressed the question whether lipid emulsions with different 
triglyceride structure have distinctive immunomodulatory effects. This was 
investigated by evaluating the effect of lipid incubation of isolated human neutrophils 
on the capacity of these cells to generate oxygen radicals. We focussed on cells from 
healthy volunteers because results of immunological assays in patients are invariably 
influenced by the underlying disease. Clear differences were observed between 
emulsions as to their effect on the early respiratory burst, suggesting that structurally 
different lipid emulsions distinctively influence neutrophil function. However, after 
2h, differences between emulsions could no longer be measured (PMA-induced 
luminescence), or were different from those oberved in the early burst (decreased 
STZ-induced luminescence). The latter observation may be explained by the fact that, 
besides oxygen radical formation, the availability of myeloperoxidase (MPO) 
originating from azurophil granules, is also a rate-limiting factor in the 
chemiluminescence process [23]. As STZ is known to be a stronger stimulus for the 
release of MPO than PMA, decreased STZ-induced luminescence may arise from 
exhaustion of azurophil granule stores. The lack of effect of Intralipid on 
chemiluminescence compared with medium is in accordance with a previous study 
[12]. In our study, maximum oxygen uptake and radical production rates were within 
ranges reported previously for neutrophils [19-21].
Very interesting was that both MCT-containing emulsions were capable of 
activating neutrophils without further stimulation in a triglyceride concentration- 
dependent manner. Triglyceride chain length might therefore be important in the 
interaction of lipid emulsions and components of the immune system.
Although the increased oxygen radical production after LCT/MCT incubation 
might suggest increased granulocyte function, inadequate activation of the respiratory 
burst, as indicated by the MCT-induced radical release, is probably detrimental for 
phagocyte function.
Whether this has repercussions for the susceptibility to infections in (often already 
immunocompromised) patients treated with MCT-containing parenteral nutrition 
regimens remains to be proven. Induction of phagocytosis by membrane-activating 
MCT particles has been suggested previously [15]. Tanaka et al. showed that 
saturated medium-chain free fatty acids stimulate neutrophil oxidative metabolism 
[14]. On the other hand, decreased oxygen radical production of neutrophils 
incubated in MCT emulsion has also been observed [15].
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Figure 2: Chemiluminescence o f unstimulated neutrophils after addition o f 2.5 mmol/L lipid 
emulsion (results representative o f four experiments performed in triplicate).
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Triglyceride concentration is an important issue when the effect of lipid emulsions 
on granulocyte function is studied [5]. Compared with previous studies, using 
concentrations up to 100 mmol/L, we have demonstrate here that a slightly increased 
triglyceride level that is ‘physiological’ in patients on TPN is sufficient to exert clear 
effects on neutrophil function. At this level the osmotic artifacts that influenced 
previous studies seem impropable.
We cannot rule out that components other than triglycerides (e.g. polyunsaturated 
free fatty acids, or radical scavengers such as tocopherol) contribute to our findings. 
As for the phospholipid emulsifiers used in the emulsions under investigation in our 
study, differential effects on immune function were ruled out in a study by Kruimel et 
al. [24].
Finally, limitations of in vitro studies have to be kept in mind. This is demonstrated 
in a study by Robin et al., which showed no difference for neutrophil luminescence in 
vitro after LCT incubation whereas in vivo a suppressed oxidative metabolism was 
noticed [12]. Differences observed in in vitro studies might be induced by isolation 
procedures and by artificial stimulation in an artificial cellular environment. Also, 
effects of a 1-h lipid incubation need not be representative for changes induced in 
neutrophils exposed to lipids during their complete lifecycle.
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Figure 3: Chemiluminescence o f unstimulated neutrophils after addition o f LCT/MCT in various 
triglyceride concentrations (results representative o f four experiments performed in triplicate).
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In conclusion, the LCT/MCT emulsion Lipofundin accelerated early but not late 
respiratory burst of isolated human neutrophils, compared with the LCT emulsion 
Intralipid and structured lipid emulsion. LCT/MCT and pure MCT emulsions, 
contrary to LCT and structured lipid, were capable of inducing oxygen radical 
formation in unstimulated neutrophils. These results necessitate in vivo studies to 
increase our understanding of the interaction between lipid emulsions and the 
immune system.
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Wanten GJA, Geijtenbeek TB, Raymakers RAP, van Kooyk Y, Roos D, Jansen JBMJ 
and Naber AHJ
JPEN 2000;24:228-33

Adhesion and degranulation
Abstract
Background: To test the hypothesis that lipid emulsions with different triglyceride 
structures have distinct immunomodulatory properties, we analyzed human 
neutrophil adhesion and degranulation after lipid incubation.
Methods: Neutrophils, isolated from the blood of 10 healthy volunteers, were 
incubated in medium or physiological (2.5 mmol/L) emulsions containing long- 
chain- (LCT), medium-chain- (MCT), mixed LCT/MCT- or structured triglycerides 
(SL). Expression of adhesion molecules and degranulation markers was evaluated by 
flowcytometry. Also, functional adhesion was investigated by means of a 
flowcytometric assay using fluorescent beads coated with the integrin ligand 
intercellular adhesion molecule (ICAM)-1.
Results: Although LCT and SL had no effect, LCT/MCT significantly increased 
expression of the a  subunit of p2 integrins lymphocyte-function-associated antigen 
(LFA)-1 (CD11a, +18%), macrophage antigen (Mac)-1 (CD11b, +387%), p150,95 
(CD11c, +82%) and a Dp2 (CD11d, +230%). Degranulation marker expression for 
azurophilic (CD63, +210%) and specific granules (CD66b, +370%) also significantly 
increased, whereas L-selectin (CD62L, -70 %) decreased. The effects of LCT/MCT 
were mimicked by the MCT emulsion. ICAM-1 adhesion (% beads bound) was 
increased by LCT/MCT (34 ± 4%), whereas LCT (19 ± 3 %) and SL (20 ± 2%) had no 
effect compared with medium (17 ± 3%).
Conclusions: LCT/MCT and MCT, contrary to LCT and SL emulsions, increased 
neutrophil p2 integrin expression, adhesion and degranulation. Apart from other 
emulsion constituents, triglyceride chain length might therefore be a key feature in the 
interaction of lipid emulsions and the phagocyte immune system.
Introduction
Total parenteral nutrition (TPN) is widely used for several indications in clinical 
medicine, especially when the gastrointestinal tract cannot be used for feeding. 
Controversy remains, however, with respect to immunosuppressive properties of lipid 
emulsions, which are a component of TPN [1,2]. Pure long-chain triglyceride (LCT) 
emulsions, such as Intralipid (Kabi Pharmacia AB, Stockholm, Sweden), have been 
shown to induce detrimental effects on neutrophil function in some but not all in vitro 
studies [3-7]. Also, the results of in vivo studies have been equivocal [8-11]. 
Lipofundin (Braun Melsungen AG, Melsungen, Germany), another widely used 
emulsion, consists of a mixture of 50% (wt/wt) medium-chain triglycerides (MCTs) 
and 50% LCTs. Studies on the effects of MCTs on neutrophil function have also 
yielded contradictory results [7,12]. Fat Emulsion 73403 (SL; Kabi Pharmacia 
Parenterals) belongs to a recently developed category of synthetic lipid emulsions, 
containing structured triglycerides with medium- and long-chain fatty acids randomly 
distributed within one triglyceride molecule. It has been suggested that these fat 
emulsions may be clinically advantageous to LCT and LCT/MCT emulsions [13,14]. 
Studies regarding effects of SL on the immune system are lacking.
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To study the influence of lipid emulsions, that differ in triglyceride structure on the 
innate immune system, we focussed on neutrophil adhesion. This important part of 
the immune response is coordinated by several adhesion molecule families. 
Especially important in neutrophils is the P2 integrin subfamily, which comprises 
several aP heterodimeric membrane glycoproteins that share a common p2 subunit 
(Table I) [15]. The a  subunits of each of the members, lymphocyte-function- 
associated antigen-1 (LFA-1), macrophage antigen-1 (Mac-1) and p150,95 are 
designated CD11a, -b and -c respectively. More recently a fourth member, a Dp2 has 
been identified [16]. The intercellular adhesion molecule (ICAM)-1, a ligand for p2 
integrins LFA-1 and Mac-1 on endothelial cells and lymphocytes, belongs to a 
second family of adhesion receptors, the immunoglobulin superfamily [15,17,18].
Table I. p2 integrins: subunits and antibodies used for detection
Name a  subunit P subunit
Subunit Antibody Subunit Antibody
LFA-1: NKI-L15, NKI-L16 aL (CD11a) MHM24 P2 AZN-L19
Mac-1: Bear-1, KIM225 aM (CD11b) 2LPM19c P2 AZN-L19
P150,95 ax  (CD11c) KB90 P2 AZN-L19
aD^2 aD (CD11d) 169A1 P2 AZN-L19
Adhesion molecule expression after lipid incubation of neutrophils has been 
investigated previously: Plusa et al. found p2 integrin expression not to be affected by 
LCT-containing TPN [19]. However, studies regarding neutrophil adhesion with 
regard to emulsions other than LCT and studies addressing the effect of lipid 
emulsions on functional adhesion are lacking. In the present study we examined the 
effect of four emulsions, with structurally different triglycerides, on adhesion of 
isolated human neutrophils. Both adhesion molecule expression and neutrophil 
binding to the endothelial ligand ICAM-1 were assessed under the influence of 
various lipid emulsions, using a novel assay to analyze the binding capacity of 
leukocytes for ICAM-1-coated fluorescent beads [20]. To establish whether 
neutrophils are activated by the emulsions, we also characterized several 
phenotypical changes, using a panel of monoclonal antibodies as markers for 
degranulation of azurophilic (CD63) and specific (CD66b) granules [21,22]. Also L- 
selectin (CD62L) and FcyRIIIb (CD16) expression were measured.
Materials and Methods
Ten healthy volunteers (5 men, 5 women, mean age, 34 ± 8 years, range, 27-50), 
none of whom was on medication, were included in the study. After an overnight fast, 
blood samples were drawn and processed as described below. Serum triglyceride 
content (mean, 0.94 ± 0.29 mmol/L, range 0.55 - 1.56 mmol/L) was determined 
colorimetrically on a Hitachi 747 analyzer (Hitachi Ltd, Tokyo, Japan).
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Reagents: Phorbol myristate acetate (PMA) was from Sigma Chemical Co (St 
Louis, MO, USA) and was stored as a 0.1 mg /mL stock in dimethylsulfoxide at - 
20°C. Hank's balanced salt solution (HBSS) was from Life Technologies (Paisley, 
Scotland). Phosphate-buffered saline (PBS) contained Na+ 163.9 mmol/L, Cl- 140.3 
mmol/L, HPO42- 10.9 mmol/L and 1 H2PO4-.8 mmol/L (pH 7.4). Isotonic lysis solution 
contained 155 mmol/L- NH4Cl, 10 mmol/L KHCO3 and 0.1 mmol/L EDTA (pH 7.4).
Incubation medium contained HBSS supplemented with 0.5% (wt/vol) human serum 
albumin (Behring, Westwood, MA, USA). Pooled human serum (PHS), 50% 
(vol/vol) in PBS was derived from whole blood of donors at the Blood Bank of the 
University Hospital Nijmegen. Percoll (p 1.129 g/mL at 20°C) was from Pharmacia 
Biotech AB, Uppsala, Sweden. LCT emulsion (Intralipid 20%) was from Kabi 
Pharmacia AB, Stockholm, Sweden. LCT/MCT emulsion (Lipofundin 20%) was 
from B. Braun Melsungen AG, Melsungen, Germany. SL emulsion (Fat Emulsion 
73403) was from Kabi Pharmacia Parenterals. A pure 20% MCT emulsion was 
provided by Pharmacia & Upjohn (Clayton, NC, USA). Blood samples were 
collected in 10 mL Monoject tubes (Sherwood Medical, Ballymoney, N. Ireland) 
with 143 USP units of lithium heparin.
Cell isolation: Granulocytes were purified from blood anticoagulated with lithium 
heparin [21]. The blood, diluted 1:1 with PBS with 0.4% (wt/vol) trisodium citrate 
(pH 7.4), was placed on Percoll (p 1.076 g/mL) and centrifuged (700 x g, 18 min, 
25°C). The pellet was suspended in 50 mL of ice-cold lysis solution for 10 min. After 
centrifugation (5 min, 400 x g, 4°C), the remaining erythrocytes were lysed in fresh 
lysis solution for another 5 min. The cells were then washed and resuspended to a 
final concentration of 2 x 106 per mL and were kept at room temperature. Cytospin 
preparations were > 97% pure and > 99% viable, as determined by May- 
Grunwald/Giemsa and trypan blue staining, respectively.
Lipid emulsion incubation: Isolated neutrophils (2x106 /mL) were incubated in a 
shaking waterbath (60 min, 37°C) in medium or lipid emulsion (triglyceride 
concentration 2.5 mmol/L) or kept at room temperature. Next, the cells were washed 
twice and membrane surface antigen expression and integrin function were 
determined. Neutrophil stimulation was performed through incubation (30 min, 37 °C) 
in the presence of PMA (100 ng /mL) after lipid incubation.
Membrane surface antigen expression: Neutrophil surface antigen expression was 
quantitated by immunofluorescent staining and subsequent flowcytometric analysis 
of neutrophils after lipid incubation. Direct monoclonal antibodies (mAb, DAKO, 
Glostrup, Denmark) were mouse anti-human immunoglobin (Ig) G1 fluorescein 
(FITC)-conjugated anti-CD11a (clone MHM24) and anti-CD11c (clone KB90) and 
phycoerythrin (RPE)-conjugated anti-CD11b (clone 2LPM19c RPE). Indirect mAbs 
Bear-1 [23], KIM225 (Robinson), NKI-L15 [24], NKI-L16 [25,26] and 169A1 [16] 
have been described before. AZN-L19 was developed at the Department of Tumor 
Immunology, University Hospital, Nijmegen, The Netherlands (see also Table I). The 
staining procedure was performed on melting ice: 4 x 105 neutrophils were incubated
85
Chapter 5
with 100 ^L of PHS for 10 min on ice and then transferred to fluorescence-activated 
celll sorting (FACS) tubes containing saturating doses of the mAb and the isotype 
control. Incubation took place for 30 min in the dark at 4°C, after which the cells 
were washed with ice-cold medium, resuspended in 200 ^L of medium and fixed in 
150 ^L of ice-cold 2% paraformaldehyde. In case of indirect mAbs, after staining 
with the primary mAb and washing, a second staining step with the secondary mAb 
(FITC-labeled goat-anti-mouse-Ig, 30 min in the dark at 4°C) was performed before 
fixation. Cell fluorescence measurement was performed on a FACScan (Becton and 
Dickinson, Oxnard, CA)
Fluorescent ICAM-1-coated beads adhesion assay: The beads assay was 
performed as described [20]. Briefly, after lipid incubation and washing, 50,000 cells 
were pre-incubated with or without LFA-1 or p2-blocking mAb (20 ^g /mL) for 10 
min at room temperature in a 96 wells V-shaped-bottom plate. The ICAM-1-coated 
beads (20 beads per cell) were added and the suspension was incubated for 30 min at 
37°C. The cells were then washed with medium and resuspended, whereafter 
adhesion was measured by flowcytometry. Values are depicted as the percentage of 
cells binding ICAM-1-coated beads.
Statistical analysis: Wilcoxon signed rank test was used for data analysis. The 
significance level was set at 0.05. Values were expressed as means ± SD unless stated 
otherwise.
Results
Expression of adhesion molecules and other membrane surface antigens after lipid 
incubation: Although LCT and SL had no clear effect compared with medium, LFA-
1, Mac-1, and p150,95 expression on LCT/MCT incubated neutrophils increased by 
18%, 411% and 75%, respectively (all P < 0.01, Table II). Upon PMA stimulation, 
these differences were abolished. In Mac-1-stained neutrophils, fluorescence 
increased about two-fold upon stimulation, whereas LFA-1 and p150,95 expression 
significantly decreased with PMA. In a second experiment (Fig. 1) this up-regulation 
of Mac-1 was shown to be LCT/MCT-concentration-dependent in a range of 
physiological trygliceride concentrations, reaching a plateau at a concentration of 2.5 
mmol/L. The effect of LCT/MCT was established within 15 minutes of lipid 
incubation and did not increase with longer incubation periods. Neutrophils incubated 
with isotype-matched control antibodies produced negligible staining, both in 
unstimulated and in PMA-stimulated assays.
Expression of other adhesion molecules and membrane surface markers is depicted 
in Figure 2. Two mAb’s (Bear-1 (+260%, not shown) and KIM225 (+180%)) 
directed towards different epitopes of the Mac-1 antigen, and 169A1 (+230%) 
directed towards the aD chain, also showed increased expression after incubation in 
LCT/MCT, compared with medium, LCT and SL (all P < 0.001). A pure MCT 
emulsion showed similar results (Bear-1, +180%; KIM225, +200%; 169A1, +450%),
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when compared with medium. Markers for azurophilic (CD63) and specific (CD66b) 
granules showed increased expression after LCT/MCT (+210% and +370%, 
respectively) and pure MCT incubation (+510% and 110%, respectively), indicating 
neutrophil degranulation. The decreased expression of L-selectin (CD62L), after 
LCT/MCT (-70%) and pure MCT incubation (-80%) is also compatible with 
neutrophil activation [21]. Expression of CD 16 remained unchanged in all 
incubations. LCT/MCT and MCT significantly increased expression of a Ca2+- 
dependent activation epitope of LFA-1, recognized by the mAb L16, by 70% and 
360%, respectively, whereas LFA-1 expression itself only marginally increased (Fig.
2, Table I).
Binding capacity to ICAM-1-coatedfluorescent beads: Fig. 3 shows that binding of 
neutrophils to ICAM-1-coated beads was increased after incubation in LCT/MCT 
(binding 34 ± 4%; P < 0.01), whereas LCT (19 ± 3%) and SL (20 ± 2%) had no 
effect compared with medium (17 ± 3%). The LFA-1-blocking antibody NKI-L15 
abolished the increased binding capacity after LCT/MCT but did not significantly 
affect binding capacity after incubation with other lipids. The p2-blocking antibody 
AZN-L19 reduced adhesion to equal base levels in all incubations, indicating that 
Mac-1-mediated adhesion is involved in the remaining ICAM-1 binding.
Figure 1. Mac-1 expression o f neutrophils, presented as mean fluorescence, after different 
incubation periods in LCT/MCT emulsion at various physiological triglyceride concentrations.
Incubation period (min) -15 30 A 60—*— 120
scence
[LCT/MCT] (mmol/L)
Results are representative for three experiments performed in triplicate. Mean fluorescence values 
o f LCT/M CT-concentrations in the range o f 0 to 2.5 mmol/L were significantly different from each 
other for any incubation period (with P<0.01), while in the range o f 2.5-5 mmol/L no significant 
differences existed.
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Table II. Adhesion molecule expression by isolated neutrophils from volunteers
LFA-1 Mac-1 P150,95
medium PMA medium PM A medium PM A
Medium 20°C 1.00 ± 0.09 0.38 ± 0.05* 1.11 ± 0.22 2.05 ± 0.39* 0.96 ± 0.18 0.79 ± 0.14*
37°C 1.00 ± 0.09 0.38 ± 0.05* 1.00 ± 0.31 2.00 ± 0.28* 1.00 ± 0.21 0.75 ± 0.11*
LCT 1.02 ± 0.09 0.39 ± 0.07* 1.11 ± 0.25 1.89 ± 0.36* 0.96 ± 0.18 0.86 ± 0.18*
LCT/MCT 1.18 ± 0.13* 0.38 ± 0.05* 5.11 ± 0.70* 2.02 ± 0.33* 1.75 ± 0.43* 0.79 ± 0.14*
STG 1.00 ± 0.09 0.39 ± 0.07* 1.05 ± 0.30 1.88 ± 0.30* 0.93 ± 0.18 0.79 ± 0.14*
Values: means±SD (n=10), determined after lipid incubation, presented as relative fluorescence 
compared to incubation in medium without PM A at 37°C. *Significant changes; P<0.01.
Figure 2. Membrane surface antigen expression, presented as mean relative fluorescence ± SD 
compared with medium, o f isolated neutrophils from volunteers (n=10) after incubation in 2.5 
mmol/L lipid emulsions.
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Expression o f all shown membrane surface antigens was significantly influenced by LCT/MCT and 
MCT incubations (all P<0.01), contrary to LCT and SL, with the exception o f CD16.
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Discussion
In patients undergoing major surgery, the use of TPN has been associated with an 
increased risk for infectious complications related to depressed cellular immune 
function, and a role for lipid emulsions in this process has been suggested [27]. We 
recently found that LCT/MCT and pure MCT emulsions induce oxygen radical 
formation in human neutrophils and that LCT/MCT enhances the ‘respiratory burst’ 
(oxygen radical formation upon stimulation) of these cells, contrary to LCT and 
structured lipid emulsions [28,29]. We concluded that, apart from other constituents 
such as tocopherol or poly-unsaturated fatty acids, triglyceride chain length might be 
important in the interaction of lipid emulsions with the phagocyte defense system. In 
the present study we investigated whether other important aspects of neutrophil 
function, viz. adhesion and degranulation, are also influenced by lipid emulsions with 
various triglyceride structures.
Most intriguing is the upregulation of the p2 integrins LFA-1, Mac-1, p150,95 and 
aD on LCT/MCT-incubated neutrophils, in combination with phenotypical changes 
compatible with neutrophil activation: increased degranulation marker expression of 
azurophilic and specific granules and decreased expression (most probably due to 
shedding) of CD62L. A pure MCT emulsion mimicked these changes induced by 
LCT/MCT emulsion. Because LCT and structured lipid had no effect compared with 
medium, the MCT component of the emulsion might be responsible for this 
observation. It has been shown that (long-chain) poly-unsaturated fatty acids are 
capable of increasing neutrophil adherence and integrin receptor expression [30]. As 
for MCT, it has been suggested before that these lipids stimulate oxidative 
metabolism by inducing phagocytosis through membrane-activating MCT particles 
and that saturated medium-chain free fatty acids stimulate in vitro neutrophil 
oxidative metabolism [7,12]. Although isolation procedures lead to changes in 
neutrophil activation [21,31], these changes cannot explain the results decribed 
above, because LCT and structured lipid showed no effect compared to medium.
Also, cells incubated in medium showed no characteristics different from cells kept 
at room temperature. Plusa et al. [19] found no evidence of neutrophil dysfunction in 
patients when adhesion molecule expression was determined before and after 
administration of LCT-containing TPN. In our study, incubation of isolated 
neutrophils from healthy volunteers in the pure LCT emulsion Intralipid also did not 
influence integrin expression compared to cells incubated in medium. The increased 
expression of Mac-1 after PMA stimulation in all incubations other than those with 
LCT/MCT and MCT is in accordance with a previous study [32]. Both p150,95 and 
Mac-1 are stored in peroxidase-negative granules that degranulate upon stimulation. 
This process rapidly increases surface expression of these molecules [32,33]. LFA-1 
is constitutively expressed on the plasma membrane and is not upregulated by various 
stimuli [34], as was confirmed in our study for PMA. However, after LCT/MCT 
incubation a small but significant increase in CD11a expression was observed.
Phagocyte adherence is known to be enhanced by inflammatory lipid mediators 
directly acting on leukocytes, and cell activation may result in increased functional
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activity (i.e. binding) of adhesion receptors due to qualitative intramolecular changes, 
which may explain our results [15,35].
Because integrins must be activated to become functional, increased adhesion 
molecule expression is not synonymous to increased adhesion. In our study adhesion 
after LCT/MCT and MCT incubation was shown to be increased in two ways. First, both
LCT/MCT and MCT emulsions, contrary to LCT and SL, substantially (170% resp2+
460%, respectively; Fig. 2) increased expression of a Ca -dependent activation epitope 
of LFA-1, recognized by the mAb NKI-L16, which has been shown to be generated 
upon cell activation [26]. It seems improbable that this can be explained by the slightly 
increased LFA-1 expression (18%) seen after LCT/MCT incubation. Furthermore, we 
investigated LFA-1 function by means of a recently developed flowcytometric assay 
[20]. This test showed that LCT/MCT increased neutrophil adhesion to the endothelial 
ICAM-1, whereas LCT and structured lipid showed no effect compared to medium. 
Because increased adhesion by LCT/MCT could be completely abolished by the LFA-1- 
blocking antibody (NKI-L15), LFA-1 alone may be predominantly responsible for the 
increased adhesion to ICAM-1.
In conclusion, these results show that LCT/MCT and MCT emulsions increase human 
neutrophil p2 integrin expression, LFA-1-mediated adhesion to ICAM-1, and 
degranulation, contrary to LCT- and SL-containing emulsions. Apart from other 
emulsion constituents, triglyceride chain length might therefore be a key feature in the 
interaction of lipid emulsions and the phagocyte immune system.
Figure 3. ICAM-1 adhesion o f isolated neutrophils from volunteers (n=10), presented as mean o f % 
ICAM-1-coated fluorescent beads bound ± SD, after incubation in 2.5 mM lipid emulsions or 
medium, in the presence or absence o f LFA-1 (NKI-L15) and p2-  (A ZN -L19) blocking anti­
bodies.
*
Significant changes compared to medium (p<0.01) are indicated with *.
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Abstract
Aim : To test the hypothesis that structurally different lipid emulsions have distinct 
immunomodulatory properties, we analyzed neutrophil migration in the presence of 
various lipid emulsions.
Methods: Neutrophils of 8 volunteers were pre-incubated in medium or 
physiological 2.5 mmol/L emulsions containing long-chain- (LCT), medium-chain- 
(MCT), mixed LCT/MCT-, a-tocopherol-enriched LCT/MCT (LCT/MCT-E)- or 
structured triglycerides (SL). Thereafter, the cells were put on top of 3-^m-pore-sized 
cell-culture filters and incubated for one hour in the presence or absence of a 
chemoattractant underneath the filter. Neutrophil migration was measured as the 
percentage of cells that had passed the filter in the presence (chemotaxis) or absence 
(random migration) of a chemotactic factor.
Results: Compared to lipid-free incubation (19±1%), random neutrophil migration 
significantly decreased with LCT/MCT (11±2%), LCT/MCT-E (12±2) and MCT 
(5±2%), while LCT (18±3%) and SL (20±1%) had no effect. N-formyl-methionyl- 
leucyl-phenylalanine- (fMLP, 10 mol/L) or zymosan-activated-serum (ZAS, 10%) - 
induced filter passage under lipid-free conditions amounted to 61±14% and 70±13%, 
respectively. These values decreased with LCT/MCT to 11±9% and 15±7%; with 
LCT/MCT-E to 18±10% and 28±12%; with SL to 39±18% and 57±14%, and with 
MCT to 5±2% and 10±6%, (all P<0.01), while LCT had no effect. Compared to 
LCT/MCT, the a-tocopherol-enriched formulation significantly increased ZAS- and 
fMLP-induced chemotaxis. fMLP-induced chemotaxis decreased in direct proportion 
to LCT/MCT triglyceride concentration.
Conclusions: Human neutrophil migration is distinctively inhibited by structurally 
different lipid emulsions, depending on triglyceride chain-length and concentration as 
well as a-tocopherol content.
Introduction
Total parenteral nutrition (TPN) is widely used in clinical practice to maintain or 
improve the nutritional status of patients. Lipid emulsions establish an integral part of 
TPN regimens, both as an energy source and as essential fatty-acid supply. The 
increased risk for infectious complications that is associated with the use of TPN has 
been related to immunosuppressive effects of the lipid components, especially with 
respect to phagocyte functions [1-3]. Neutrophil migration is an early event in the 
activation of the non-specific defence system and represents an important aspect of 
granulocyte function. Intralipid, the most widely used lipid formulation, is a long- 
chain triglyceride (LCT) emulsion that has shown detrimental effects on neutrophil 
migration in some [4] but not all [5] in vitro studies, a controversy remaining after 
several in vivo studies [6-12].
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Another emulsion, Lipofundin, consists of a mixture of 50% medium-chain trigly - 
cerides (MCT, with saturatedfatty acids of 6-12 carbons) and 50% LCT. LCT/MCT 
and MCT emulsions decreased chemotaxis in an in vitro study [13], whereas in vivo 
no effects of LCT/MCT were found [14]. Data on the influence of a novel Lipofundin 
formulation, enriched with a-tocopherol (LCT/MCT-E), on neutrophil migration are 
lacking. The same applies for recently developed synthetic structured lipids (SL), 
with medium- and long-chain fatty acids randomly distributed within one triglyceride 
molecule. It has been suggested that SL emulsions may be clinically advantageous to 
LCT and LCT/MCT emulsions [15,16].
We recently reported that LCT/MCT and MCT emulsions, contrary to LCT and 
SL, have distinct effects on in vitro neutrophil oxygen radical formation, adhesion 
and cellular signaling pathways [17-20]. In the present study we investigate the effect 
of various structurally different emulsions, in a physiological concentration (i.e. 
concentrations reached in the circulation when administering TPN), on random 
neutrophil migration and chemotaxis.
Materials and Methods
Eight volunteers (4 men, 4 women, mean age 30 ± 8 years, range 27-45), were 
included in the study. After an overnight fast, blood samples were drawn and 
processed as described below. Serum triglyceride content (mean 0.94 ± 0.29 mmol/L, 
range 0.55 - 1.56 mmol/L) was determined colorimetrically on a Hitachi 747 analyser 
(Hitachi Ltd, Tokyo, Japan).
Reagents: Reagents were from Sigma Chemicals (St Louis, MO, USA) unless stated 
otherwise. N-formyl-methionyl-leucyl-phenylalanine (fMLP) was stored as a 1 
mmol/L stock solution in dimethylsulfoxide at -20°C. Hank's balanced salt solution 
(HBSS) was from Life Technologies (Paisley, Scotland). Phosphate-buffered saline 
(PBS) contained Na+ 163.9 mmol/L, Cl" 140.3 mmol/L, HPO42- 10.9 mmol/L and 
H2PO4- 1.8 mmol/L (pH 7.4). Isotonic lysis solution contained 155 mmol/L NH4Cl, 10 
mmol/L KHCO3 and 0.1 mmol/L- EDTA (pH 7.4). Incubation medium contained 
HBSS supplemented with 0.5% (wt/vol) human serum albumin (HSA; from Behring, 
Westwood, MA, USA). Percoll (p 1.129 g/mL at 20°C) was from Pharmacia Biotech 
AB, Uppsala, Sweden. LCT emulsion (Intralipid 20%) was from Pharmacia & 
Upjohn AB, Stockholm, Sweden. LCT/MCT and a-tocopherol-enriched (170 ± 40 
mg) LCT/MCT emulsions (Lipofundin 20%) were from B. Braun Melsungen AG, 
Melsungen, Germany. SL emulsion (Fat Emulsion 73403) was from Pharmacia & 
Upjohn Parenterals, Stockholm, Sweden. A pure 20% MCT emulsion was provided 
by Pharmacia & Upjohn (Clayton, NC, USA). For lipid emulsion characteristics see 
Table 1, Chapter 3. Blood samples were collected in 10 mL Monoject tubes 
(Sherwood Medical, Ballymoney, N. Ireland) with 143 USP units of lithium heparin.
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Cell isolation: Granulocytes were purified from blood anticoagulated with lithium 
heparin [21]. The blood, diluted 1:1 with PBS with 0.4% (wt/vol) trisodium citrate 
(pH 7.4), was placed on Percoll (p 1.076 g /mL) and centrifuged (700 x g, 18 min, 
25°C). The pellet was suspended in 50 mL of ice-cold lysis solution for 10 min. After 
centrifugation (5 min, 400 x g, 4°C), the remaining erythrocytes were lysed in fresh 
lysis solution for another 5 min. The cells were then washed and resuspended in 
incubation medium to a final concentration of 2 x 106 per mL and were kept at room 
temperature. Cytospin preparations were > 97% pure and > 99% viable, as 
determined by May-Grunwald/Giemsa and trypan blue staining.
Chemotactic factors: fMLP (10- mol/L final concentration) or zymosan-activated 
serum (ZAS, 10% vol/vol) were used as chemotactic factors. ZAS was prepared as 
follows. Zymosan particles were washed twice and resuspended in medium to a final 
concentration of 10 mg /mL. After incubation (30 min, 37°C) of 900 ^L of human 
serum and 100 ^L of zymosan particles and centrifugation (10 min, 700 x g), a 10% 
solution (vol/vol) of the supernatant was used as chemotactic factor.
Chemotactic assay: Neutrophil chemotaxis was evaluated as described previously, 
using MilliCell-PC culture plate inserts equipped with Isopore polycarbonate 
membranes with a diameter of 12 mm, a membrane thickness of 10 ^m and a pore size 
of 3.0 ^m (Sigma Chemicals, St Louis, MO, USA) [22]. Six hundred ^L of 
chemotactic factor in PBS was added to the bottom chamber of the culture plate. After 
preincubation of cells (1 x 106 per mL) with 2.5 mmol/L lipid emulsions or medium 
(10 min, 37°C), 400 ^L of neutrophil-lipid suspension was loaded above the filter of 
the cell culture inserts and incubated for 1 h at 37°C. After rinsing of the filter bottom 
surface to include adherent cells, the total number of cells that had passed the 
membrane was counted in a hemocytometer. Results are expressed as the percentage of 
cells that had passed the membrane after incubation, in the presence or absence of 
chemoattractant. Light microscopy revealed no significant cell adherence to the 
membrane bottom surface after rinsing.
Statistical analysis: Wilcoxon’s signed ranks test (two-tailed) was used for 
analysis of results. The significance level was set at 0.05. Values are given as means 
± SD.
Results
Neutrophil migration under influence of various lipid emulsions and in the 
presence (chemotaxis) or absence (random migration) of ZAS or fMLP was measured 
as the percentage of cells that had passed a culture insert membrane with known 
poresize and membrane thickness. These results are shown in Table 2. Compared to 
membrane passage under lipid-free conditions neutrophil chemotaxis significantly 
decreased with LCT/MCT, LCT/MCT-E, SL and MCT. All MCT-containing 
emulsions decreased chemotaxis (with both stimulants) compared to LCT
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and SL (all P<0.02). Compared to lipid-free incubation, random neutrophil migration 
significantly decreased with LCT/MCT, LCT/MCT-E and MCT, while LCT and SL 
had no effect. Compared to LCT/MCT, the a-tocopherol-enriched formulation 
LCT/MCT-E slightly but significantly increased both ZAS- and fMLP-induced 
chemotaxis (P-values 0.004 and 0.008, respectively), but not random migration.
For LCT/MCT the detrimental effect on chemotaxis was shown to be directly 
proportional to triacylglycerol concentration, reaching a plateau at 2 mmol/L (Fig. 1).
Table 2. Migration of isolated human neutrophils (as % membrane passage of the total numer o f cells) 
after incubation (1 h at 37 °C) in 2.5 mmol/L lipid emulsions in the presence [chemotaxis, with fMLP 
or zymosan-activated serum (ZAS)] or absence (random migration) o f chemotactic factors.
Random migration ZAS fMLP
lipid-free medium 19 ± 1 70 ± 13 61 ± 14
LCT 18 ± 3 67 ± 11 53 ± 10
LCT/MCT 11 ± 2 a 15 ± 7 a 11 ± 9 a
LCT/MCT-E 12 ± 2 a 28 ± 12 a 18 ± 10 a
SL 20 ± 1 57 ± 14 b 39 ± 18 a
MCT 5 ± 2 a 10 ± 6 a 5 ± 2 a
Results are presented as means ± SD o f 8 independent experiments. Significant changes compared to 
lipid-free incubation are indicated: a P<0.001, b P<0.02.
Discussion
Our results show, in agreement with studies regarding other aspects of phagocyte 
function, that structurally different lipid emulsions distinctly influence human 
neutrophil granulocyte function [17-20]. One previous study showed both increased 
expression of adhesion molecules as well as increased functional adhesion in the 
presence of MCT-, but not LCT- or SL emulsions [19]. Increased adhesion and cell 
‘stickiness’ may well explain the detrimental effect of these emulsions on neutrophil 
migration in the present study. This is further supported by the observation that 
incubation in MCT emulsions, in contrast with LCT, results in a significantly 
decreased fluorescence anisotropy [23]. The latter most probably reflects an increase 
in membrane fluidity. It has been shown that such modulation of the physicochemical 
nature of the cell membrane may activate neutrophils [24,25].
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Importantly, in the present study no evidence for a detrimental effect of the LCT 
emulsion Intralipid on neutrophil migration was found, supporting the results of 
previous studies [5,7,9-12].
The question remains what emulsion constituent is responsible for the observed 
differences. Because the emulsifier of both the pure LCT and MCT emulsions (from 
the same manufacturer) is identical, this factor can be excluded as an explanation. 
Triglyceride structure is another aspect in which the emulsions under investigation 
differ. Indeed, the (triglyceride dose-dependent) impairment in chemotaxis of cells 
incubated with medium-chain-fatty-acid (MCFA) containing emulsions, compared to 
the LCT emulsion indicates that triglyceride chain length is important in the interaction 
of lipid emulsions and the phagocyte system. Bellinati-Pires et al. reported similar 
findings in an in vitro study with 10% LCT/MCT and MCT emulsions, employing a 
similar technique (Boyden chamber) to analyze neutrophil migration [13]. The rather 
mild inhibiting effect of the structured lipid emulsion compared to the LCT/MCT and 
MCT emulsions in our study might suggest that the MCFA effect is mitigated in the 
presence of long-chain fatty acids within the same triglyceride molecule.
Figure 1: fMLP-induced chemotaxis of purified human neutrophils in the presence of various 
LCT/MCT concentrations.
[LCT/MCT] (mM)
Results, presented as the percentage membrane passage (3-^m pore-size, 10-^m thickness 
polycarbonate filter) compared to lipid-free conditions after 1 hour o f incubation at 37 °C, are 
representative of four experiments performed in duplicate.
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Another discriminator is the content of lipid-soluble anti-oxidant vitamin E 
(tocopherol) isoforms. Tocopherol occurs as the a-, ß-, y- or S-isomer, depending on 
the number and/or position of methyl groups on the chromanol ring. a-Tocopherol, the 
form with the highest biological activity, is found in the highest concentration in 
human plasma and tissues, whereas y-tocopherol, with a relative biological activity of
0.15. is present in at least equally high concentrations in the diet [26,27]. Although the 
a-tocopherol-enriched LCT/MCT-E formulation showed a (slight) increase in 
neutrophil chemotaxis compared to LCT/MCT, there was no effect on random 
migration. Taken together with the fact that the a-tocopherol-content of LCT/MCT is 
much higher than that of the LCT emulsion (see Table 1) it therefore seems unprobable 
that the effects of the MCT-containing emulsions can be attributed for a significant part 
to their vitamin E content.
In conclusion human neutrophil migration is distinctly influenced by structurally 
different lipid emulsions, depending on their triglyceride chain length and 
concentration as well as a-tocopherol content. These data indicate that triglycerides 
have distinct immunomodulatory properties, depending on their composition.
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Phagocytosis and killing
Abstract
Background: To test the hypothesis that structurally different lipid emulsions have 
distinct immune-modulating properties, we analyzed the elimination of Candida 
albicans by neutrophils after exposure to various emulsions.
Methods: Neutrophils from 8 volunteers were incubated in physiological 5 mmol/L 
emulsions containing long-chain- (LCT), medium-chain- (MCT), mixed LCT/MCT-, 
a-tocopherol-enriched LCT/MCT (LCT/MCT-E)- or structured lipids (SL). After 
washing, the neutrophils were incubated with C. albicans. Phagocytosis was 
measured as the number of yeast-associated neutrophils relative to the total neutrophil 
count. Killing was expressed as the percentage of Candida survival relative to the 
initial yeast-cell count.
Results: No significant differences in yeast-neutrophil association could be 
demonstrated following neutrophil incubation in various lipid emulsions or medium, 
after correction for non-specific adhesion. Candida survival after 1 h incubation with 
non-lipid-exposed neutrophils amounted to 53 ± 11% and was not influenced by LCT 
(60 ± 11%). However, LCT/MCT (78 ± 7%), LCT/MCT-E (72 ± 12%), SL (67 ± 6%) 
and pure MCT (70 ± 13%) significantly impaired the killing capacity of neutrophils.
Conclusions: The decreased killing capacity of neutrophils after exposure to 
medium-chain fatty acid-containing emulsions and the absence of this effect with 
LCT suggest that lipid emulsions influence the elimination of C. albicans depending 
on the triglyceride chain length.
Introduction
Total parenteral nutrition (TPN) is widely used in clinical practice to maintain or 
improve the nutritional status of patients. Lipid emulsions represent an integral part of 
TPN regimens, both as energy source and essential fatty-acid supply [1]. The increased 
risk for infectious complications associated with the use of TPN has been related to 
immune-suppressive effects of the lipid component, especially with regard to 
phagocyte function [2-4]. Neutrophil phagocytosis and microbial killing establish 
major phagocyte functions within the human non-specific defense system. Intralipid, 
the most widely used lipid formulation, is a long-chain triglyceride (LCT) emulsion 
that has shown detrimental effects on neutrophil function in some studies [5-8]. 
However, these findings could not be confirmed by other investigators [9-13].
Another emulsion, Lipofundin, consists of a physical mixture of 50% medium- 
chain triglycerides (MCT, with saturated fatty acids of 6 to 12 carbons) and 50% 
LCT. As with LCT, equivocal data exist regarding the effects of LCT/MCT on 
phagocytosis and the killing capacity of neutrophils [9,10,14-16]. Data on a novel 
Lipofundin formulation, enriched with the anti-oxidant and radical scavenger a- 
tocopherol (LCT/MCT-E), are lacking. Information on the recently introduced 
synthetic structured lipids (SL), with medium- and long-chain fatty acids randomly 
distributed within one single triglyceride molecule, is limited. It has been suggested
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that SL may be advantageous to LCT/MCT with regard to reticulo-endothelial system 
function [17].
Recently, we reported that in human neutrophils, contrary to LCT and SL, MCT 
emulsions increase both the spontaneous and stimulus-induced formation of oxygen 
radicals in a concentration-dependent manner [18]. These reactive intermediates are 
essential for the elimination of pathogens. This is best shown by the susceptibility to 
infections of individuals with chronic granulomatous disease (CGD), a disorder in 
which the oxygen radical- generating enzyme complex NADPH oxidase is inactive 
[19-21]. Inadequate cell activation by lipids might impair neutrophil function and 
thus compromise host defense. In the present study we investigated the effect of 
various emulsions, in a physiological concentration reached in the circulation when 
lipids are administered IV, on the elimination of Candida albicans, a pathogen 
responsible for life-threatening infectious complications in patients treated with TPN.
Materials and Methods
Eight volunteers (4 men, 4 women, mean age 30 ± 8 years, range 27-45), were 
included in the study. After an overnight fast, blood samples were drawn and 
processed as described below. Serum triglyceride content (mean 0.94 ± 0.29 mmol/L, 
range 0.55 - 1.56) was determined colorimetrically on a Hitachi 747 analyser (Hitachi 
Ltd., Tokyo, Japan).
Reagents: Reagents were from Sigma Chemicals (St Louis, MO, USA) unless 
stated otherwise. Hank's balanced salt solution (HBSS) was from Life Technologies 
(Paisley, Scotland). Phosphate-buffered saline (PBS) contained Na+ 163.9 mmol/L, 
Cl- 140.3 mmol/L, HPO42- 10.9 mmol/L- and H2PO4- 1.8 mmol/L. Isotonic lysis 
solution contained 155 mmol/L NH4Cl, 10 mmol/L KHCO3 and 0.1 mmol/L EDTA 
(pH 7.4). Incubation medium contained HBSS supplemented with 0.5% (wt/vol) 
human serum albumin (HSA; from Behring, Westwood, MA, USA). Percoll (p 1.129 
g/mL at 20°C) was from Pharmacia Biotech AB, Uppsala, Sweden. Bis-carboxyethyl- 
carboxy-fluorescein penta-acetoxymethylester (BCECF-AM, as a 1 mg /mL stock in 
dimethylsulphoxide) was from Molecular Probes Inc., Eugene, OR, USA. LCT 
emulsion (Intralipid 20%) was from Pharmacia & Upjohn AB, Stockholm, Sweden. 
LCT/MCT and a-tocopherol-enriched (170 ± 40 mg/L) LCT/MCT emulsions 
(Lipofundin 20%) were from B. Braun Melsungen AG, Melsungen, Germany. SL 
emulsion (Fat Emulsion 73403) was from Pharmacia & Upjohn Parenterals, 
Stockholm, Sweden. Pure 20% MCT was provided by Pharmacia & Upjohn 
(Clayton, NC, USA). For emulsion characteristics see Table I, Chapter 3. Blood 
samples were collected in 10 mL Monoject tubes (Sherwood Medical, Ballymoney, 
N. Ireland) with 143 USP units of lithium heparin. Sabouraud glucose agar, 
containing peptone 10 g/L, glucose 40 g /L and agar 15 g /L was from Oxoid Ltd, 
Basingstoke, Hampshire, England. Petri dishes (Sterilin Triple Vent, 90mm diameter) 
were from Bitsby Sterilin Ltd, Stone, Staffordshire, England.
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Cell isolation: Neutrophils were purified from blood anti-coagulated with lithium 
heparin [22]. The blood, diluted 1:1 with PBS with 0.4% (wt/vol) trisodium citrate 
(pH 7.4), was placed on Percoll (p 1.076 g /mL) and centrifuged (700 x g, 18 min, 
25°C). The pellet was suspended in 50 mL of ice-cold lysis solution for 10 min. After 
centrifugation (5 min, 400 x g, 4°C), remaining erythrocytes were lysed in fresh lysis 
solution for another 5 min. The cells were then washed and resuspended in incubation 
medium to a final concentration of 2 x 106 per mL and were kept at room 
temperature. Cytospin preparations were > 97% pure and > 99% viable as determined 
by May-Grunwald/Giemsa staining and trypan blue exclusion.
Phagocytosis: Phagocytosis of Candida albicans was evaluated as described [23]. A 
C. albicans isolate (reference strain U820) was labeled by overnight incubation at 32°C 
of one colony in 2 mL Sabouraud medium containing 20 ^mol/L BCECF-AM. This 
dye diffuses into the cells and is cleaved by cytoplasmic esterases to yield the 
fluorescent, membrane impermeable product bis-carboxyethyl-carboxy-fluorescein 
(BCECF). Labeled yeast particles were washed twice, suspended at a density of 1 to 5 
x 107 per mL in PBS and kept on ice before use. Isolated neutrophils (3 x 106 per mL) 
were incubated in medium or 5 mmol/L lipid emulsions for 60 min at 37 °C and 
washed twice. The cells were then labeled with saturating doses of the direct immune- 
fluorescent phycoerythrin-cyanin-conjugated IgG1 mouse-anti-human monoclonal 
antibody CD45-PC5 (Beckman Coulter Inc., Fullerton, CA, USA) for 20 min at 4°C in 
the dark, washed and suspended in medium. Equal volumes of CD45-stained 
neutrophil suspension and BCECF-labelled yeast particle suspension were then mixed 
and gently stirred at 37 °C in the presence of 5% (vol/vol) pooled serum. Samples were 
taken at various timepoints by pipetting 50-jxL aliquots into 100 ^L of 2% ice-cold 
paraformaldehyde. The association of yeast cells and neutrophils was analysed by 
microfluorescence measurements, performed on a FACScan (Becton and Dickinson 
& Co., Oxnard, CA, USA). Data were acquired using an instrument status with a 
logarithmic mode for the FL1 (BCECF fluorescence) and FL3 (CY5 fluorescence) 
channels. Yeast-associated neutrophils (FL1-FL3 positive) were analysed relative to 
the total FL3-positive particle count. Controls included (i) incubations at 4 °C and (ii) 
phagocyte-free yeast cell incubations.
Killing: C. albicans (reference strain U820) was plated onto Sabouraud glucose 
agar and cultured overnight at 32°C. Next, one colony was cultured in liquid 
Sabouraud medium for 12 h at 32°C. Prior to use, the yeast suspension was washed 
and suspended in ice-cold PBS to a density of 1 to 5 x 106 CFU per mL. Isolated 
neutrophils (5 x 106 per mL) were incubated in medium or 5 mmol/L lipid emulsions 
for 1 h at 37 °C and washed twice. Thereafter, killing of C. albicans was evaluated by 
adding 250 ^L washed neutrophil suspension (5 x 106 per mL in medium with 10% 
(vol/vol) pooled human serum) to 250 ^L C. albicans suspension (1-5 x 106 per mL) 
in 10 mL polypropylene tubes. Incubation took place at 37 °C with gentle end-to-end 
mixing. As a control for yeast viability, phagocyte-free incubations were included. At 
various timepoints incubation was terminated through lysis of all neutrophils by
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pipetting 50 ^L aliquots into 950 ^L ice-cold distilled water. Samples were kept on 
ice and finally plated onto Sabouraud glucose agar plates using an automated plating 
device (Whitley automatic spiral plater, Don Whitley Scientific Ltd, Shipley, West 
Yorkshire, England) with a counting range of 400 to 4x105 CFU per mL). After 24 h 
of incubation at 32°C the colonies were counted and killing was expressed as the 
number of colonies counted relative to the count at the initiation of incubation.
Statistical analysis: Wilcoxon’s signed ranks test (two-tailed) was used for 
analysis of results. The significance level set at 0.05.
Results
Phagocytosis: Table II shows the number of yeast-associated neutrophils relative 
to the total neutrophil count at various intervals during incubation for neutrophils 
previously exposed to lipid emulsions in a physiological triglyceride concentration of 
5 mmol/L, i.e. a concentration that is easily reached in patients when lipid emulsions 
are administered IV. In case of MCT-exposed neutrophils (with LCT/MCT, 
LCT/MCT-E and MCT), contrary to LCT and SL, immediately from the start of 
incubation with C. albicans, an increased yeast-neutrophil association was observed. 
This phenomenon remained unaltered during incubation and was also seen with 
incubation at 4°C, suggesting non-specific adhesion rather than true phagocytosis. 
For all incubations, yeast-neutrophil association reached a plateau level within 20 
minutes. After correction for non-specific adhesion, different rates for yeast- 
neutrophil association could no longer be demonstrated. During the experiment there 
were no signs for decreased cell viability, as there was no loss of label from either 
neutrophils or yeast cells.
Table II. Association o f Candida albicans and lipid (5 mmol/L)- or medium-exposed neutrophils, 
presented as the Candida-associated neutrophil count relative to the total neutrophil count.
Start 10 min 20 min 30 min
4°C 
30 min
Phagocytosis 
30 min
medium 24 ± 5 65 ± 9 71 ± 10 69 ± 8 24 ± 5 45 ± 13
LCT 29 ± 13 70 ± 14 74 ± 20 76 ± 13 30 ± 7 46 ± 20
LCT/MCT 37 ± 15 77 ± 9 84 ± 8 86 ± 5 38 ± 7 48 ± 12
LCT/MCT-E 39 ± 15 75 ± 11 85 ± 7 85 ± 8 39 ± 9 46 ± 16
SL 30 ± 13 70 ± 10 74 ± 14 72 ± 18 32 ± 7 40 ± 25
MCT 44 ± 17 73 ± 12 83 ± 7 82 ± 12 46 ± 11 36 ± 23
True phagocytosis after 30 min, calculated by correction for non-specific adhesion after 30 min at 4°C, was 
not significantly different in various incubations. Data represent means ± SD of eight experiments.
Killing o f Candida: Fig. 1 shows that after 1 h of incubation with non-lipid- 
exposed neutrophils Candida survival amounted to 53 ± 11% and was not influenced 
by LCT-incubation (60 ± 11%, P=0.16). In contrast, all medium-chain fatty acid-
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containing emulsions (LCT/MCT (78 ± 7%, P=G.G1), LCT/MCT-E (72 ± 12%, 
P=G.G1), SL (67 ± 6%, P=G.G1) and MCT exposition (7G ± 13%, P=G.G3)) clearly 
impaired neutrophil killing. After 2 and 3 h of incubation, neutrophil killing only 
slightly further increased compared to the 1 -h incubation, and similar lipid effects on 
Candida survival were observed.
Discussion
Our results demonstrate that lipid emulsions, in a concentration that is clinically 
relevant, affect the capacity of human neutrophils to eliminate Candida albicans, a 
pathogen that causes life-threatening infections in TPN-treated patients. This effect of 
lipid emulsions appears to be dependent on the triglyceride structure, as medium- 
chain fatty acid-containing emulsions all displayed similar effects, whereas LCT 
lacked such impact. To our knowledge, this is the first time that the effects of 
structured lipids and tocopherol-enriched LCT/MCT on phagocytosis and killing are 
described. Regarding the MCT effect, it is interesting to note that despite an increased 
association of neutrophils and yeast cells -due to non-specific adhesion- true 
phagocytosis remained unaltered and actual killing decreased. This is in line with the 
assumption that inadequate, continuous neutrophil activation by MCT might be 
disadvantageous, eg, due to exhaustion of the cellular metabolism. The latter was 
concluded in a study that showed that MCT-containing emulsions, contrary to LCT, 
trigger neutrophils to produce reactive oxygen intermediates, even at triglyceride 
concentrations well below 2.5 mmol/L- [18].
Thus, the decreased killing rate after exposure to MCT in the present study might 
result from neutrophil exhaustion during the lipid pre-incubation, before the addition 
of Candida in the killing assay. Furthermore, we previously have shown that 
exposure of neutrophils to MCT-containing, but not LCT emulsions, within minutes 
and in a triglyceride concentration-dependent manner, results in cell activation, ie, 
degranulation and increased expression and function of adhesion molecules [24]. 
Thus, neutrophil activation might explain the increased cell ‘stickiness’, in the 
present study.
Several investigators have focussed on the effects of LCT on neutrophil 
phagocytosis and reticulo-endothelial system (RES) function, yielding negative, as 
well as positive or complete absence of any effects [5-10,13]. These equivocal results 
might well be associated with study design-related issues (in vitro vs in vivo, 
measurements in the presence of lipids or after cell rinsing), or the use of techniques 
to assay phagocytosis that do not take into account non-specific adhesion. In some 
cases nonphysiologically high lipid concentrations, up to 100 mmol/L, were used, 
which probably also result in osmolar effects [6,7]. Bellinati et al. found LCT not to 
affect phagocytosis, while LCT/MCT impaired microbial ingestion [10]. Similarly, 
numerous animal studies have been performed [14-16,25-28].
1G9
Chapter 7
Figure 1: Killing o f Candida albicans by neutrophils after incubation for one hour in 5 mmol/L 
lipid emulsions or medium, presented as Candida survival relative to initial yeast cell counts.
C represents yeast survival in the absence o f neutrophils. Data are presented as means ± SD o f eight 
separate experiments. Significant changes compared with non-lipid- exposed neutrophils are 
indicated for yeast survival after 60 (x), 120 (xx) and 180 min (xxx) o f incubation.
In the single study reporting on structured lipid effects, RES function in rats after 
exposure to structured lipids was better preserved when compared to LCT/MCT. 
Unfortunately, this study did not include LCT, and neutrophil phagocytosis was not 
measured [17].
The absence of an effect of LCT on the killing capacity of neutrophils has been 
reported before [12,13], although others found killing to be decreased with LCT 
[5,9]. In accordance with our findings Waitzberg et al., using rat neutrophils, found 
bacterial killing to be decreased in response to exposure to LCT/MCT, whereas LCT 
had no effect [14].
A limitation associated with the in vitro nature of our study is that in this setting 
the impact of immune mediators resulting from fatty acid metabolism can not be 
tested. The potential for an in vivo study to show more complex effects therefore is 
apparent: it can not be excluded that medium-chain-fatty-acid-containing emulsions
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even display beneficial effects as a result of alterations in the production of lipid- 
derived mediators.
The radical scavenger a-tocopherol (a vitamin E isoform) may be added to lipid 
emulsions in order to improve the anti-oxidant status of the emulsion and thus 
prevent lipid peroxidation to take place. In the present study no evidence was found 
for an effect of a-tocopherol enrichment in the given dosage (170 ± 40 mg/l) on 
neutrophil function.
In conclusion, our results suggest that medium chain fatty acid-containing lipid 
emulsions, contrary to LCT emulsions, decrease the elimination process of C. 
albicans by human neutrophils. No effects on yeast cell phagocytosis were 
demonstrated, despite an increased non-specific adhesion in the presence of MCT 
emulsions. Triglyceride chain-length of lipids is critical with respect to their immune- 
modulating effects.
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Saturated triglycerides and fatty acids activate neutrophils depending on 
carbonchain-length
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Carbonchain-length and radical production
Abstract
Background: Unsaturated fatty acids are known as neutrophil activators. In the 
present study we investigated whether saturated triglycerides (TG) and fatty acids (FA) 
may also contribute to the previously observed activation of neutrophils by nutritional 
lipid emulsions. Furthermore we tested the hypothesis that carbonchain-length is of 
importance in this respect.
Methods: Neutrophils (lx l0 6 /mL) were isolated from the blood of 9 volunteers. 
Chemiluminescence was used to evaluate neutrophil activation, characterized by the 
production of oxygen radicals by neutrophils during incubation with l mmol/L 
saturated FA (6-20 carbon) or TG (6-12 carbon FA), dissolved in aqueous medium by 
preparing micelles with dipalmitoyl phosphatidylcholine (DPPC). Results were 
expressed as means ± SEM’s of the overall luminescence signal relative to the signal 
of cells incubated in medium.
Results: Similar to a positive control, the polyunsaturated FA arachidonic acid 
(C20:4), the TG tricaproin (TC6:0), tricaprylin (TC8:0), and trilaurin (TC12:0) as well 
as the FA lauric acid (C12:0), palmitic acid (C16:0), stearic acid (C18:0) and arachidic 
acid (C20:0) all induced oxygen radical production in neutrophils, while the medium 
chain TG tricaprin (TC10:0) and FA caproic acid (C6:0), caprylic acid (C8:0) and 
capric acid (C10:0) exerted no clear effects, similar to negative controls (DPPC and 
glycerol).
Conclusions: Besides their (poly)-unsaturated counterparts, also saturated TG and 
FA activate neutrophils. Carbonchain-length is pivotal in the interaction of FA and TG 
and cells of the immune system.
Introduction
Despite its undisputed importance in clinical practice, the use of parenteral 
nutrition remains associated with increased morbidity due to the risk for infectious 
complications. Apart from catheter-related problems, immune suppressive effects of 
the lipid component seem to play a role [1]. Distinct immune modulating effects of 
structurally different lipid emulsions have been observed, as medium-chain 
triglyceride (TG) emulsions, containing saturated fatty acids (FA) of 6  to 12 C atoms, 
contrary to long-chain-TG (14 to 22 C) emulsions, activate human neutrophils [2,3]. 
Medium-chain lipid effects on these non-specific phagocytes comprise increased 
cellular adhesion and degranulation, production of toxic oxygen radicals, decreased 
cellular motility and impaired killing capacity of yeast pathogens [2,4-6]. Also, various 
nutritional lipid emulsions distinctively modulate cellular signaling of neutrophils [7].
However, it remains unclear which emulsion component is responsible for the 
observed emulsion effects: apart from lipids, also emulsifiers, anti-oxidants such as 
tocopherol, and other bio-products may be responsible, as well as free (poly)- 
(un)saturated fatty acids. Polyunsaturated fatty acids (PUFA), such as arachidonic acid 
(C20:4), are mediators of leukocyte function in humans and PUFA of the n-3
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series in fish oils, such as eicosapentaenoic (C20:5) and docosahexaenoic acid 
(C22:6)), have anti-inflammatory properties [8,9]. Cellular adherence, degranulation 
and oxygen radical production of neutrophils is stimulated in a dose-dependent 
manner in vitro by both C20:5 and C22:6, as well as by C20:4 [10-13]. On the other 
hand, saturated fatty acids of the same chain length lacked effects on neutrophil 
function [11]. Therefore, the number and position of double bonds, carbon chain 
length and state of oxidation are considered to be critical for the neutrophil 
stimulatory properties of PUFA. However, data regarding the effects of individual 
saturated fatty acids and lipids of medium chain length on neutrophil function are 
lacking.
Given the stimulatory effects of medium-chain lipid-containing emulsions in 
previous studies, the aim of the present work was to investigate whether saturated 
triglycerides (TG) and fatty acids (FA) of medium chain length may be responsible for, 
or contribute to, the observed neutrophil activation by medium-chain lipid-containing 
emulsions.
For the nomenclature and information on the presence of fatty acids and lipids in 
commercial parenteral lipid emulsions see Table 1 of the present study and Table 2, 
respectively.
Table 1. Evaluated fatty acids and triglycerides: nomenclature and carbonchain-length
Fatty Acids Triglycerides
Tributyrin TC4:0
Caproic acid C6:0 Tricaproin TC6:0
Caprylic acid C8:0 Tricaprylin TC8:0
Capric acid C10:0 Tricaprin TC10:0
Lauric acid C12:0 Trilaurin TC12:0
Palmitic acid C16:0
Stearic acid C18:0
Arachidic acid C20:0
Arachidonic acid C20:4
Materials and methods
Subjects: After an overnight fast, blood samples were drawn from 9 healthy 
volunteers (age 32 ± 6  (range 20-50) years), none of whom was on medication. Fasting 
serum triglyceride values were determined colorimetrically on a Hitachi-747 analyser 
(Hitachi Ltd., Tokyo, Japan). Mean fasting serum triglyceride in volunteers was 0.96 
± 0.41 mmol/L (range 0.49-1.68).
Reagents: Reagents were from Sigma Chemicals (St Louis, MO, USA) unless stated 
otherwise. Hank's balanced salt solution (HBSS) was from Life Technologies (Paisley, 
Scotland). Phosphate-buffered saline (PBS) contained Na+ 163.9 mmol/L, Cl" 140.3 
mmol/L, HPO42- 10.9 mmol/L- and H2 PO4- 1.8 mmol/L- (pH 7.4). Isotonic lysis solution 
contained 155 mmol/L- NH4 Cl, 10 mmol/L KHCO3  and 0.1 mmol/L- EDTA (pH 7.4). 
Incubation medium contained HBSS supplemented with 0.5% (wt/vol) human serum
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albumin (HSA; from Behring, Westwood, MA, USA). Percoll (1.129 g/mL at 20°C) 
was from Pharmacia Biotech AB, Uppsala, Sweden.
Cell isolation: Granulocytes were purified from blood anti-coagulated with lithium 
heparin as described previously [2,14]. The blood, diluted 1:1 with PBS with 0.4% 
(wt/vol) trisodium citrate (pH 7.4), was placed on Percoll (1.076 g/mL) and centrifuged 
(700 x g , 18 min, 25°C). The pellet was suspended in 50 mL of ice-cold lysis solution 
for 10 minutes. After centrifugation (5 min, 400x g, 4°C), the remaining erythrocytes 
were lysed in fresh lysis solution for another 5 min. The cells were then washed and re­
suspended to a final concentration of 2 x 106  /mL and were kept at room temperature. 
Cytospin preparations were > 97% pure and > 99% viable as determined by May- 
Grünwald/Giemsa staining and trypan blue exclusion, respectively.
Preparation o f triglyceride and fatty acid micelles: FA, TG (both 48 mmol/L) and 
dipalmitoyl phosphatidylcholine (DPPC, 10.9 mmol/L) were dissolved in redistilled 
chloroform. From these stock solutions mixed micelles of DPPC and FA or TG in 
HBSS were prepared as previously described by adding 50 jxL FA/TG stock to 50 ^L 
DPPC stock in a 10 mL glass tube [13]. After evaporation of the solvent under 
nitrogen, one mL of HBSS was added and the mixture sonicated for 5 min at 48 kHz. 
Final concentrations of DPPC and FA/TG were 0.545 and 2.4 mmol/L respectively, to 
reach a final concentration of 1 mmol/L per well in the luminescence measurement. 
Control incubations contained micelles of DPPC and/or glycerol. See table 1 for 
information on FA and TG. The results of a dose-response study for neutrophil 
oxygen radical production under the influence of various concentrations of tricaproin 
(TC6:0) and DPPC are shown in Fig. 1.
Chemiluminescence: For kinetic measurements in 96-well microplates an 
automated LB96V Microlumat Plus luminometer (EG&G Berthold, Bad Wildberg, 
Germany) was used [2]. Per well 20 ^L of a 1:20 dilution of Luminol stock (10 
mol/L in dimethyl sulfoxide) in HBSS was added to 100 ^L of TG/FA emulsion 
(1 mmol/L final). Chemiluminescence, expressed as relative light units per second 
(RLU/sec), was measured at 37°C for 120 min after addition of 100 ^L of neutrophil 
suspension (2x106/mL in HBSS/HSA) per well. Mean overall luminescence (area 
under curve), representing total light emission during 120 min (RLU) was calculated 
with Winglow software (EG&G Berthold, Bad Wildberg, Germany). The kinetics of 
oxygen radical formation by neutrophils, as measured by chemiluminescence, under 
influence of TG (TC6:0) and FA (C16:0) are depicted in Fig. 2.
Statistical analysis: Results are expressed as means ± SEM’s of nine separate 
experiments. Wilcoxon’s signed rank test (two-tailed) was used for the analysis of 
results. The significance level was set at 0.05.
Results
The results of the measurements of oxygen radical production by neutrophils (1x106  
/mL) after addition of dissolved saturated triglycerides and fatty acids (1 mmol/L) 
compared to radical production after addition of medium are depicted in Table 3. 
Similar to a positive control, the polyunsaturated FA arachidonic acid (C20:4), the TG
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tricaproin (TC6:0), tricaprylin (TC8:0), tricaprin (TC10:0) and trilaurin (TC12:0) as 
well as the FA lauric acid (C12:0), palmitic acid (C16:0), stearic acid (C18:0) and 
arachidic acid (C20:0) all induced significant oxygen radical production in neutrophils, 
while the medium chain FA caproic acid (C6:0), caprylic acid (C8:0) and capric acid 
(C10:0) exerted no clear effects, similar to negative controls (DPPC and glycerol). 
With the method described to dissolve fatty acids and lipids in an aqueous 
environment, it was not possible to obtain clear preparations from triglycerides 
containing fatty acids longer than C12:0. Therefore, long-chain triglycerides were not 
included in the present study.
Table 3. Oxygen radical production by neutrophils (1x106 /mL) after addition of dissolved saturated 
triglycerides and fatty acids (1 mmol/L) compared to radical production after addition of medium, as 
measured by Luminol-enhanced chemiluminescence (n=9).
Overall chemiluminescence
(mean ± SEM)
Controls Glycerol 1.2 ± 0.2
DPPC 2.1 ± 0.2
C20:4 6.5 ± 0.9*
Fatty acids C6:0 1.5 ± 0.1
C8:0 1.6 ± 0.1
C10:0 1.9 ± 0.1
C12:0 18.9 ± 5*
C16:0 78.6 ± 21*
C18:0 24.1 ± 5.2*
C20:0 27.8 ± 7.8*
Triglycerides TC6:0 145.3 ± 23.9*
TC8:0 5.0 ± 0.5*
TC10:0 2.4 ± 0.5
TC12 :0 10.9 ± 2.4*
Significant changes (P< 0.05) compared to controls (Glycerol and DPPC) are indicated with *.
Discussion
The present study shows that saturated triglycerides (TG) and fatty acids (FA), like 
their polyunsaturated counterparts, display immune modulating effects and therefore 
should not be regarded merely as inert nutritional compounds. This observation was 
made at a ‘clinically physiological’ triglyceride concentration of 1 mmol/L, i.e. well 
within the ranges (up to 10 mmol/L) reported with the infusion of parenteral lipid 
emulsions in clinical practice [15,16]. Furthermore, as for PUFA, the effects at this 
concentration seem dependent on the carbonchain-length of the involved fatty acids.
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Figure 1: Triglyceride- and DPPC-induced chemiluminescence: dose-response curves.
0.125 0.25 0.5 1 
mmol/L
10 200 5
Oxygen radical production by a suspension of human neutrophils (1x106 /mL) as measured by 
chemiluminesce (CL) after addition of a solubilized saturated triglyceride (tricaproin, TC6:0) or a 
negative control (DPPC, dipalmitoyl phosphatidylcholine) at various concentrations (in mmol/L). 
Data are presented as the mean relative chemiluminescence ± SEM’s, relative to incubation in 
medium, of three separate experiments.
We have previously reported on oxygen radical production by stimulated 
neutrophils in the presence of triglyceride emulsions [2]. It appeared that triglyceride 
effects were stimulus-dependent: in response to a receptor-dependent stimulus 
(serum-treated zymosan particles (STZ)) the respiratory burst decreased with 
medium-chain triglycerides, while radical production induced by non-receptor 
dependent stimulation (phorbol myristate acetate (PMA)) was not affected. However, 
the most important finding in this study was that, although more than ten times 
weaker than obtained with STZ or PMA, significant neutrophil radical production 
could be measured in the absence of any stimulus after addition of emulsions 
containing saturated medium-chain triglycerides. In contrast, a pure long-chain 
triglyceride emulsion exerted no such effect. Therefore, in the present study we 
wanted to identify individual fatty acids and triglycerides that may be responsible for 
this observation. Our results suggest that the previously observed neutrophil activation 
by medium-chain lipid-containing emulsions (at triglyceride concentrations up to 5 
mmol/L) may well be caused by the medium-chain triglycerides in the emulsion [2-7]. 
Especially tricaproin (TC6:0), which was established as a very potent neutrophil 
activator in the present study, might contribute to the described effects.
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Figure 2: Kinetics o f neutrophil oxygen radical formation.
Oxygen radical production, in relative light units per sec (RLU/sec), by a suspension o f human 
neutrophils (1x106 /mL) as measured by chemiluminesce (CL) after addition of solubilized satu-rated 
triglyceride (tricaproin, TC6:0, line) or fatty acid (palmitic acid, C16:0, dotted line), at a concentration 
o f 1 mmol/L.
Studies regarding the effects of saturated (medium-chain) triglycerides on the 
immune system are lacking. In a Medline search in the literature from 1966 until 
January 2001 we found no reports on such effects for the medium-chain triglycerides 
tricaproin and tricaprylin. Information on tricaprin was confined to a single study from 
1975 demonstrating that this lipid increases the spreading of macrophages on glass 
[17].
Modulation of neutrophil function by free fatty acids has been reported before [18]. 
In a rabbit study, caproic acid and lauric acid were found to stimulate neutrophil 
aggregation, but to leave secretory responses (degranulation) upon stimulation with the 
tripeptide f-Met-Leu-Phe unaffected. Also, enrichment of an enteral diet with medium- 
chain triglycerides, rich in caprylic, capric and lauric acid, palmitic acid or stearic acid 
significantly affected rat lymphocyte functions depending on the type of saturated FA 
[19]. In combination with our results, these findings indicate that cellular functions 
may be modulated in a positive or in a negative manner, depending on the presence or 
absence of other activators.
All components were tested at a concentration of 1 mmol/L because this is a 
physiological concentration with lipid infusion in parenteral nutrition regimens in 
clinical situations. Dose-finding studies with a broad concentration range would be
120
Carbonchain-length and radical production
necessary to find maximum stimulatory effects for each component. However, this was 
considered beyond the scope of the present investigation.
Although the relative effects might be influenced by conditions such as protein 
binding, some fatty acids and triglycerides displayed surprisingly strong activating 
effects compared with the eicosanoid mediator arachidonic acid. This implies a role for 
these compounds in inflammatory processes, which cause tissue damage through the 
release of reactive oxygen radicals. It also suggests possibilities for the use of 
nutritional formulations to direct immune functions depending on the clinical situation, 
e.g. to avoid depressed cellular functions in already compromised patients.
The production of various oxygen radical species can be evaluated by a number of 
assays [2 ]. As can be seen in Fig. 2, neutrophil responses as measured with the 
Luminol-enhanced chemiluminescence assay are non-linear of nature. We therefore 
tried to confirm our results with a linear method, the cytochrome-c reduction assay, 
which essentailly evaluates superoxide production. However, spectrophotometric 
analysis appeared to be technically impossible, most probably due to adhesion of 
DPPC to glass cuvettes.
In conclusion the present study shows that saturated fatty acids and triglycerides 
have immune modulating properties, depending on their carbonchain-length and 
therefore should no longer be regarded as inert nutrients.
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Abstract
Background: The use of total parenteral nutrition (TPN) is associated with an 
increased risk for infectious complications, probably due to impaired host defenses.
Methods: To test the hypothesis that the lipid component of TPN modulates immune 
functions depending on lipid structure, we administered emulsions containing long- 
chain triglycerides (LCT), mixed long- and medium-chain triglycerides (LCT/MCT) or 
a lipid-free control (saline) to eight volunteers in a crossover study design. A 
triglyceride clamp was applied to stabilize plasma concentrations at a physiological 
level of 3-5 mmol/L, seen with the clinical use of TPN. Before and after four hours of 
lipid administration, leukocyte population counts and various aspects of neutrophil 
function were evaluated.
Results: While LCT had no effect compared with the lipid-free saline control, 
LCT/MCT significantly increased peripheral neutrophils, decreased lymphocytes and 
left monocyte counts unchanged. Neither emulsion distinctively affected functions or 
phenotype of peripherally sampled neutrophils compared to the lipid-free control.
Conclusions: MCT-containing lipid emulsions, more than pure LCT differentially 
modulate human circulating leukocyte population numbers. In contrast with previous 
in vitro studies, MCT effects on the function of peripherally sampled neutrophils were 
not observed.
Introduction
Despite extensive use in clinical practice, it remains unclear whether immune 
suppressive properties of total parenteral nutrition (TPN) formulations contribute to the 
associated risk for infectious complications. Especially the lipid component, which is 
administered as an emulsion, has been subject to extensive investigations, so far with 
equivocal results [1-10]. As previous in vivo and in vitro studies have yielded 
conflicting results, the underlying mechanisms behind the lipid effects are not clearly 
understood [11-16]. Most emulsions that are used in clinical practice either consist 
solely of long-chain triglycerides (LCT), or contain a physical mixture of medium- 
chain triglycerides (MCT) and LCT. Recently, we have shown for the in vitro setting 
that MCT emulsions, contrary to LCT, directly activate human neutrophils to produce 
oxygen radicals [17]. Furthermore, MCT emulsions, but not pure LCT, induce 
neutrophil adhesion and degranulation, decrease motility and yeast-killing capacity, 
and modulate cellular signaling [18-21].
We performed the present study to test the hypothesis that structurally different 
lipids distinctly modulate immune functions in healthy subjects in the in vivo setting 
as well, by assessing the effects of parenteral administration of emulsions on 
circulating leukocyte population numbers and neutrophil functions.
Materials and methods
Eight healthy Caucasian males [median age: 28 y; range: 24-31; body mass index 
(BMI; in kg/m ) range: 20.5-24.2], none of whom was on medication, were included
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in the study. All procedures followed were performed after obtaining informed 
consent and were in accord with the ethical standards of the institutional committee 
on human experimentation. After an overnight fast, blood samples were drawn and 
processed as described. Serum triglyceride concentrations were determined 
colorimetrically on a Hitachi-747 analyzer (Hitachi Ltd., Tokyo, Japan).
Lipid administration: Emulsions containing long-chain triglycerides (LCT), mixed 
long- and medium-chain triglycerides (LCT/MCT) or lipid-free control (saline) were 
administered intravenously in a crossover study design (blinded for subjects and 
laboratory co-workers, and after randomisation) with a washout period of one week. 
Thus, all subjects were exposed to both lipid emulsions and lipid-free control over a 
study period of 2 weeks. To stabilize triglyceride (TG) concentrations (and immune 
cell lipid exposure) at a clinically relevant level over a prolonged (4-h) period, 
emulsions were infused according to the plasma triglyceride clamp technique as 
described by Iriyama et al. [22,23]. Because lipid elimination rates are considered to 
be faster in Caucasian subjects when compared with Japanese, we used infusion rates 
for the triglyceride clamp of 4-5 mmol/L in the ‘Japanese setting’ to aim at slightly 
lower concentrations in our Caucasian subjects [22,23]. Also, as described by Iriyama 
et al., we kept equal weight-based infusion rates to reach and maintain equal steady 
plasma concentrations for both LCT and LCT/MCT emulsions [22].
In order to clamp plasma TG concentrations at a concentration of 3-5 mmol/L, 
emulsions were infused at a rate of 0.5 g/kg BW/h for 10 min (priming), and were 
then reduced to 0.3 g/kg BW/h to reach a stable plasma concentration of 3-5 mmol/L. 
Fifty minutes after the initiation of lipid administration, the TG concentration in 
plasma was clamped by infusion at a rate of 0.11 g/kg BW/h for another 190 min.
Reagents: Reagents were from Sigma Chemicals (St Louis, MO, USA), unless 
stated otherwise. Phorbol myristate acetate (PMA) was stored as a 0.1 mg/mL stock 
in dimethyl sulfoxide (DMSO) at -20°C. Serum-treated zymosan (STZ) was prepared 
as described [24]. Hank's balanced salt solution (HBSS) was from Life Technologies 
(Paisley, Scotland, UK). Isotonic lysis solution contained 155 mmol/L NH4 Cl, 10 
mmol/L KHCO3  and 0.1 mmol/L EDTA (pH 7.4). Phosphate-buffered saline (PBS) 
contained Na+ 163.9 mmol/L, Cl- 140.3 mmol/L, HPO42- 10.9 mmol/L- and H2 PO4- 1.8 
mmol/L (pH 7.4). Neutrophil medium contained HBSS supplemented with 0.5% 
(wt/vol) human serum albumin (from Behring, Westwood, MA, USA). Percoll (p 
1.129 g/mL at 20°C) was from Pharmacia Biotech AB (Uppsala, Sweden). LCT 
emulsion (Intralipid 20%) was from Fresenius Kabi (Stockholm, Sweden). LCT/MCT 
emulsion (Lipofundin 20%) was from B. Braun Melsungen AG (Melsungen, 
Germany). For lipid emulsion characteristics see Table 1, Chapter 3. Blood samples 
were collected in 10 mL Monoject tubes (Sherwood Medical, Ballymoney, N. 
Ireland, UK) with 143 USP units of lithium heparin.
Leukocyte isolation: Leukocyte isolation was performed as described previously 
[17,25]. Leukocytes were purified from blood anti-coagulated with lithium-heparin. 
The blood, diluted 1:1 with PBS with 0.4% (wt/vol) trisodium citrate (pH 7.4), was 
placed on Percoll (p 1.076 g/mL) and centrifuged (700 x g, 18 min, 25°C). The
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granulocyte-containing pellet was suspended in 50 mL ice-cold isotonic lysis solution 
for 10 min. After centrifugation (5 min, 400 x g) at 4°C, the remaining erythrocytes 
were lysed on ice in fresh lysis solution for another 5 min. The granulocytes were 
then washed and suspended to a final concentration of 2 x 106/mL and kept at room 
temperature. Cells were counted on a Coulter counter (Coulter electronics, Mijdrecht, 
The Netherlands). Cytospin preparations were > 97% pure, as determined by May- 
Grunwald/Giemsa staining, and contained > 99% viable cells, as determined by 
trypan blue exclusion. Leukocyte populations were identified and counted using flow 
cytometry, based on their specific forward and sideward scatter patterns.
Measurement of maximum oxygen uptake rate of neutrophils: After pre-incubation 
of neutrophil suspension (1x106 /mL) for 5 min at 37°C, STZ (1 mg/mL final) was 
added and the maximum oxygen uptake rate was measured for 5 min with a Clark­
type oxygen electrode and expressed as nmol oxygen/min/106  cells [17,26].
Measurement o f  superoxide production by neutrophils: Superoxide production was 
determined at 37°C on a thermostatted Perkin-Elmer Lambda 12 spectrometer 
(Perkin-Elmer Corp., Norwalk, CT, USA) as the superoxide dismutase inhibitable 
reduction of ferricytochrome c, as described previously [17,27]. Results were 
expressed as the maximum rate of cytochrome c reduction induced by PMA (100 
ng/mL final) in nmol/min/106  neutrophils, at 550 nm, using 21.1 /mmol/L/cm for the 
extinction coefficient for (reduced-oxidized) cytochrome c [28].
Measurement o f  hydrogen peroxide production by neutrophils: Hydrogen peroxide 
production was determined as the peroxide-dependent oxidation of homovanillic acid 
to a fluorescent dimer that is mediated by horseradish peroxidase, as described before 
[17,29], and was expressed as nmol H2 O2 / 2 0  min/105  neutrophils after PMA 
stimulation. In brief, following lipid incubation, 105  neutrophils were added to 650 jxL 
of medium and 250 ^L of a solution of 400 ^M homovanillic acid containing 4 U of 
horseradish peroxidase per mL in medium. Stimulation of neutrophils with 1 ^L of 
PMA stock was performed (20 min, 37 °C) and the reaction was terminated by adding 
125 ^L of 0.1 mol/L glycine-NaOH, with pH 12, containing 15 mmol/L- EDTA. After 
centrifugation ( 2 2 0 0  x g, 1 0  min) the fluorescent product of the supernatant was 
determined on a Shimadzu RF-5000 spectrofluoro-photometer (Kyoto, Japan) with Xex 
314 nm and X em 425 nm. Standards of hydrogen peroxide were used for calibration.
Measurement o f neutrophil luminol-enhanced chemiluminescence: Chemilumi- 
nsescence was measured as described before in an automated LB96V Microlumat 
Plus luminometer (EG&G Berthold, Bad Wildberg, Germany) in 96-well microplates
for 120 min at 37°C 17. STZ (1 mg/mL final) or PMA (0.1 ^g/mL final) were used
- 2for cell stimulation. Luminol stock solution (10 mol/L in DMSO) was diluted in 
medium to a final concentration of 2 x 10- 5  mol/L. Luminescence was expressed as 
relative light units per second (RLU/sec). The mean total luminescence, representing 
total light emission during 120 min, was used. Per well 20 ^L of a 1:20 dilution of 
Luminol stock in incubation medium was added to 150 ^L of neutrophil suspension
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(2 x 106 /ml). Data were analyzed with Winglow software (EG&G Berthold, Bad 
Wildberg, Germany).
Measurement o f neutrophil membrane surface antigen expression: Membrane 
surface antigen expression was quantitated as described before by immune- 
fluorescent staining and subsequent flow cytometric analysis of neutrophils before 
and after lipid administration [18]. Characterization was performed using antibodies 
directed against various neutrophil adhesion molecules of the p2  integrin family 
(CD11a, CD11b, CD11c and CD11d), as well as a degranulation and and activation 
markers (CD6 6 b and CD62L, respectively). Direct monoclonal antibodies (mAb; 
DAKO, Glostrup, Denmark) were mouse anti-human immunoglobulin (Ig) G1 
fluorescein isothiocyanate (FITC)-conjugated anti-CD11a (clone MHM24), anti- 
CD11c (clone KB90), anti CD62L (clone Dreg 56) and anti-CD6 6 b (clone 80H3 ) 
and phycoerythrin (RPE)-conjugated anti-CD11b (clone 2LPM19c RPE). Indirect 
mAbs were anti-CD14 (clone M5E2, PharMingen GmBH, Hamburg, Germany) and 
anti-CD11d (169A1 30) expression. The staining procedure was performed on 
melting ice: 4 x 105  neutrophils were incubated with 100 ^L of pooled human serum 
for 10 min on ice and then transferred to FACS tubes containing saturating doses of 
the mAb and the isotype control. Incubation took place for 30 min in the dark at 4°C, 
after which the cells were washed with ice-cold medium, suspended in 2 0 0  ^L of 
medium and fixed in 150 ^L of ice-cold 2% paraformaldehyde. In case of indirect 
mAbs, after staining with the primary mAb and washing, a second staining step with 
the secondary mAb (FITC-labeled goat anti-mouse Ig, 30 min in the dark at 4°C) was 
performed before fixation. Microfluorescence measurement was performed on a 
FACScan (Becton and Dickinson, Oxnard, CA).
Measurement o f neutrophil adhesion: Neutrophil adhesion was evaluated using the 
fluorescent intercellular adhesion molecule (ICAM)-1 -coated beads adhesion assay 
[18,31]. Briefly, 50,000 cells were pre-incubated for 10 min at room temperature in a 
96 well, V-shaped-bottom plate. The ICAM-1-coated beads (20 beads/cell) were 
added and the suspension was incubated for 30 min at 37°C. The cells were then 
washed with medium and suspended, whereafter adhesion was measured by flow 
cytometry. Values represent the ratio of the percentage of neutrophils binding ICAM- 
1 -coated beads after/before lipid administration.
Statistical analysis: Results are expressed as means ± SEMs for the number of 
observations indicated. The statistical significance of the effects of lipid 
administration was determined with use of analysis of variance (ANOVA) with 
Bonferroni correction for multiple comparisons. When significant to the level of P < 
0.05, data were analyzed further by Wilcoxon’s signed ranks test.
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Results
Triglyceride concentrations: Infusion of lipid emulsions according to clamp 
criteria increased triglyceride concentrations, contrary to isovolumetric saline 
infusion (Table 2). There were no significant differences between serum triglyceride 
levels after LCT or LCT/MCT infusion.
Table 2. Triglyceride concentrations before and after parenteral lipid administration 1
Before After After-before
Lipid-free control 1.44 ± 0.23 1.19 ± 0.23 -0.25 ± 0.15
LCT 1.36 ± 0.30 3.27 ± 0.56 *2 1.91 ± 0.56 **2
LCT/MCT 1.24 ± 0.18 3.54 ± 0.89 *2 2.43 ± 0.68 **2
1 Triglyceride concentrations (means ± SEMs, in mmol/L) in subjects (n = 8) before and after 4-h 
infusion of lipid emulsions or lipid-free control (saline), according to triglyceride clamp criteria. LCT, 
long-chain triglyceride; LCT/MCT, physical mixture of long-chain and medium-chain triglycerides.
2 Significant changes (P < 0.05, W ilcoxon’s signed ranks test) compared with pre-infusion 
concentrations ( ) and saline ( ). Post-infusion triglyceride concentrations after LCT and LCT/MCT 
administration were not significantly different (P = 0.40).
Leukocyte counts: While LCT had no effect compared with lipid-free control, 
LCT/MCT significantly increased absolute peripheral neutrophil counts and 
decreased lymphocyte counts after four hours of lipid administration (Tables 3 and 
4). Monocyte numbers remained unchanged. Saline infusion also slightly but 
significantly decreased lymphocyte counts, while neutrophil and monocyte counts 
remained unchanged. Pre-infusion leukocyte counts between categories were not 
different. After saline infusion, a slight but significant drop in lymphocyte numbers 
was noted.
Table 3. Leukocyte counts before and after lipid administration 1
Lipid-free control 
before after
LCT
before after
LCT/MCT
before after
Neutrophils
Monocytes
Lymphocytes
3.78 ± 0.77 4.80 ± 0.98 
0.63 ± 0.11 0.56 ± 0.09 
1.99 ± 0.23 1.43 ± 0.11
3.20 ± 0.65 
0.58 ± 0.05 
2.00 ± 0.27
4.61 ± 0.78 
0.57 ± 0.05 
1.69 ± 0.12
2.94 ±0.53 
0.57 ±0.07 
2.03 ±0.29
6.36 ± 1.13 
0.47 ± 0.03 
0.81 ± 0.15
1 Peripheral leukocyte population counts (absolute, in 109/L, presented as means ± SEMs) before
and after 4-h infusion o f lipid emulsions or lipid-free control (saline). LCT, long-chain triglyceride;
LCT/MCT, physical mixture of long-chain and medium-chain triglycerides.
For significance o f pre/post-infusion (bold print) and inter-emulsion effects also see Table 4.
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Membrane surface antigen expression and adhesion molecule function: The 
phenotypical changes in leukocytes induced by either treatment were not significantly 
different. Adhesion molecule- and degranulation marker expression was equally 
influenced by either treatment, with decreased expression of p2  integrins CD11b, 
CD11c, CD11d and degranulation marker CD6 6 b after infusion of lipid-free control 
as well as LCT and LCT/MCT (all P < 0.05). No effects of either treatment on the 
expression of the p2  integrin CD11a, and L-selectin (CD62L) were observed. 
Similarly, neutrophil adhesion, as a measure for adhesion molecule function, 
evaluated in the ICAM-1-coated bead assay, did not reveal any effect of either 
treatment (Table 5).
Table 4. The ratio o f leukocyte counts (means ± SEM ’s) after/before parenteral administration1
Lipid-free
control
LCT LCT/MCT ANOVA 3
Total leukocytes 0.99 ± 0.08 1.22 ± 0.08 1.39 ± 0.26 NS
Neutrophils 1.21 ± 0.11 1.42 ± 0.10 2.42 ± 0.47 ***2 a
Monocytes 0.91 ± 0.07 0.99 ± 0.06 0.88 ± 0.12 NS
Lymphocytes 0.74 ± 0.04 0.91 ± 0.08 0.40 ± 0.06 *,n2 b
1 The ratio o f absolute leukocyte counts (medians ± SEM ’s) after/before parenteral administration 
o f lipid emulsions or lipid-free control (saline) in subjects (n = 8). LCT, long-chain triglyceride; 
LCT/MCT, physical mixture o f long-chain and medium-chain triglycerides.
2 Significant treatment effects compared with saline (W ilcoxon’s signed ranks test, P < 0.05) are 
indicated with , significant effects o f LCT/MCT (P < 0.05) compared with LCT are indicated with**
3
Two-way ANOVA: a: significant effect (P = 0.014) o f lipid administration on neutrophil counts; 
b, significant effect o f lipid administration (P < 0.001) on lymphocyte counts.
The expression of CD14, the most important LPS-receptor, on peripheral blood 
mononuclear cells (PBMC), comprising lymphocytes and monocytes, was not altered 
by either treatment.
Neutrophil oxygen consumption and oxygen radical production: Neutrophil 
oxygen consumption and chemiluminescence, indicating overall oxygen radical 
production, were not influenced by either treatment, neither after stimulation with a 
receptor-independent (PMA) or a receptor-dependent stimulus (STZ), nor in the 
absence of any stimulus. Also, the production of specific reactive oxygen 
intermediates, superoxide and hydrogen peroxide, was not distinctively altered by 
either treatment (Table 6 ). Remarkably, with the exception of oxygen consumption, 
all other function tests yielded slightly, but significantly decreased outcomes after the 
infusion of saline, as well as with both lipid emulsions (all P < 0.05).
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Table 5. Leukocyte antigen expression and adhesion before and after parenteral lipid administration 1
membrane surface 
antigen expression
Lipid-free
control
LCT LCT/MCT ANOVA 2
Neutrophil CD11a 0.84 ± 0.06 0.87 ± 0.06 0.78 ± 0.08 NS
CD 11b 0.83 ± 0.05 0.87 ± 0.06 0.72 ± 0.06 NS
Cd11c 0.75 ± 0.04 0.82 ± 0.04 0.65 ± 0.04 NS
CD11d 0.50 ± 0.07 0.53 ± 0.05 0.54 ± 0.05 NS
CD62L 1.10 ± 0.11 1.10 ± 0.09 1.14 ± 0.14 NS
CD66b 0.83 ± 0.03 0.94 ± 0.12 0.80 ± 0.12 NS
PBMC CD 14 1.00 ± 0.05 0.92 ± 0.05 0.99 ± 0.06 NS
Neutrophil adhesion 3 0.90 ± 0.08 0.94 ± 0.12 0.84 ± 0.14 NS
1 Effects o f parenteral administration o f lipid emulsions or lipid-free control (saline) in subjects (n = 
8) on the expression o f membrane antigens (adhesion (CD11a, CD11b, CD11c, CD11d), 
degranulation (CD66b) and activation markers (CD62L) and lipopolysaccharide (LPS) receptor 
(CD14)), depicted as the ratios (means ± SEMs) o f fluorescence after/before lipid administration. 
LCT, long-chain triglyceride; LCT/MCT, physical mixture o f long-chain and medium-chain 
triglycerides.
2 Two-way ANOVA revealed no significant treatment effects o f any lipid emulsion compared with 
saline for the expression o f neutrophil and PBMC membrane antigens or adhesion.
3 Effects o f administration o f lipid emulsions or saline on neutrophil adhesion, depicted as the ratios 
(medians ± SEMs) o f the percentage beads, coated with intercellular adhesion molecule-1 (ICAM- 
1), bound by neutrophils after/before lipid administration.
Discussion
Our results indicate that MCT-containing lipid emulsions, at clinically relevant 
concentrations and more than pure LCT or the lipid-free control saline, differentially 
modulate peripheral human leukocyte population numbers in vivo, with increased 
neutrophil and decreased lymphocyte numbers. As presented in tables 3 and 4, the 
effect on leukocyte numbers was most pronounced with LCT/MCT, although a 
tendency towards leukocyte population shifts in the same direction was observed with 
LCT and the lipid-free saline control. In contrast with LCT/MCT, the effects of LCT 
and saline infusion were not significantly different.
Our observations suggest that MCT, more than LCT, trigger some response of the 
immune system. This is in accordance with previous studies showing that MCT, but 
not pure LCT, activate neutrophils at triglyceride concentrations in a similar 
clinically relevant concentration range (2.5 mmol/L and well below) [17-19]. The 
mechanism behind this MCT effect is unclear and intriguing, given the fact that the 
number of various leukocyte types present in peripheral blood is regulated by 
numerous homeostatic mechanisms that govern cell production, release and 
elimination [32]. Also, it remains to be established to what extent the function of the 
immune system is compromised by the observed MCT effect, as all leukocyte counts 
in the present study remained within fairly normal ranges. In this respect, another point
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of interest is whether the MCT effect on cell numbers is more pronounced after 
prolonged periods of lipid administration, such as in patients on home TPN.
Apart from the fact that with both saline and lipid emulsions solutions are 
administered that are free of serum proteins, we have no explanation for the finding that 
the lipid-free saline control induced alterations in lymphocyte population numbers and 
neutrophil phenotype similar to LCT/MCT. It is clear that saline infusion in the context 
of our experimental setting should not be regarded as a true placebo, but merely as a 
lipid-free control. The fact that the LCT emulsion exerted no effects compared with the 
lipid-free control makes it improbable that emulsion components other than lipids, such 
as the emulsifier or anti-oxidants, are responsible for the emulsion effects.
In contrast with previous in vitro studies [17,18], with the in vivo design in the present 
study no activating effects of LCT/MCT were observed on neutrophil functions and 
phenotype. Contradicting observations with different study designs are numerous [11­
13,15,16,33]. An explanation for this discrepancy might be given by the tendency of 
activated leukocytes to leave the circulating blood pool, from which blood samples are 
taken. Leukocyte activation, with increased cellular adhesion, leukocyte margination and 
pulmonary leukostasis is a well-known phenomenon in hemodialysis [34-37]. Sampling 
of peripheral neutrophils in this situation might result in false-negative findings. This is 
supported in the present study by the observed leukocyte population shifts with 
LCT/MCT, in contrast with an unaltered peripheral neutrophil phenotype after exposure 
tot the same emulsion.
Table 6. Neutrophil oxygen radical production before and after parenteral lipid administration 1
Lipid-free
control
LCT LCT/MCT ANOVA 2
Oxygen consumption 0.93 ± 0.10 0.95 ± 0.20 0.95 ± 0.12 NS
Superoxide (PMA) 0.74 ± 0.15 0.79 ± 0.18 0.78 ± 0.08 NS
Hydrogen peroxide 
(PMA)
0.77 ± 0.07 0.81 ± 0.10 0.72 ± 0.07 NS
Chemiluminescence
PMA 0.72 ± 0.15 0.82 ± 0.16 0.74 ± 0.12 NS
STZ 0.81 ± 0.13 0.85 ± 0.13 1.00 ± 0 .27 NS
1 Effects o f intravenous administration o f lipid emulsions or lipid-free control (saline) according to 
triglyceride clamp criteria in volunteers (n = 8) on the ratios (after/before; means ± SEMs) of 
neutrophil oxygen consumption and oxygen radical production, as indicated by superoxide and 
hydrogen peroxide production or chemiluminescence, as induced by phorbol myristate acetate
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(PMA) or serum-treated zymosan particles (STZ)). LCT, long-chain triglyceride; LCT/MCT, 
physical mixture o f long-chain and medium-chain triglycerides.
2 ANOVA revealed no significant different treatment effects o f LCT and LCT/M CT compared with 
saline.
The fact that neutrophil numbers did not decline after migration from the peripheral 
vascular compartment might be explained by influx of non-activated leukocytes from 
the marginal pool.
That the original leukocyte population is replenished by an influx of leukocytes 
(most probably from the marginal pool) might also be indicated by the observation 
that various neutrophil membrane markers and functions were significantly decreased 
after lipid or saline administration: substitution of activated leukocytes that have left 
the vascular compartment by ‘fresh’ leukocytes from the marginal pool might result 
in such decreased expression of neutrophil antigens may well indicate the presence of 
a new leukocyte population.
In conclusion, MCT-containing emulsions, more than pure LCT, differentially 
modulate human circulating leukocyte population counts. However, in contrast with 
previous in vitro studies, lipid effects on the function of peripherally sampled 
neutrophils were not observed. The latter might be due to selective disappearance of 
activated leukocytes from the circulation, thus explaining the contradicting results of 
previous in vivo and in vitro studies.
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Parenteral administration of medium-, but not long-chain lipid emulsions may 
increase the risk for infections by Candida albicans
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Cytokines and growth of Candida
Abstract
We have previously observed that medium-chain triglyceride- (MCT) containing 
lipid emulsions decrease the capacity of neutrophils to kill Candida albicans in vitro. 
In the present in vivo study we evaluated various lipids for their effects on aspects of 
the pathogenesis of infections by Candida: i) yeast growth and ii) balance of pro- and 
anti-inflammatory cytokine production. Long-chain- (LCT), a physical mixture of LCT 
and MCT emulsions, or placebo were administered to eight volunteers in a crossover 
study design. Before and after lipid administration, growth of Candida in serum and 
Candida-induced cytokine production by mononuclear cells were evaluated. The 
growth of Candida in serum increased after administration of LCT/MCT, while LCT 
showed no effect compared with placebo. When compared with placebo, LCT/MCT, 
contrary to LCT, also modulated Candida-induced cytokine production in a way that 
favors fungal infections. These results suggest that MCT, contrary to LCT, increase 
the risk for infections by C. albicans.
Introduction
Total parenteral nutrition (TPN) has proven to be an indispensable strategy to 
maintain and improve the nutritional status in critically ill patients. It remains 
controversial however, whether alteration of immune responses by the lipid component 
of TPN contributes to the increased risk for infectious complications that is observed in 
these patients [1]. Most infections during TPN are central-venous-line-associated and 
due to Gram-positive microorganisms (Staphylococcus, Enterococcus) or fungi 
(Candida species) [11]. In a recent Australian study it was reported that 5.2% of all 
patients receiving TPN eventually developed candidaemia, with significant mortality 
and morbidity and need for toxic antifungal chemotherapy [40].
It is unclear whether the structurally different emulsions that are used as part of 
parenteral nutrition formulations exert distinct immune-modulating effects. The most 
widely used emulsions contain either pure long-chain triglycerides (LCT) or a 
physical mixture of long- and medium-chain triglycerides (LCT/MCT). Previous 
studies have shown equivocal results with respect to effects on function of the immune 
system of intravenous lipid emulsions [1,10,12,16,17,27,30,34,39,50]. Furthermore, 
results of in vivo and in vitro studies have also yielded contradictory results 
[5,9,20,35,44,49]. Recently it has been shown that MCT-containing emulsions in vitro, 
at clinically relevant concentrations and contrary to pure LCT, exert immune- 
modulating effects by directly inducing human neutrophils to produce oxygen radicals 
and enhance radical production by stimulated neutrophils [22,45].
Also, exposure to MCT, but not LCT, results in neutrophil activation, with increased 
cellular adhesion and decreased motility [46,47].
Importantly, we also observed that neutrophil killing of Candida in vitro is impaired 
after exposure to MCT emulsions, while exposure to pure LCT had no adverse effects 
[48]. We therefore performed the present study to confirm our findings in the in vitro 
setting. In contrast with previous studies, we created a setting where parenteral admi­
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nistration, in clinically relevant concentrations, exposes the lipid emulsions to whole 
body metabolism and the immune system of healthy volunteers. Given its clinical 
importance as a major pathogen in the patient category receiving TPN, we 
investigated the lipid effects on two important aspects of the pathogenesis of 
infections by Candida: yeast growth and the balance of pro- and anti-inflammatory 
cytokines [31,36]. The latter are mediators produced by mononuclear cells of the 
adaptive immune system, which trigger the innate immune system, especially 
macrophages and neutrophils, known to be the major component of the anti-fungal 
defense system. In this setting we studied the production of pro-inflammatory 
(interferon-y, tumor necrosis factor-a, interleukin-1 p and interleukin-6 ) and anti­
inflammatory (interleukin-10) cytokines [3,8,21,32]. Because of the previously 
described effects on neutrophil function we also evaluated the chemokine interleukin- 
8 , which has multiple functions and acts as a chemotactic and activating factor for 
neutrophils [18].
Materials and methods
Subjects and study design: Appropriate informed consent from all participating 
volunteers was obtained and the human experimentation guidelines of the authors’ 
institution were followed in the conduct of this study. Eight healthy Caucasian male 
volunteers [median age: 28yrs; range 24-31; body mass index (BMI; in kg/m ) range: 
20.5-24.2], none of whom was on medication, were included in the study. After an 
overnight fast, blood samples were drawn and processed as described. Serum 
triglyceride concentrations were determined colorimetrically on a Hitachi-747 
analyzer (Hitachi Ltd., Tokyo, Japan).
Lipid administration: Emulsions containing long-chain triglycerides (LCT), mixed 
long-chain and medium-chain triglycerides (LCT/MCT) or placebo (saline) were 
administered intravenously in a crossover study design, with a washout period of one 
week. Emulsions were infused according to the plasma triglyceride (TG) clamp 
technique as described by Iriyama et al. [18,19]. In order to clamp plasma TG 
concentrations at a concentration of 3-5 mmol/L, emulsions were infused at a rate of 
0.5 g/kg BW/h for 10 min (priming), and were then reduced to 0.3 g/kg BW/h to 
reach a stable plasma concentration of 3-5 mmol/L. Fifty minutes after the initiation 
of lipid infusion, the TG concentration in plasma was clamped by infusion at a rate of 
0.11 g/kg BW/h for another 190 min.
Materials: Reagents were from Sigma Chemicals (St Louis, MO), unless stated 
otherwise. Isotonic lysis solution contained 155 mmol/L NH4 Cl, 10 mmol/L KHCO3  
and 0.1 mmol/L EDTA (pH 7.4). Phosphate-buffered saline (PBS) contained Na+ 
163.9 mmol/L, Cl- 140.3 mmol/L, HPO42- 10.9 mmol/L- and H2 PO4- 1.8 mmol/L- (pH 
7.4). Percoll (p 1.129 g/mL at 20°C) was from Pharmacia Biotech AB (Uppsala, 
Sweden). LCT emulsion (Intralipid 20%) was from Fresenius Kabi (Stockholm, 
Sweden). LCT/MCT emulsion (Lipofundin 20%) was from B. Braun Melsungen AG 
(Melsungen, Germany). For lipid emulsion characteristics see Table 1. Blood samples
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were collected in 10 mL Monoject tubes (Sherwood Medical, Ballymoney, N. 
Ireland, UK) with 143 USP units of lithium heparin. Sabouraud glucose medium (and 
agar), containing peptone 10 g/L, glucose 20 g/L, chloramphenicol 0.2 mg/ml (and 
agar 15 g/L) were from Oxoid Ltd, Basingstoke, Hampshire, UK. Petri dishes 
(Sterilin Triple Vent, 90 mm diameter) were from Bitsby Sterilin Ltd, Stone, 
Staffordshire, UK.
Leukocyte isolation: Leukocyte isolation was performed as described previously 
[7,45]. Leukocytes were purified from blood anticoagulated with lithium heparin. The 
blood, diluted 1:1 with PBS with 0.4% (wt/vol) trisodium citrate (pH 7.4), was placed 
on Percoll (p 1.076 g/mL) and centrifuged (700 x g, 18 min, 25°C). The overlying 
peripheral blood mononuclear cell (PBMC) fraction was collected, washed twice in 
saline, and suspended in medium (RPMI 1640 DM, Flow Laboratories, Irvine, UK) 
supplemented with human serum 5%, gentamycin 1% (50 ^g/mL), L-glutamine 1% 
(2 mmol/L) and pyruvate 1% (1 mmol/L). Cells were counted on a Coulter counter 
(Coulter Electronics, Mijdrecht, The Netherlands). Cytospin preparations were > 97% 
pure, as determined by May-Grunwald/Giemsa staining, and contained > 99% viable 
cells, as determined by trypan blue exclusion.
Cytokine measurements: Heat-killed Candida albicans (strain UC820, at 1 x 107  
CFU/mL final concentration) was used for ex vivo stimulation of PBMC in the 
cytokine assays. After PBMC isolation, cell numbers were adjusted to 5 x 106  
cells/mL and 100 ^L cell suspension was incubated in 96-well plates (Greiner B.V., 
Alphen a/d Rijn, The Netherlands) with Candida for 24 h at 37 °C. After incubation, 
the supernatants were frozen at -20°C until assay. Interleukin-1p (IL-1P, in ng/mL) 
and tumor necrosis factor-a (TNFa, in ng/mL) concentrations in supernatants were 
measured in duplicate by radioimmunoassays (RIA) as described elsewhere (25). 
Detection limits of the assay were 20 pg/mL for TNFa and 40 pg/mL for IL-1p. The 
inter-assay variation of this RIA was less than 15%, and the intra-assay variation was 
less than 10%. Controls for spontaneous cytokine release were included in the form 
of unstimulated samples. IL-6 , IL-8 , IL-10 and IFNy concentrations were determined 
in duplicate with commercially available enzyme-linked immunosorbent assay 
(ELISA) kits (Pelikine Compact™ human ELISA, CLB, Amsterdam, The 
Netherlands), according to the instructions of the manufacturer.
Growth of Candida in cell-free serum: After inoculation and overnight culturing at 
37 °C in 50 mL Sabouraud medium, C. albicans was centrifuged (5 min, 400 x g), 
washed and suspended in Sabouraud medium at 106  CFU/mL. 10 ^L Candida 
suspension was incubated for 24h at 37°C with 500 ^L serum samples and 500 jxL 
Sabouraud medium. Growth controls (containing 10 ^L Candida suspension and 
1000 ^L medium) and sample controls (containing 500 ^L serum, 500 ^L medium 
and 10 ^L Candida suspension) were included. After incubation and mixing, 50 jxL 
samples were plated onto Sabouraud glucose agar plates using an automated plating 
device (Whitley automatical spiral plater, Don Whitley Scientific Ltd., Shipley, West 
Yorkshire, UK, with a counting range of 400 to 4 x 105  CFU/mL) and incubated at 29
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°C for 8 h and 24h. Thereafter the colonies were counted and presented as CFU/mL. 
Results are expressed as the ratio of CFU of samples after/before lipid administration.
Statistical analysis: Results are expressed as medians ± SEMs for the number of 
observations indicated. The statistical significance of the effects of lipid 
administration was determined with use of analysis of variance (ANOVA) with 
Bonferroni correction for multiple comparisons, after establishing a sufficiently 
normal data distribution. When significant to the level of P < 0.05, data were 
analyzed further by Wilcoxon’s signed ranks test.
Results
Triglyceride concentrations: Infusion of lipid emulsions according to clamp 
criteria increased triglyceride concentrations, contrary to isovolumetric saline 
infusion (Table 2). There was no significant difference in the serum triglyceride 
levels between after LCT and after LCT/MCT infusion.
Table 2. Effects o f parenteral lipid administration on triglyceride concentrations *
Before After After-before
Placebo 1.48 ± 0.23 1.06 ± 0.23 -0.11 ± 0.15
LCT 0.97 ± 0.30 3.15 ± 0.56f,i 1.67 ± 0.56 §,i
LCT/MCT 1.28 ± 0.18 3.54 ± 0.89f,i 2.43 ± 0.68 §,i
* Triglyceride concentrations (medians ± SEMs, in mmol/L) in subjects (n=8) before and after 4h- 
infusion of lipid emulsions or placebo (saline), according to triglyceride clamp criteria. LCT, long- 
chain triglyceride; LCT/MCT, physical mixture o f long-chain and medium-chain triglycerides.
 ^ Significant changes (P < 0.05, W ilcoxon’s signed ranks test) compared with pre-infusion 
concentrations (*) and placebo (§). Post-infusion triglyceride concentrations after LCT and LCT/MCT 
administration were not significantly different.
Ex vivo cytokine production by PBMC: Here, distinct treatment effects were 
observed (Table 3). Candida-induced production of TNFa, IL-1ß and IL-10 
increased after LCT/MCT exposure of PBMC, while LCT again showed no different 
effects compared with placebo. Candida-induced IFNy production showed a tendency 
to decrease, but did not reach statistical significance. Infusion of LCT or placebo did 
not result in significantly altered production of any cytokine. IL- 8  production of 
PBMC was not distinctively influenced by either treatment.
Growth o f Candida in serum: After infusion of LCT/MCT a significant increase in 
the growth of Candida after 8 h and 24h was observed compared with infusion of both 
placebo and LCT (Fig. 1). Effects of placebo and LCT were not significantly 
different.
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Table 3. Effects o f lipid administration on ex vivo cytokine production by peripheral blood 
mononuclear cells
Stimulus Cytokine Placebo LCT LCT/MCT ANOVA T
Candida Interferon y 1.G1 ± G.65 1.GG ± G.19 G.38 ± G.1G G.11
IL1G G.82 ± G.G9 G.76 ± G.15 1.87 ± G.77i’§ G.G3
TNFa G.69 ± G.12 1.24 ± G.12 2.G1 ± 1.74* G.G4
IL -1ß G.64 ± G.1G 1.G7 ± G.G9 1.75 ± G.23*’§ G.GG1
IL-6 G.74 ± G.44 G.81 ± G.17 1.86 ± G.93 G.16
IL-8 G.83 ± G.G9 1.G9 ± 1.G2 1.35 ± G.25 G.38
Effects o f parenteral administration o f lipid emulsions or placebo (saline) according to triglyceride 
clamp criteria in subjects (n = 8) on the ratio (after/before) o f ex-vivo cytokine production (medians 
± SEMs) by peripheral blood mononuclear cells. LCT, long-chain triglyceride; LCT/MCT, physical 
mixture o f long-chain and medium-chain triglycerides
 ^ Two-way ANOVA revealed significant differences (P < G.G5) as indicated. Significant differences 
compared with placebo (W ilcoxon’s signed ranks test) are indicated with *, significant effects of 
LCT/MCT compared with LCT are indicated with §.
Figure 1: Effects o f parenteral lipid emulsions on growth o f Candida albicans
era
IÌ5
Ll_o
♦ placebo
*  - -LCT
-A—  LCT/MCT
Incubation time (h)
Effects o f intravenous administration o f lipid emulsions or placebo in subjects (n=8) on growth 
(expressed as the ratio (median±SEM) o f CFU/mL after 8h and 24h incubation o f samples obtained 
after/before lipid infusion) o f Candida albicans}n  cell-free serum from subjects.
* Significance (P < 0.01, W ilcoxon’s signed ranks test) of treatment effects compared with placebo 
and LCT as indicated.
** Significance (P < 0.02, W ilcoxon’s signed ranks test) o f treatment effects compared with placebo 
and LCT as indicated.
*
143
Chapter 10
Discussion
Infections by fungal pathogens such as C. albicans pose a serious threat to the use of 
TPN in often already critically ill patients [11,40] Outcome in these infections is 
largely dependent on candidal growth rates on one side and counteracting immune 
responses on the other. The latter involves the interplay of candidacidal cells of the 
innate immune system (macrophages and neutrophils) and cells of the adaptive 
immune system that produce cytokines with an activating (IFN-y, IL-1P, IL-6 , TNF-a) 
or a de-activating (IL-10) effect on the phagocytes [32,33]. The main conclusion from 
the present study is that parenteral administration of an MCT-containing lipid 
emulsion, at clinically relevant concentrations and contrary to pure LCT, favors the 
development of infections by Candida in both ways. First, yeast growth-rate in cell- 
free serum of healthy humans appears to be enhanced by the MCT-emulsion. In 
addition, an altered balance of pro- and anti-inflammatory cytokines is established by 
the MCT emulsion that is known to deactivate the innate immune system and hence 
increases the risk for fungal infection [32,33].
The present in vivo findings support those of an in vitro study in which we observed 
that MCT emulsions, in contrast with pure LCT, impair the killing of Candida by 
neutrophils [48].
It has been shown that infusion of lipoproteins into healthy human subjects promotes 
the growth of C. albicans [31], and enhanced candidal growth has also been 
established in hyperlipoproteinemic mice [6 ]. Furthermore, earlier in vitro studies 
performed with LCT-containing parenteral solutions already have reported that 
Candida grows better in a lipid-rich environment [13,26,38]. The fact that we could not 
demonstrate a growth-enhancing effect on Candida for LCT after parenteral 
administration suggests that with its metabolic breakdown the effects of LCT on 
candidal growth disappear, a clear contrast with the situation for MCT. Although the 
effect on yeast growth may well reflect a direct effect of (metabolites of) the MCT 
lipid emulsion, a role for mediators released by immune-competent cells cannot be 
excluded. In this respect it is important to note that MCT emulsions have been shown 
to activate human neutrophils, with subsequent degranulation and oxygen radical 
production [45,46].
The relative importance of the finding of the increased TNF-a and IL-1P, and -to a 
lesser extent- IL-8 - production after MCT infusion, which should be considered 
protective, remains unclear and probably can only be evaluated in a clinical study.
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Others have studied the effects of various lipid emulsions on cytokine production 
by mononuclear cells in both humans and animals, yielding inconsistent data 
[2,4,14,15,38,42,43]. Gogos et al. administered LCT or LCT/MCT to malnourished 
patients for more than 30 days. These authors found TNFa production to be increased 
in the LCT group, while no effects were detected in the LCT/MCT group [14]. 
Altogether, these studies suggest that varying results can be obtained in (i) in vitro 
versus in vivo experiments, (ii) studies in seriously ill patients versus healthy 
volunteers and (iii) studies employing different periods of lipid administration.
The altered balance of Candida-induced cytokine production by PBMC, with 
increased production of IL-10 (by Th2-lymphocytes) and unchanged or decreased 
IFN-y (by Th1-lymphocytes) results in a decreased IFN-y / IL-10 ratio. Such 
imbalance in Th1 and Th2 responses is considered as a major risk factor for the 
development of fungal infections [8,32,36]. On the other hand, it is also possible that 
the IL-10 measured in our experiments was produced by monocytes.
IFN-y activates phagocytic cells to kill Candida, whereas IL-10 has been shown to 
inhibit the pro-inflammatory cytokine production and to aggravate the course of 
disseminated candidiasis [24,28,41]. The influence of the LCT/MCT emulsion on 
IFN-y (decreased) and monokine production (increased), in combination with the lack 
of such effects with pure LCT, suggest that MCT have a differential effect on T-cells 
and monocytes. LCT exerted no effects on cytokine production when compared with 
placebo, rendering it improbable that components other than the lipids, e.g. emulsifier 
or anti-oxidants, are responsible for the emulsion effects. Finally, it has to be kept in 
mind that definite proof for the effects of lipids on the susceptibility to fungal 
infections in humans can only be obtained in large-scale clinical studies.
In conclusion, the results of this in-vivo study, in accordance with in-vitro 
observations, suggest that parenteral administration of MCT-containing lipid 
emulsions, contrary to pure LCT, increases the risk for infections with C. albicans, 
both by increasing candidal growth rates as well as by a detrimental effect on immune 
responses that trigger anti-fungal defenses.
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Membrane fluidity
Abstract
Background: We have previously reported that medium-chain-triglyceride (MCT)- 
containing lipid emulsions, contrary to long-chain (LCT) emulsions, activate human 
neutrophils. This activation might result from functional alterations in cellular 
membranes induced by MCT. Membrane fluidity is such a feature with known 
clinical implications, and can be assessed by fluorescence polarization measurements. 
The present study was performed to investigate whether exposure to various 
emulsions distinctively influences neutrophil membrane fluidity.
Methods: Neutrophils from 8  volunteers were incubated in medium or physiolo­
gical 2.5 mmol/L emulsions containing LCT, mixed LCT/MCT or structured lipids 
(SL). Subsequently, the cells were washed and anisotropy, i.e. the reciprocal of 
fluidity, was measured using the fluorescent probes 1 ,6 -diphenyl-1,3,5-hexatriene 
(DPH) and trimethyl-ammonium (TMA)-DPH.
Results: Compared to non-lipid-exposed neutrophils, LCT/MCT and, to a lesser 
degree, SL decreased fluorescence anisotropy, and thus increased membrane fluidity, 
as measured by DPH-anisotropy, while LCT had no effect. Similar results were 
obtained with the more polar probe TMA-DPH.
Conclusions: These data suggest that the neutrophil-activating effect of MCT- 
containing emulsions may, at least in part, be mediated by an effect on cellular 
membrane fluidity.
Introduction
Lipids and fatty acids are recognized as important mediators in immune responses 
and inflammatory processes. On the other hand, immune suppressive effects of the 
lipid component, especially with regard to phagocyte function, seem to play a role in 
the increased infectious complication rate in patients on total parenteral nutrition 
(TPN) [1,2]. Previously, long-chain triglyceride (LCT) emulsions have shown 
detrimental effects on several aspects of neutrophil function in some, but not all 
studies [3,4]. Another emulsion type consists of a physical mixture of 50% medium- 
chain triglycerides (MCT, with saturated fatty acids of 6  to 12 carbons) and 50% 
LCT. As with LCT, equivocal data exist regarding the effects of LCT/MCT on 
neutrophil function [5-7]. Information on synthetic structured lipids (SL), with 
medium- and long-chain fatty acids randomly attached to a single glycerol molecule, 
remains limited so far.
We have previously reported that MCT-containing emulsions, in contrast with pure 
LCT, influence several aspects of human neutrophil function, with increased 
spontaneous and stimulus-induced formation of oxygen radicals and adhesion, 
degranulation, decreased motility and impaired killing of the yeast pathogen Candida 
albicans [8-11]. The latter suggests that ‘inappropriate’ activation of immune 
competent cells by MCT results in decreased cellular effector functions, for instance 
due to an exhausted cellular metabolism. Also, distinct effects of MCT- versus LCT-
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2+containing emulsions on cellular Ca -signaling and activation of neutrophils have 
been observed [1 2 ].
The underlying mechanism for this activating effect of MCT-emulsions is the 
focus of our present investigation. Apart from pathways involving enzymes such as 
protein kinase C (PKC), enzyme-independent activation has also been identified in 
neutrophils [13,14]. The latter may be accomplished by modulation of the 
physicochemical nature of the cellular membrane [15,16]. This might imply an effect 
on membrane fluidity: a complex feature involving mobility and order of membrane 
components as well as membrane permeability properties, with an important role in 
membrane-bound enzyme and -receptor functions [17,18]. Changes in membrane 
fluidity are implicated in the pathophysiology of numerous diseases, such as 
rheumatoid arthritis and diabetes mellitus [19,20]. Membrane fluidity can be assessed 
by spectroscopy using fluorescent probes, such as 1,6-diphenyl-1,3,5-hexatriene 
(DPH) or the more polar trimethyl-ammonium (TMA)-DPH [20,21]. These probes 
have been widely used to measure membrane fluidity, as they characterize the 
complete cell membrane apparatus by penetrating both the plasma- and intracellular 
membranes [2 2 ].
To test the hypothesis that the neutrophil-activating effects of lipid emulsions are 
mediated through effects on cellular membrane fluidity, we investigated the effect on 
fluorescence polarization measurements of various emulsions.
Materials and methods
Subjects: Eight healthy Caucasian volunteers (4 males, median age 28 yrs; range: 
27-37), none of whom was on medication, were included in the study. All procedures 
followed were performed after obtaining informed consent and were in accordance 
with the ethical standards of the institutional committee on human experimentation. 
After an overnight fast, blood samples were drawn and processed as described below. 
Serum triglyceride concentrations (median 0.95 mmol/L; range 0.55 - 1.37) were 
determined colorimetrically by means of an in vitro enzymatic assay in which 
triglycerides are hydrolyzed with lipase to yield glycerol. Next, via glycerolphosphate 
hydrogen peroxide is produced, which reacts with aminophenazone to give a red 
chromophore that can be measured spectrophotometrically at 505 nm with a Hitachi 
747 analyzer (ROCHE Diagnostics, Almere, The Netherlands).
Reagents: Reagents were from Sigma Chemicals (St. Louis, MO) unless stated 
otherwise. Hank's balanced salt solution (HBSS) was from Life Technologies 
(Paisley, Scotland). Phosphate-buffered saline (PBS) contained Na+ 163.9 mmol/L, 
Cl" 140.3 mmol/L, HPO42- 10.9 mmol/L and H2 PO4" 1.8 mmol/L- (pH 7.4). Isotonic 
lysis solution contained 155 mmol/L- NH4 Cl, 10 mmol/L- KHCO3 and 0.1 mmol/L 
EDTA (pH 7.4). Incubation medium contained HBSS supplemented with 0.5% (w/v) 
human serum albumin (HSA; from Behring, Westwood, MA). Percoll (p 1.129 g/mL 
at 20°C) was from Pharmacia Biotech AB, Uppsala, Sweden. LCT (Intralipid 20%) 
and SL (Structolipid) were from Fresenius Kabi, Stockholm, Sweden. LCT/MCT
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emulsion (Lipofundin 20%) was from B. Braun Melsungen AG, Melsungen, 
Germany. For emulsion characteristics see Table 1. Blood samples were collected in 
10 mL Monoject tubes (Sherwood Medical, Ballymoney, N. Ireland) with 143 USP 
units of lithium heparin.
Cell isolation: Neutrophils were purified from whole blood, anti-coagulated with 
lithium heparin [14,23]. The blood, diluted 1:1 with PBS with 0.4% (wt/vol) 
trisodium citrate (pH 7.4), was placed on Percoll (p 1.076 g/mL) and centrifuged 
(700 x g, 18 min, 25°C). The pellet was suspended in 50 mL of ice-cold lysis solution 
for 10 min. After centrifugation (5 min, 400 x g, 4°C), remaining erythrocytes were 
lysed in fresh lysis solution for another 5 min. The cells were then washed and 
resuspended in incubation medium to a final concentration of 2 x 106  /mL and were 
kept at room temperature. Cytospin preparations were > 97% pure and > 99% viable 
as determined by May-Grunwald/Giemsa staining and trypan blue exclusion.
Lipid incubation of neutrophils: Isolated neutrophils were incubated for 1 h at 
37°C in medium or 2.5 mmol/L lipid emulsions: a ‘physiological’ lipid concentration 
that is easily reached in the circulation when lipids are administered intravenously 
and which established distinct effects between various emulsion types in previous 
studies [8-12]. After lipid incubation the cells were washed twice in medium and 
than labeled with the fluorescent probe.
Fluorescence labeling o f neutrophils: 1,6-diphenyl-1,3,5-hexatriene (DPH) was 
dissolved in tetrahydrofuran at a concentration of 2 mmol/L [20,24]. For cell labeling, 
the DPH stock solution was diluted 1000-fold by injection into vigorously stirred PBS. 
One mL of this DPH solution was added to 1 mL of neutrophil suspension (2 x 106  
cells/mL). After 30-min incubation at 37° C the labeled cells were used for 
fluorescence measurements.
For TMA-DPH labeling a TMA-DPH stock solution in acetone was prepared [25]. 
One mL of neutrophil suspension (2 x 106  cells/mL) was pre-incubated for 4 min at 
4°C with 1 ml of 1000-fold diluted TMA-DPH stock solution (2 ^mol/L TMA-DPH 
final, in PBS) and incubated for 20 min at 37°C. Next, fluorescence polarization 
measurements were performed.
Fluorescence polarization analysis: DPH fluorescence polarization was measured 
using a thermostatted Shimadzu RF-5000 spectrofluoro-photometer (Kyoto, Japan) 
coupled to a polarization unit. The excitation and emission wavelengths were 365 nm 
and 430 nm, respectively. The fluorescence anisotropy rs, the reciprocal of fluidity, 
was measured by determining emission intensities (I) through an analyzer oriented 
parallel (111) and perpendicular (I 1) to the direction of polarization of the excitation 
light according to rs = (111 - I x) / (111 + 2 I x) at 37°C [26].
Statistical analysis: Results are expressed as medians ± SEM for the number of 
observations indicated. Wilcoxon’s signed ranks test (two-tailed) was used for 
analysis of results.
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Results
When compared with medium, exposure of neutrophils to 2.5 mmol/L- LCT/MCT 
and SL emulsions, contrary to LCT, resulted in significantly decreased fluorescence 
anisotropy with both the DPH and the more polar TMA-DPH probes, indicating 
increased membrane fluidity (Table 2). DPH anisotropy of the LCT/MCT emulsion 
was also decreased compared to SL (P=0.012), while for TMA-DPH the difference 
between LCT/MCT and SL emulsions was not statistically significant (P=0.22). 
Results for LCT and SL were different from each other for measurements with TMA- 
DPH (P=0.04), but were not statistically significant for DPH (P=0.09).
Table 2. M easurement o f fluorescence polarization with DPH and TM A-DPH as fluorescent probes 
in neutrophils isolated from whole blood o f volunteers (n=8), after ex-vivo exposure to medium or 
2.5 mmol/L lipid emulsions containing long-chain triglycerides (LCT), mixed long-chain and 
medium-chain triglycerides (LCT/MCT) or structured lipids (SL).
DPH TMA-DPH
Medium 0.181 ± 0.009 0.256 ± 0.006
LCT 0.170 ± 0.007 0.255 ± 0.006
LCT/MCT 0.129 ± 0.012 * 0.240 ± 0.003 **
SL 0.160 ± 0.012 * 0.249 ± 0.003 **
Data are presented as medians ± SEMs o f eight separate experiments. Significant changes compared 
to non-lipid- exposed neutrophils are indicated with * (P < 0.01) or ** (P < 0.03).
Discussion
Our results suggest that lipids modulate neutrophil membrane fluidity depending 
on their triglyceride structure: increased fluidity was measured after exposure to an 
MCT-containing emulsion, while pure LCT showed no effect. Structured lipids, with 
both medium- and long-chain fatty acids attached to the glycerol backbone, displayed 
an intermediate effect. The latter may be due to the presence of medium-chain fatty 
acids in structured lipids, resulting in a partial MCT effect. On the other hand, also 
structural characteristics involving the relatively unique triglyceride backbone of the 
structured triglyceride may play a role. Our findings are in accordance with findings 
in a pilot study where pure MCT increased neutrophil membrane fluidity even more 
than the LCT/MCT mixture [27].
Importantly, our results reveal altered cellular membrane fluidity as a possible 
mechanism for the previously observed activation of neutrophils by MCT [8-12]. 
Three different pathways have been postulated for the stimulus-dependent activation
of neutrophils. The first is a protein kinase C (PKC)-mediated reaction induced by
2+phorbol esters, dioctanoyl glycerol and Ca -ionophores. The second is a reaction 
induced by the tripeptide formyl-methionyl-leucyl-phenylalanine (fMLP) or
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opsonized zymosan particles [13,15]. The third is a modulation of the 
physicochemical nature of the cellular membrane by detergents or fatty acids [15,16]. 
Membrane fluidity is such a feature of the physicochemical nature of the cellular 
membrane with an important role in regulating cellular functions through membrane- 
bound enzyme- and receptor functions. Fluidity as measured by spectroscopic 
techniques comprises various aspects of mobility and order of membrane components 
as well as membrane permeability properties [20,28].
The experiments were performed using DPH as well as the more polar TMA-DPH. 
With the lipophilic DPH, deposition of the fluorescent probe in emulsion particles in 
theory could disturb the fluidity measurements. This factor is ruled out by the similar 
results obtained with the lipophobic TMA-DPH, which has been previously shown to 
locate specifically in plasma membranes of whole living cells [2 1 ].
Neutrophil activation by various mediators has been shown to be accompanied by 
an increase in fluidity of the cellular membrane [29,30]. We have previously shown 
that MCT-containing emulsions activate human neutrophils, in contrast with pure 
LCT, in the absence of other stimulating agents [8,10]. It could therefore be argued 
that changes in membrane fluidity after lipid exposure are simply the consequence of, 
rather than the cause for, neutrophil activation by MCT. However, it is difficult to 
explain that structured lipids significantly increased membrane fluidity while 
exposure to this emulsion did not result in significant neutrophil activation in the 
previous studies, unless a threshold for the effect is assumed.
In conclusion the results of the present study suggest that the previously observed 
activation of neutrophils by MCT-containing emulsions may be mediated through 
effects on cellular membrane fluidity, while pure LCT lack such an effect.
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STZ-induced calcium signaling
Abstract
To answer the question whether immunomodulation contributes to the increased 
infection rate observed in patients treated with parenteral nutrition, we evaluated the 
effects of structurally different lipid emulsions on the activation of human neutrophils
with either serum-treated zymosan particles (STZ) or N-formyl-methionyl-leucyl-
2 +phenylalanine (fMLP). STZ evoked a biphasic increase of the average cytosolic Ca
2 +concentration ([Ca ]i,av) in a suspension of fura-2 -loaded cells, consisting of a first
2 +slow phase that gradually turned into a second fast phase until a plateau [Ca ]i,av was
2 +reached. STZ-induced Ca signalling was abolished by the phospholipase C inhibitor
U73122 and the protein kinase C (PKC) inhibitor staurosporine, whereas the PKC
2 +activator PMA markedly increased the initial rate of [Ca ]i,av rise. In addition, PMA 
2 + 2 + reduced the [Ca ]i,av plateau. The effect of PMA on the rate of [Ca ]i,av rise was
mimicked by emulsions that contained medium-chain triglycerides (MCTs) but not
by emulsions that consisted solely of long-chain triglycerides or structured lipids.
However, all lipid emulsions activated partially purified PKC in a PMA-like manner.
Taken together, these findings indicate that only the MCT-containing emulsions can
activate PKC in the context of the intact cell. Both PMA and MCT-containing
emulsions evoked a leftward shift of the dose-response curve for the effect of STZ on
2 +the initial rate of [Ca ]i,av rise, reflecting PKC-dependent sensitization of PMNs for 
stimulation by STZ. The effect of PMA on the STZ-induced [Ca2 +]i,av plateau was
mimicked by all lipid emulsions. Similarly, all lipid emulsions reduced the fMLP-
2 +induced peak increase in [Ca ]i,av. Because this latter inhibition was not reversed by 
staurosporine it occurs in a PKC-independent manner. This study shows that 
nutritional lipid emulsions can modulate neutrophil stimulation in two ways: i) lipid 
emulsions containing MCTs sensitize these cells for STZ in a PKC-dependent manner, 
and ii) all lipid emulsions reduce the stimulatory effect of STZ and fMLP in an 
aspecific manner.
Introduction
Total parenteral nutrition (TPN) implies that all nutritional requirements are met by 
the administration of an intravenous solution. In the last decades this technique has 
established itself as an indispensable strategy to improve and maintain the nutritional 
status in critically ill patients. Unfortunately, the associated risk for infectious 
complications remains a major drawback in which immunosuppressive effects of TPN 
components, especially lipids, seem to play a role [1-3]. Thus far, however, the 
immunomodulatory properties of the most widely used emulsion, Intralipid, containing 
long-chain triglycerides (LCT), are not clearly understood as several studies, both in vivo 
and in vitro, have yielded equivocal results [4-13]. Furthermore, data on structurally 
different emulsions, e.g. physical mixtures of LCT and medium-chain triglycerides 
(LCT/MCT) or the synthetic structured lipids (SL, with long-chain and medium-chain 
fatty acids attached to one glycerol molecule), are limited or lacking [14-16].
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The latter also applies for a new LCT/MCT emulsion, enriched with vitamin E, in the 
form of a-tocopherol (LCT/MCT-E).
We recently reported distinct effects of various lipid emulsions on several important 
human neutrophil effector functions, such as oxygen radical production, adhesion and 
degranulation, and migration [17-19]. It was found that, in a for TPN patients 
physiological triglyceride concentration range (up to 10 mM), MCT-containing 
emulsions, contrary to pure LCT or SL emulsions, directly activate neutrophils to 
execute these functions. Considering the possible repercussions in clinically important 
situations, e.g. in case of invading pathogens, the present study was undertaken to 
study the effects of these various lipid emulsions at physiological concentration levels
on signaling pathways that are involved in neutrophil activation: second messenger
2 +(Ca ) mobilization and protein kinase C (PKC) activation. Two different receptor- 
mediated neutrophil activators were used: opsonized yeast particles (serum-treated 
zymosan; STZ) as a model for opsonized pathogens and the chemotactic peptide N- 
formyl-methionyl-leucyl-phenylalanine (fMLP) as a soluble stimulus.
Materials and methods
Blood samples were drawn from healthy volunteers and processed as described 
below. Serum triglyceride content of these samples was always in the normal range 
(0.55-1.56 mmol/L), as determined colorimetrically on a Hitachi 747 analyser 
(Hitachi Ltd, Tokyo, Japan).
Materials: Myelin basic protein (MBP), aprotinin, leupeptin, trypsin inhibitor, N- 
formyl-methionyl-leucyl-phenylalanine (fMLP), and 12-O-tetradecanoylphorbol 13- 
acetate (PMA) were purchased from Sigma Diagnostics, St. Louis, MO, USA. 
Staurosporine and calpain inhibitor were obtained from Boehringer, Mannheim, 
Germany; phenylmethylsulfonyl fluoride (PMSF) from Serva Feinchemica GmbH,
32Heidelberg, Germany; [y- P]ATP (specific activity 3000 Ci/mmol) from Amersham, 
Buckinghamshire, UK; U73122 and U73343 from The Upjohn Company, 
Kalamazoo, MI, USA; phosphatidyl serine (PS) from Lipid Products, Nutfield 
Nurseries, Surrey, UK; 4-a-phorbol 12-myristate 13-acetate from LC Services 
Corporation, Woburn, MA, USA; human serum albumin (HSA) from Behring, 
Westwood, MA, USA and Fura-2/AM from Molecular Probes Inc., Eugene, OR, 
USA. All other chemicals were of analytical grade. PMA was stored as a 10 mol/L 
stock in dimethylsulfoxide (DMSO) at -20°C. Serum-treated zymosan (STZ) was 
prepared as described [20]. FMLP was stored as a 10 mol/L stock in DMSO at - 
20°C. Hank's balanced salt solution (HBSS) was from Life Technologies (Paisley, 
Scotland). Phosphate-buffered saline (PBS) contained Na+ 163.9 mmol/L, Cl- 140.3 
mmol/L, HPO42- 10.9 mmol/L- and H2 PO4- 1.8 mmol/L- (pH 7.4). Isotonic lysis 
solution contained 155 mmol/L- NH4 Cl, 10 mmol/L- KHCO3 and 0.1 mmol/I EDTA 
(pH 7.4).
Incubation medium contained HBSS supplemented with 0.5% (wt/vol) HSA. Percoll 
(p 1.129 g/mL at 20°C) was from Pharmacia Biotech AB, Uppsala, Sweden. LCT
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emulsion (Intralipid 20% wt/vol) was from Pharmacia & Upjohn AB, Stockholm, 
Sweden. LCT/MCT and a-tocopherol-enriched (170 ± 40 mg/L) LCT/MCT emulsions 
(Lipofundin 20% wt/vol) were from B. Braun Melsungen AG, Melsungen, Germany. 
SL emulsion (Fat Emulsion 73403) was from Pharmacia & Upjohn Parenterals, 
Stockholm, Sweden. A pure 20% MCT (wt/vol) emulsion was provided by Pharmacia 
& Upjohn, Clayton, NC, USA. For lipid emulsion characteristics see Table 1 in 
Chapter 3. Blood samples were collected in 10 mL Monoject tubes (Sherwood 
Medical, Ballymoney, N. Ireland) with 143 USP units of lithium heparin.
Cell isolation: Neutrophils were purified from blood anticoagulated with lithium 
heparin [21]. The blood, diluted 1:1 with PBS with 0.4% (wt/vol) trisodium citrate 
(pH 7.4), was placed on Percoll (p 1.076 g/mL) and centrifuged (700 x g , 18 min, 
25°C). The pellet was suspended in 50 ml of ice-cold lysis solution for 10 min. After 
centrifugation (5 min, 400 x g, 4°C), the remaining erythrocytes were lysed in fresh
lysis solution for another 5 min. The cells were then washed and resuspended in
6
incubation medium to a final concentration of 2 x 10 cells/mL and kept at room 
temperature. Cytospin preparations were > 97% pure and > 99% viable as determined 
by May-Grünwald/Giemsa and trypan blue staining.
Fluorescence measurements: Neutrophils (2x106  cells/mL) were loaded with 5 
^mol/l Fura-2/AM for 30 min at 37° C. Excess Fura-2/AM was removed by washing 
the neutrophils twice with HBSS/0.5% (wt/vol) HSA and the neutrophils were 
transferred to a cuvette placed in a Shimadzu RF-5301 spectrofluorophotometer
equipped with a magnetic stirrer and a thermostated cuvette holder. The fluorescence
2 +
emission ratio at 490 nm was monitored as a measure of the average cytosolic free Ca
2 +
concentration ([Ca ]iav) after excitation at 340 and 380 nm.
PKC activity measurements: PKC activity was determined as described previously 
[22]. The reaction mixture (200 ^L) contained 20 mmol/L HEPES (pH 7.1), 0.1 
mmol/L PMSF, 2 ^mol/l leupeptin, 0.05 ^g/mL aprotinine, 0.1 ^mol/L calpain 
inhibitor, 0.02 mg/mL trypsin inhibitor, 0.5 mmol/L DTT, 10 mmol/L MgCl2, 5032
^mol/L [y- P]ATP (specific activity 0.05 Ci/mmol), 50 ^g/mL myelin basic protein
(MBP), 1 mmol/L EGTA, 0.2 mmol/L EDTA and 1.39 mmol/L CaCl2
2 +(approximately 300 ^mol/L free Ca ). Where indicated, the reaction mixture 
contained in addition phosphatidyl serine (PS; 100 ^g/mL) and/or PMA (50 nmol/L) 
and/or lipid emulsion (3.75 mmol/L). The reaction mixture was preincubated for 2 
min at 30°C and the reaction was started by addition of 20 ^L enzyme solution. The 
enzyme solution consisted of a cytosolic fraction of Chinese hamster ovary (CHO) 
cells transiently overexpressing PKCa. After 30 min, the reaction was stopped by 
addition of 5 mL of ice-cold 5% (wt/vol) trichloroacetic acid/0.1 mol/L H3 PO4  and 
the acid-precipitable material was collected on a Schleicher & Schüll AE-95 
membrane filter (pore size 0.8 ^m). The filters were washed three times with 5 ml 
ice-cold 5% (wt/vol) trichloroactic acid/0.1 mol/L H3 PO4, added to 4 mL Opti-fluor 
(Packard, Meriden, CT, USA), and counted by Liquid scintillation analysis. In each
161
Chapter 12
2 +experiment, the level of MBP phosphorylation obtained with Ca , PS and PMA was 
set at 1 0 0 %, to which all other values were related.
Statistical analysis. In all experiments, the data are expressed as the mean ± S.E.M. 
Overall statistical significance was determined by analysis of variance (ANOVA). In 
the case of significance (P < 0.05) individual groups were compared by contrast 
analysis according to Scheffé. P values of less than 0.05 were considered significant.
Results
Effects o f staurosporine, PMA and U73122 on the STZ- and fMLP-induced 
increases in [Ca2+]iav in a suspension o f human neutrophils
Serum-treated zymosan (STZ) induced a typical biphasic increase of the fluorescence
emission ratio in a suspension of fura-2-loaded human neutrophils (Fig. 1a). This
2 +increase, which reflects the increase in average cytosolic free Ca concentration
2 +([Ca ]iav), consisted of a first slow phase that gradually turned into a second fast
2 +phase until a plateau [Ca ]iav was reached that was maintained for prolonged periods
of time. Increasing the STZ concentration from 0.2 mg/mL to 0.8 mg/mL markedly
2 + 2 + increased both the initial rate of [Ca ]iav rise and the final plateau [Ca ]iav without
changing, however, the biphasic nature of the STZ response.
2 +Fig. 1 a also shows that STZ-induced Ca mobilization was abolished by the PKC 
inhibitor staurosporine (1 ^mol/L). Conversely, pretreatment with the PKC activator
PMA (0.1 ^mol/L) markedly potentiated the first slow phase of the STZ-induced
2 +[Ca ]iav rise, while abolishing, however, the second fast phase of this response. In
2 +addition, PMA significantly lowered the plateau [Ca ]i,av obtained with the lower 
(0.2mg/mL), but not the higher (0.8 mg/mL), STZ concentration. PMA alone did not 
change the fluorescence emission ratio, indicating that activation of PKC in itself had 
no effect on [Ca2 +]i,av.
Pretreatment with the phospholipase C inhibitor U73122 (1 ^mol/L) abolished the
2 +STZ-induced increase in [Ca ]iav (Fig. 1b). In contrast, U73343 (1 ^mol/L), which is
an inactive analog of U73122, did not prevent STZ-induced Ca2+ mobilization.
2 +However, it should be noted that U73343 decreased the rate of [Ca ]i,av rise both 
during the first slow phase and the second fast phase of the STZ response.
The peptide hormone fMLP (1 nmol/L) evoked an immediate and rapid increase in 
[Ca2+]iav (Fig.1c). The effect of fMLP was transient by nature in that [Ca2+]iav, after
having reached its peak, more gradually returned to lower levels. Pretreatment with
2 +PMA (0.1 ^mol/L) abolished the fMLP-induced increase in [Ca ]iav. This inhibitory
action of PMA was completely reversed by staurosporine (1 ^mol/L). The fMLP-
2 +induced increase in [Ca ]iav was also abolished by U73122 (1 ^mol/L). In contrast,
2 +U73343 (1 ^mol/L) did not interfere with the fMLP-induced [Ca ]i,av response. 
Importantly, none of the effects of PMA were observed following pretreatment of the
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neutrophils with the inactive phorbol ester, 4-a-phorbol 12-myristate 13-acetate (data 
not shown).
Effects o f  various lipid emulsions on the STZ- and fMLP-induced increases in 
[Ca2+]iav in a suspension o f  human neutrophils: Fig. 2a shows that Lipofundin (LF;
2.5 mmol/L) completely mimicked the effects of PMA in that it increased the first 
slow phase, abolished the second fast phase and lowered the sustained plateau of the 
increase in [Ca2+]1av in response to a suboptimal concentration of STZ (0.2 mg/mL).
Conversely, Intralipid (IL; 2.5 mmol/L) did not affect the biphasic response to STZ
2 +with the understanding, however, that it lowered the plateau [Ca ]1av (Fig.2b).
The effects of LF were also observed with LF enriched with a-tocopherol (LFE;
2.5 mmol/L) and MCT (2.5 mmol/L). But, whereas PMA (0.1 imol/L) evoked a 5­
fold increase in the initial rate of the STZ-induced increase in [Ca2+]1av, LF, LFE and
MCT increased this initial rate only by a factor 2 to 3 (Fig.3a). Similar to LF and IL
2 +(see Fig.2), all other lipid emulsions significantly lowered the STZ-induced [Ca ]1av 
plateau (Fig.3b). Importantly, none of the lipid emulsions alone had an effect on 
[Ca^J^v (see also Fig.2).
The potentiating effect of LF on the first slow phase of the STZ-induced increase
2 +in [Ca ]1,av was dose-dependent and a more than 3-fold increase was obtained with a 
lipid concentration of 5 mmol/L- (Fig.4). Unfortunately, lipid concentrations beyond 5 
mmol/L caused technical problems making it impossible to assess whether LF was as
efficacious as PMA. Fig. 4 also shows that even at a maximal concentration of 5
2 +mmol/L, IL did not affect the STZ-induced increase in [Ca ]1av.
The rate at which [Ca2+]1av increased during the first slow phase of the STZ-
2 +induced increase in [Ca ]1av clearly depended on the STZ concentration (Fig.5a). At
2 +concentrations below 0.13 mg/mL, STZ did not affect [Ca ]1av, while the maximal
2 +effect on the initial rate of [Ca ]1av increase was obtained at a concentration of 0.6 
mg/mL. Both PMA (0.1 iM ) and LF (2.5 mmol/L) sensitized the human neutrophils
for stimulation by STZ as indicated by a shift to the left of the dose-response curve
2 +for the effect of STZ on the initial rate of [Ca ]1,av increase. Moreover, both PMA and
2 +LF potentiated the initial rate of [Ca ]1av increase at all STZ concentrations tested
thereby abolishing the second fast fase (see, Figs. 1a and 2a). Figure 5b shows that
2 +also the [Ca ]1av plateau depended on the STZ concentration and that a maximum 
was reached at 0.4 mg/mL. Both PMA and LF lowered the STZ-induced plateau with 
the understanding, however, that the inhibitory effect of PMA, unlike that of LF, was
reversed at higher STZ concentrations.
2 +The peak increase in [Ca ]1,av obtained with fMLP was a function of the fMLP
2 +concentration (Fig.6 ). The peptide hormone did not affect [Ca ]1,av at concentrations 
at or below 0.1 nmol/L, whereas its maximum effect was observed at a concentration 
of 0.1 imol/L. PMA (0.1 jimol/L) desensitized the neutrophils for fMLP as was
indicated by a shift to the right of the dose-response curve for the fMLP-induced peak
2 +increase in [Ca ]1av. Moreover, PMA halved the maximal effect of fMLP.
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2 +LF markedly lowered the maximal effect of fMLP on the peak increase in [Ca ]iav 
without causing, however, a significant shift to the right of the dose-response curve 
for the effect of the hormone. Unexpectedly, the same result was obtained with IL. 
This latter finding urged us to investigate the involvement of PKC. Pretreatment of 
the cells with the PKC inhibitor staurosporine (0.1 ^mol/L) abolished the inhibitory 
effect of PMA, while only slightly reducing the inhibitory effect of LF (Fig.6 , open
symbols). The inhibitor did not interfere with the inhibitory action of IL. These
2 +findings indicate that the primary effect of lipid emulsions on fMLP-induced Ca 
mobilization occurs in a PKC-independent manner.
Effect o f  PMA and various lipid emulsions on the PKC activity in a cytosolic
extract: Optimal PKC activity in a cytosolic extract was obtained in the presence of
2 +Ca , phosphatidyl serine (PS) and PMA (Fig.7b). Figure 7a shows that in the
2 +presence of Ca alone, MBP phosphorylation is only 7% of maximal. The figure also
shows that addition of PMA increased the level of MBP phosphorylation by a factor
2 +2. None of the lipid emulsions changed the phosphorylation level obtained with Ca
2 +alone or with Ca and PMA. Addition of PS increased the level of MBP 
phosphorylation to approximately 70% of maximal and a further increase to 100% 
was achieved when in addition PMA was added to the reaction mixture (Fig.7b). This 
latter effect of PMA was mimicked by all lipid emulsions (3.75 mmol/L) tested, with 
the understanding that the increase obtained with lipid emulsion was even higher than 
that obtained with PMA. The combination of PMA and lipid emulsion did not further 
increase the level of MBP phosphorylation. Importantly, these findings indicate that 
all lipid emulsions mimic the PMA effect and not the PS effect.
Discussion
The present work provides evidence that nutritional lipid emulsions that contain 
medium-chain triglycerides including Lipofundin (LF) can activate PKC in human 
neutrophils and that this activation sensitizes these cells to stimulation by STZ. This 
conclusion is based on the observation that these lipid emulsions, in contrast to those 
that consisted solely of long-chain triglycerides (Intralipid; IL) or synthetic 
triglycerides in which both long-chain and medium-chain fatty acids were attached to 
one glycerol molecule (structural lipid emulsion; SL), mimicked the stimulatory effect
of the PKC activator PMA on the initial slow rate of the STZ-induced increase in
2 +[Ca ]iav thereby shifting the dose-response curve for the effect of STZ to the left. 
Importantly, these effects were observed at a clinically relevant emulsion
concentration of 2.5 mmol/L. Because PKC inhibitors such as staurosporine were
2 +found to abolish the STZ-induced increase in [Ca ]i,av they could not be used to 
provide additional evidence for the involvement of PKC in the mechanism of action 
of the MCT containing emulsions.
In agreement with the idea that MCT containing emulsions affect STZ-induced
2 +Ca mobilization through PKC, these emulsions were found to activate partially
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purified PKC in a PMA-like fashion. Intriguingly, however, also the LCT and SL
emulsions displayed this activity. The finding that the latter emulsions did not
2 +
mimick the effect of PMA on the STZ-induced [Ca ]iav rise then suggests that they 
do not activate PKC in the context of the intact cell.
In cell physiological terms, the experimental data obtained with the PKC activator 
PMA unveil an interesting and new priming mechanism involving PKC. PKC 
activation sensitizes the neutrophil to phagocytosis and killing of opsonized 
pathogens (represented by STZ particles) and, in the mean time, desensitizes the 
neutrophil from being distracted from this activity by chemoattractants such as the 
chemotactic peptide fMLP. As far as the nutritional lipid emulsions are concerned, 
those that contain MCT mimick the PKC-mediated sensitizing effect of PMA, 
whereas all lipid emulsions decrease the maximal effect of STZ and fMLP in a PKC- 
independent manner. The importance of these lipid effects are evident, regarding the 
immune compromised state of the patient category receiving TPN.
The present finding that only the MCT-containing emulsions mimick the effects of
2 +the PKC activator, PMA, on the initial phase of the STZ-induced [Ca ]iav rise is in 
agreement with previous studies in which we demonstrated that MCT-containing 
emulsions, but not emulsions that consisted solely of LCT (IL) or synthetic structural 
lipids (SL), significantly increased oxygen radical production, adhesion and 
degranulation, and migration of these cells in a PKC-dependent manner [17-19]. 
Here, we provide evidence that these MCT-containing emulsions exert their PMA- 
like actions by directly activating PKC in a PMA-like fashion. Neutrophils express 
five PKC isoforms, a, ßl, ßII, ô and £, [23], and future research will show which PKC 
isoforms are involved in the various actions of the MCT-containing lipid emulsions on
neutrophil function. Importantly, the MCT-containing emulsions did not increase
2 +[Ca ]iav by themselves. This indicates that these lipids do not act through an effect
2 +on [Ca ]i,av to increase oxygen radical production, adhesion and degranulation, and 
migration.
The antioxidant effects of lipid-soluble vitamin E, or tocopherol, are considered to 
be beneficial for both emulsion (stability by prevention of lipid peroxidation) and 
patient (detoxification of oxygen radicals produced by immune cells). On the other 
hand the a-tocopherol isoform has shown well-defined inhibitory effects on the 
respiratory burst of leukocyes, i.e. inhibition of PKC as well as impaired assembly of 
the NADPH-oxidase [24]. However, enrichment of an LCT/MCT emulsion with 170 
± 40 mg/L a-tocopherol (see, Table 1) did not influence the emulsion effect in our 
study with regard to PKC activity.
The present work furthermore shows that both an MCT-containing emulsion (LF)
and an emulsion that consisted solely of LCT (IL) can markedly lower the fMLP-
2 +induced increase in [Ca ]iav. Although the same effect was obtained with PMA, the 
involvement of PKC in the mechanism of action of these lipid emulsions was 
excluded by the fact that staurosporine did not significantly reduce their inhibitory
effect whereas it abolished the inhibition by PMA. Similarly, all lipid emulsions that
2 +were tested were found to reduce the STZ-induced [Ca ]i,av plateau. Most probably
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this also occurs in a PKC-independent fashion. For reasons outlined above, however,
we could not use PKC inhibitors to experimentally verify this idea. Taken together,
these findings show that all nutritional lipid emulsions, when added at clinically
relevant concentrations, can significantly reduce the fMLP-induced peak increase in 
2 + 2 +[Ca ]iav and the STZ-induced [Ca ]iav plateau and that this reduction occurs in a
PKC-independent fashion. It remains open to speculation whether this finding
represents an ‘aspecific’ lipid effect. Lipid-receptor interactions have been suggested in
previous studies regarding an LCT emulsion [7].
It is unlikely that the ‘PMA-like’ factor present in the lipid emulsions tested in this
study consists of a short-chain carboxylic acid as these acids have been shown to
2 +evoke a rapid increase in inositol 1,4,5-trisphosphate and cytosolic free Ca [25].
2 +Similarly, phosphatidic acid has been shown to evoke a rapid rise in [Ca ]iav in 
human neutrophils [26]. Evidence has been provided that also polyunsaturated fatty 
acids, which are present in all emulsions (see, Table 1), can stimulate neutrophil 
responses such as the oxygen-dependent respiratory burst through activation of 
phospholipase A2 [27]. It has been demonstrated that neutrophils can secrete 
phospholipase A2  [28]. In principle, secreted phospholipase A2  can hydrolyse lipids 
of the lipid emulsions to produce reactive lipids. These lipids, in turn, may prime the 
cell for activation by STZ.
2 +Our finding that STZ evokes a biphasic increase in [Ca ]i,av, consisting of a first 
slow increase that gradually turnes into a second fast increase until a plateau is 
reached, has been described before [29]. The present study shows that the
phospholipase C inhibitor U73122 abolished both the STZ- and fMLP-induced
2 +increase in [Ca ]i,av and that both PMA and all MCT-containing lipid emulsions
2 +markedly potentiated the rate of [Ca ]iav rise during the initial phase of the response
to STZ. This finding suggests that PKC activation promotes iC3b receptor signalling
as it has been argued that this receptor, and not the FcyRIIa, mediates STZ activation
of granulocytes [30]. Possible mechanisms for this action of PKC include an increase
in i) affinity of the receptor for its ligand, ii) receptor number, and iii) coupling
between receptor and G protein. An effect at the level of the inositol 1,4,5­
2 +trisphosphate-mediated release of Ca from the endoplasmic reticulum is not very 
likely as PMA decreased rather than increased the fMLP-induced increase in 
[Ca2+]iav. The second and fast phase of the STZ-induced increase in [Ca2+]iav has been 
proven to be brought about by endogenously produced platelet activating factor 
(PAF) [29]. The present observation that PMA and the MCT emulsions abolished this 
second phase may suggest that PKC inhibits the STZ-triggered production of PAF. 
Alternatively, however, PKC may accelerate the STZ-induced production of PAF,
thus shortening the first slow phase. Inhibition of the fMLP-induced increase in
2 +[Ca ]i,av following PMA treatment and inhibition by PMA of the STZ-induced
2 +increase in [Ca ]i,av have been reported before [31-33]. However, these authors did
2 +not observe a biphasic increase in [Ca ]i,av and most probably referred to the PMA-
2 +induced decrease of the plateau [Ca ]i,av as described in the present study.
166
STZ-induced calcium signaling
In conclusion this study shows that nutritional lipid emulsions can modulate the 
stimulation of neutrophils in that MCT-containing emulsions sensitize these cells for 
STZ in a PKC-dependent manner and all lipid emulsions reduce the stimulatory effect 
of STZ and fMLP in an aspecific manner.
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Figure 1. Effects o f staurosporine, PM A and U73122 on the STZ- and fM LP-induced increases in 
[Ca2l,a v  in a suspension o f human neutrophils.
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Human neutrophils, loaded with the fluorescent Ca2+ indicator fura-2, were transferred to a cuvette 
placed in a Shimadzu RF-5301 spectrofluorophotometer equipped with a magnetic stirrer and a 
thermostated (37°C) cuvette holder. Cells were preincubated with PM A (0.1 ^mol/L; fig. 1a, c), 
staurosporine (1 ^mol/L; fig. 1a,c), U73122 (1 ^mol/L; fig. 1b,c) or U73343 (1 |imol/L; fig. 1b,c) 
for 3 min. After 3 min, STZ (at the concentrations indicated; fig. 1a,b) and fMLP (1 nmol/L; fig. 1c) 
were added. The fluorescence emission ratio at 490 nm was monitored as a measure o f the average 
cytosolic free Ca2+ concentration ([Ca2+]i>av) after excitation at 340 and 380 nm.
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Figure 2. Effects o f the nutritional lipid emulsions Lipofundin (LF) and Intralipid (IL) on the STZ- 
induced increase in [Ca2+]i>av in a suspension o f human neutrophils.
Figure 2a. Figure 2b.
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Fura-2-loaded neutrophils were preincubated with either LF (2.5 mmol/L; fig. 2a) or IL (2.5 
mmol/L; fig. 2b) for 3 min and subsequently stimulated with STZ (0.2 mg/mL). Details on [Ca2+]i>av 
measurement are given in the legend o f Fig. 1.
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Figure 3. Effects o f PM A and the various lipid emulsions on the initial rate o f [Ca2+]i>av rise and the
[Ca2l,a v  plateau following stimulation with STZ.
Figure 3a. Figure 3b.
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Fura-2-loaded neutrophils were preincubated with either PM A (0.1 |imol/L) or 2.5 mmol/L o f the 
indicated lipid emulsion for 3 min. The cells were then stimulated with STZ (0.2 mg/mL) and the 
increase in [Ca2+]i av was monitored as described in the legend o f Fig. 1. a) The initial rate of 
[Ca2+]i,av rise obtained with PM A-treated cells is set at 100%, to which all other values are related. 
b) The value for the [Ca2+]i>av plateau obtained with PM A-treated cells is set at 100%, to which all 
other values are related. The data presented are the mean ± SEM of at least 3 measurements. * 
Significantly different from STZ alone (P < 0.05); # Significantly different from PM A + STZ (P < 
0.05); & Significantly different from both IL + STZ and SL + STZ (P < 0.05).
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Figure 4. Dose dependence o f the effects o f Lipofundin (LF) and Intralipid (IL) on the initial rate of 
[Ca2+]Uv rise in response to STZ stimulation.
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Fura-2-loaded cells were preincubated in the presence o f either 2.5 mmol/L Lipofundin (LF) or 
Intralipid (IL) for 3 min and subsequently stimulated with 0.2 mg/mL STZ. The initial rate of 
[Ca2+],av rise following stimulation with STZ was monitored as described in the legend o f Fig. 1. 
and expressed as percentage of the value obtained with cells preincubated with PM A (0.1 |imol/L). 
The figure represents a single experiment.
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Figure 5. Effects o f PM A and Lipofundin (LF) on the dose-response curve for the STZ-induced 
initial rate o f [Ca2+]i>av rise in human neutrophils.
Figure 5a. Figure 5b.
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Fura-2-loaded neutrophils, preincubated with either PM A (0.1 ^mol/L) or LF (2.5 mmol/L) for 3 
min, were stimulated with the indicated concentration o f STZ. The increase in [Ca2+]i>av was 
monitored as described in the legend o f Fig. 1. a) The initial rate o f [Ca2+]i>av rise obtained with 
PM A-treated cells is set at 100%, to which all other values are related. b) The value for the [Ca2+]i>av 
plateau obtained with PM A-treated cells is set at 100%, to which all other values are related. W here 
indicated by error bars, the data presented are the mean ± SEM of at least 3 measurements. * 
Significantly different from STZ alone (P < 0.05); # Significantly different from LF + STZ (P <
0.05).
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Figure 6. Effects o f PMA, Lipofundin and Intralipid on the dose-response curve for the fMLP- 
induced peak increase in [Ca2+]i>av in human neutrophils.
log [fMLP] (M)
Neutrophils loaded with fura-2 were preincubated in the presence of PMA (0.1 ^M), LF (2.5 mM), or 
IL (2.5 mmol/L) and in the absence (closed symbols) or presence (open symbols) o f staurosporine (1 
^mol/L) for 3 min, after which the cells were stimulated with the indicated concentration of fMLP. 
[Ca2+]i,av was monitored as described in the legend o f Fig. 1. The peak increase in [Ca2+]i>av obtained 
with 1 ^mol/L fMLP is set at 100%, to which all other values are related. W here indicated by error 
bars, the data presented are the mean ± SEM of at least 3 measurements. * Significantly different 
from fMLP alone (P < 0.05); # Significantly different from IL + fMLP (P < 0.05); & Significantly 
different from LF + fMLP (P < 0.05).
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Figure 7. Effect of the various nutritional lipid emulsions on protein kinase C activity.
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A cytosolic fraction o f Chinese hamster ovary (CHO) cells transiently overexpressing P K C a was 
used to assess the effects o f the various lipid emulsions on PKC activity. PKC activity was 
measured at an ambient free Ca2+ concentration o f 0.3 mM and a temperature o f 37°C and is 
defined as the PMA- and phosphatidylserine (PS)-dependent increase in myelin basic protein 
(MBP) phosphorylation. In each experiment, the level o f MBP phosphorylation obtained with PM A 
(50 nmol/L) and PS (100 ^g/mL) is set at 100%, to which all other values are related. W here 
indicated, lipid emulsions were added at a concentration o f 3.75 mmol/L. Measurements were 
performed in the presence o f either Ca2+ (open bars) or Ca2+ and PS (closed bars). The data 
presented are the mean ± S.E.M. o f 3 measurements. * Significantly different from Ca2+ or Ca2+ + 
corresponding lipid emulsion alone (P < 0.05); # Significantly different from Ca2+ + PM A or Ca2+ + 
corresponding lipid emulsion (P < 0.05); & Significantly different from Ca2+ + PM A + 
corresponding lipid emulsion (P < 0.05); $ Significantly different from Ca2+ + PS (P < 0.05).
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Prompt inhibition of fMLP-induced Ca2+ mobilization by parenteral lipid 
emulsions in human neutrophils
Wanten GJA, Rops A, van Emst-de Vries SE, Naber AH, Willems PHGM
J  Lipid Res 2002;43:550-6

fMLP-induced calcium signaling
Abstract
It remains unclear whether modulation of immune system functions by lipids 
contributes to the increased infection rate observed in patients treated with parenteral 
nutrition. We therefore evaluated the effects of lipid emulsions derived from fish oil 
(VLCT), olive oil (LCT-MUFA), soya oil (LCT), or a physical mixture of coconut and
soya oil (LCT/MCT) on neutrophil activation. N formyl-methionyl-leucyl-
2+phenylalanine (fMLP) evoked an immediate increase in the cytosolic Ca
2+concentration ([Ca ]i,av) in a suspension of neutrophils. When added 3 min before
fMLP, however, all four lipid emulsions reduced the hormone-induced increase in
2+[Ca ]i,av with the same efficacy but with different potency. Half-maximal inhibition 
was reached at emulsion concentrations of 0.24 mmol/L (VLCT), 0.32 mmol/L 
(LCT/MCT), 0.52 mmol/L- (LCT) and 0.82 mmol/L- (LCT-MUFA). Similarly to the
lipids, the protein kinase C (PKC) activator PMA markedly reduced the fMLP-
2+induced increase in [Ca ]iav. PMA inhibition was abolished by the PKC inhibitor 
staurosporine. In contrast, however, this drug did not interfere with the inhibitory 
lipid effect, indicating that the lipids act primarily in a PKC-independent manner. In 
summary, this study shows that nutritional lipids can evoke a prompt and significant 
attenuation of hormone-induced neutrophil stimulation and that the emulsions based on 
fish oil (VLCT) and a mixture of coconut oil and soya oil (LCT/MCT) are among the 
most potent ones in this respect.
Introduction
Total parenteral nutrition (TPN) implies that all nutritional requirements are met by 
the administration of an intravenous solution. In the last decades this technique has 
established itself as an indispensable strategy to improve the nutritional status of 
critically ill patients. Unfortunately, the associated risk for infectious complications 
remains a drawback in which immune-suppressive effects of the lipid component seem 
to play a role [1-3].
Thus far, the immune-modulatory properties of the most widely used emulsion,
containing long-chain triglycerides (LCT), remain unclear [4-13]. The data on
structurally different emulsions, containing physical mixtures of LCT and medium-
chain triglycerides (LCT/MCT) or synthetic structured lipids (SL, with long- and
medium-chain fatty acids attached to a glycerol molecule) are limited [14].
We recently observed distinct effects of emulsions containing LCT, LCT/MCT or SL
on various neutrophil functions [15-18]. It was found that MCT, in a for TPN patients
physiological triglyceride concentration range (up to 10 mmol/L), directly activate
neutrophils, in contrast with LCT or SL. We also found that treatment of neutrophils
with MCT mimicked the effects of 12-O-tetradecanoylphorbol 13-acetate (PMA), a
phorbol ester and potent activator of protein kinase C (PKC), on the increase in 
2+ 2+ cytosolic Ca concentration ([Ca ]iav) evoked by serum-treated zymosan particles
(STZ) [19]. Here MCT, but not LCT or SL, caused a leftward shift of the dose-
2+response curve for the effect of STZ on [Ca ]iav, indicating that structurally different
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lipids distinctively modulate neutrophil activation. We also observed that each
2+emulsion markedly reduced the increase in [Ca ]i,av in response to N-formyl- 
methionyl-leucyl-phenylalanine (fMLP).
2+In the present study, we investigate the effects on fMLP-induced Ca mobilization 
in neutrophils of two recently developed lipid emulsions. One is based on fish oil (very 
long-chain triglycerides, VLCT), rich in very long-chain poly-unsaturated fatty acids 
eicosapentaenoic acid and docosahexaenoic acid, the other is an LCT emulsion based 
on olive oil (long-chain triglycerides-mono-unsaturated fatty acid, LCT-MUFA), rich 
in mono-unsaturated fatty acids oleic acid and linoleic acid. Thus far, a wide range of 
effects on neutrophil function of various fatty acids have been described, ranging from 
cell activation to inhibited immunological responses [20-25].
Materials and methods
Blood samples were drawn from healthy volunteers and processed as described 
below. Serum triglyceride content of these samples was always in the normal range 
(0.55-1.56 mmol /L), as determined colorimetrically on a Hitachi 747 analyser 
(Hitachi Ltd., Tokyo, Japan).
Reagents: fMLP and 12-O-tetradecanoylphorbol 13-acetate (PMA) were purchased 
from Sigma Diagnostics (St. Louis, MO, USA). Staurosporine was obtained from 
Boehringer (Mannheim, Germany); 4-a-phorbol 12-myristate 13-acetate from LC 
Services Corporation (Woburn, MA, USA); human serum albumin (HSA) from 
Behring (Westwood, MA, USA) and Fura-2/AM from Molecular Probes Inc. (Eugene, 
OR, USA). All other chemicals were of analytical grade. PMA was stored as a 10 
mol/L stock in DMSO at -20°C. fMLP was stored as a 10-3 mol/L stock in DMSO at - 
20°C. Hank's balanced salt solution (HBSS) was from Life Technologies (Paisley, 
Scotland). PBS contained Na+ 163.9 mmol/L, Cl" 140.3 mmol/L, HPO42- 10.9 mmol/L­
and H2PO4- 1.8 mmol/L (pH 7.4). Isotonic lysis solution contained 155 mmol/L NH4Cl, 
10 mmol/L- KHCO3 and 0.1 mmol/L- EDTA (pH 7.4). Incubation medium contained 
HBSS supplemented with 0.5% (wt/vol) HSA. Percoll (p 1.129 g/mL at 20°C) was 
from Pharmacia Biotech AB (Uppsala, Sweden). LCT emulsion (Intralipid 20% w/v) 
was from Pharmacia & Upjohn AB, Stockholm, Sweden. LCT/MCT (Lipofundin 20% 
w/v) was from B. Braun Melsungen AG (Melsungen, Germany). Fish oil emulsion 
(VLCT, Omegaven 10% wt/vol) was from Fresenius (Bad Homburg, Germany) and 
olive oil emulson (LCT-MUFA, ClinOleic 20% wt/vol) was provided by Baxter SA 
(Lessines, France). For lipid emulsion characteristics see Table 1. Blood samples were 
collected in 10 mL Monoject tubes (Sherwood Medical, Ballymoney, N. Ireland) with 
143 USP units of lithium heparin.
Cell isolation: Neutrophils were purified from blood anticoagulated with lithium 
heparin [26]. The blood, diluted 1:1 with PBS with 0.4% (w/v) trisodium citrate (pH 
7.4), was placed on Percoll (p 1.076 g/mL) and centrifuged (700 x g, 18 min, 25°C). 
The pellet was suspended in 50 mL of ice-cold lysis solution for 10 min. After 
centrifugation (5 min, 400 x g, 4°C), the remaining erythrocytes were lysed in fresh
180
fMLP-induced calcium signaling
lysis solution for another 5 min. Subsequently the cells were washed and 
resuspended in incubation medium to a final concentration of 2 x 106 cells/mL and 
kept at room temperature. Cytospin preparations were > 97% pure and > 99% viable 
as determined by May-Grünwald/Giemsa and trypan blue staining.
Table 1. Composition and characteristics o f the different lipid emulsions (data provided by the 
manufacturer).
LCT/MCT VLCT LCT-
M UFA
LCT
Triglyceride source 
Fatty acid (% wt/wt o f total)
Coconut oil/ 
Soya oil (1:1)
Fish oil Olive oil Soya oil
Caproic acid (C6:0) 0.2 - -
Caprylic acid (C8:0) 21.2 - - -
Capric acid (C10:0) 19.9 - - -
Lauric acid (C12:0) 0.2 - - -
Myristic acid (C14:0) - 5.1 0.2 -
Pentadecanoic acid (C15:0) - 0.7 - -
Palmitic acid (C16:0) 7.4 11.7 12.2 11.3
Palmitoleic acid (C16:1) - 9.2 1.4 -
C16:3 acid - 2.7 0.3 -
C16:4 acid - 2.6 0.5 -
Stearic acid (C18:0) 3.2 4.4 2.1 4.5
Oleic acid (C18:1) 14.2 15.1 62.3 21.0
Linoleic acid (C18:2) 29.1 4.4 18.7 53.4
Linolenic acid (C18:3) 4.5 1.8 2.3 9.7
Octadecatetraenoic acid (C18:4) - 3.7 - -
Eicosenoic acid (C20:1) - 1.6 - -
Dihomo-y-linolenic acid (C20:3) - 0.6 - -
Arachidonic acid (C20:4) 0.2 2.1 - 0.1
Eicosapentaenoic acid (C20:5n-3) - 19.2 - -
Heneicosanoic acid (C21:5) - 1.0 - -
Docosapentaenoic acid (C22:5) - 2.1 - -
Docosahexaenoic acid (C22:6n-3) - 12.1 - -
Fluorescence measurements in suspensions o f human neutrophils: Neutrophils
(2x106 cells/mL) were loaded with 5 ^mol/L Fura-2/AM for 30 min at 37° C. Excess
Fura-2/AM was removed by washing the neutrophils twice with HBSS/0.5% (wt/vol)
HSA and the neutrophils were transferred to a cuvette placed in a Shimadzu RF-5301
spectrofluorophotometer equipped with a magnetic stirrer and a thermostated cuvette
holder. The fluorescence emission ratio at 490 nm was monitored as a measure of the
2+ 2+ average cytosolic free Ca concentration ([Ca ]i,av) after excitation at 340 and 380 nm.
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Table 2. Composition and characteristics o f the different lipid emulsions (data provided by the 
manufacturer).
LCT/MCT VLCT LCT-MUFA LCT
M ean molecular weight 634 882 873 865
Egg phospholipids (g/l) 12 12 12 12
Glycerol (g/l) 25 25 22.5 22.5
pH 8.0 7.5-8.7 7-8 8.0
Statistical analysis: Half-maximal inhibitory emulsion concentrations were 
calculated by means of the nonlinear regression computer programme OriginPro 6.1 
(OriginLab Corporation, Northampton, MA, USA). In all experiments, the data are 
expressed as the mean ± SEM. Overall statistical significance was determined by 
analysis of variance (ANOVA). In the case of significance (P < 0.05) individual 
groups were compared by contrast analysis according to Fisher. P values of less than
0.05 were considered significant.
Results
2+fMLP-induced Ca mobilization in human neutrophils: We have previously shown
that fMLP induces a transient rise of the fluorescence emission ratio in a suspension
of fura-2-loaded human neutrophils. This rise, which reflects the effect of fMLP on2+ 2+ 
the average cytosolic free Ca concentration ([Ca ]i,av), is the result of the stimulated
2+release of Ca from the endoplasmatic reticulum. To be able to detect possible
2+stimulatory and/or inhibitory effects of the lipid emulsions on fMLP-induced Ca
mobilization, we first determined the fMLP concentration that caused half-maximal
2+Ca mobilization. Fig. 1 shows that fMLP dose-dependently increased the peak
2+value of the [Ca ]i av transient. Maximal and half-maximal fMLP concentrations were
2+calculated to be 100 nM and 1 nM, respectively. No increase in [Ca ]iav was 
observed following stimulation with 0.1 nmol/L fMLP.
2+Fish oil and Lipofundin inhibit fMLP-induced Ca mobilization more potently
than olive oil and Intralipid in human neutrophils: Pretreatment of the cells with 0.1
2+mmol/L fish oil caused a significant reduction of the increase in [Ca ]i,av in response
to 1 nmol/L fMLP (Fig. 2a). On the other hand, Fig. 2b shows that fMLP-induced
2+Ca signaling was hardly affected in cells pretreated with the same concentration of 
olive oil.
In a previous study we showed that both an emulsion of pure LCT as well as a 
mixture of LCT and MCT (LCT/MCT), caused inhibition of fMLP-induced Ca2+ 
mobilization in human neutrophils [19]. The initial finding that 0.1 mM VLCT 
markedly inhibited the stimulatory effect of fMLP, whereas the same concentration
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of LCT-MUFA was virtually without effect urged us to construct dose-inhibition
curves for the four different lipid emulsions. Fig. 3a shows that, in the absence of2+
serum albumin in the medium, VLCT inhibited the fMLP-induced [Ca ]iav rise much 
more efficacious than the other three lipid emulsions. At a concentration of 0.1 
mmol/L, VLCT, LCT/MCT, LCT-MUFA, and LCT inhibited the effect of fMLP by 
60%, 35%, 20% and 15%, respectively. In all four cases the effect was statistically 
significant. At a lower concentration of 0.025 mmol/L, however, only VLCT and 
LCT/MCT caused a significant inhibition of the fMLP-induced [Ca2+]i,av rise by 35% 
and 20%, respectively. Non-linear curve fitting revealed that 0.031 mmol/L VLCT 
was required for half-maximal inhibition of the response to fMLP.
In the presence of 0.5 % (wt/vol) serum albumin, the inhibitory effect of 0.1 
mmol/L VLCT was significantly lowered to no more than 20% (Fig. 3b). At the same 
concentration, however, the inhibitory effect of the other three lipid emulsions was 
only slightly reduced. All four lipid emulsions maximally inhibited the fMLP 
response by on average 55%. With VLCT and LCT/MCT this value was reached at a 
concentration of 1 mmol/L, whereas with LCT-MUFA and LCT a concentration of 
2.5 mmol/L was required to obtain the maximal effect. Half-maximal inhibition was 
calculated to be reached at 0.24 mmol/L (VLCT), 0.32 mmol/L (LCT/MCT), 0.52
mmol/L- (LCT) and 0.82 mmol/L (LCT-MUFA). These values show that LCT/MCT
2+and VLCT inhibit fMLP-induced Ca mobilization 1.6 to 3.4 times more potently 
than LCT and LCT-MUFA in human neutrophils incubated in the presence of serum 
albumin.
2+Protein kinase C is not involved in inhibition o f  fMLP-induced Ca mobilization 
by lipid emulsions in human neutrophils: Phorbol esters, such as PMA, are widely
used to study the role of protein kinase C (PKC). Pretreatment of the neutrophils with
2+PMA resulted in complete inhibition of the increase in [Ca ]iav in response to 10 
nmol/L fMLP (Fig. 4a). This inhibitory effect of PMA was abolished by the putative 
PKC inhibitor staurosporine. These findings are indicative of the potential of PKC to 
function as an internal regulator of fMLP-induced transmembrane signaling. In 
contrast to PMA, the inactive phorbol ester 4-a-phorbol 12-myristate 13-acetate did 
not change the response to fMLP (data not shown). Fig. 4 b shows that staurosporine 
was unable to reverse the inhibitory effect of LCT/MCT (2.5 mmol/L). A similar 
observation was reached with the other three lipid emulsions (data not shown). This 
demonstrates that the lipid emulsions, when added at a clinically relevant 
concentration of 2.5 mmol/L, do not exert their inhibitory effect through PKC.
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Discussion
Clinical and experimental studies suggest that altered immune responses by lipids
contribute to the increased rate of infectious complications in patients treated with
inraveneus (parenteral) nutrition [1-3]. On the other hand, modulation of
inflammatory responses by nutritional lipids offers therapeutic strategies in the
treatment of various diseases, ranging from vasculopathy, to inflammatory bowel
disease and cancer [27-30]. However, our understanding of the underlying
mechanisms behind these observations remains limited.
The present work shows that short-term (3 min) treatment with nutritional lipid
emulsions can markedly affect the activation of human neutrophils with the bacterial
tripeptide N-formyl-methionyl-leucyl-phenylalanine (fMLP). The extent of neutrophil
activation was expressed as function of the peak height of the fMLP-induced increase
2+ 2+ of the average cytosolic Ca concentation ([Ca ]iav) in a suspension of cells loaded
2+with the fluorescent Ca indicator fura-2. Four structurally different lipid emulsions 
were included in this study, namely Omegaven (fish oil), ClinOleic (olive oil), 
Lipofundin (a mixture of coconut oil and soya oil) and Intralipid (soya oil). In the 
presence of 0.5 % (wt/vol) human serum albumin, each of these lipid emulsion 
maximally reduced the fMLP response by 50% to 60%. The inhibitory effect of the 
lipid emulsions was dose-dependent and the order of potency was VLCT, being the 
most potent emulsion, followed by LCT/MCT, LCT and LCT-MUFA, being the least 
potent emulsion (half-maximally inhibitory concentrations of 0.24 mmol/L, 0.32 
mmol/L, 0.52 mmol/L: and 0.82 mmol/L, respectively). The same order of potency 
was reached in the absence of human serum albumin, albeit that the half-maximal 
inhibitory concentrations were significantly decreased. Thus, in the absence of serum 
albumin, VLCT inhibited the fMLP response 8-fold more potently than in its presence 
(half-maximal inhibitory concentrations of 0.031 mmol/L- and 0.24 mmol/L, 
respectively.
In a broader context, the present findings contribute to our understanding of the 
results of previous clinical studies in which fish-oil preparations were effective in the 
treatment of inflammatory bowel disease, as well as in attenuating inflammatory 
responses in cancer patients [29-33].
We have previously shown that lipid emulsions containing MCT, including
Lipofundin, completely mimicked the effects of PMA on the serum-treated zymosan
2+(STZ)-induced increase in [Ca ]i,av [19]. Conversely, lipid emulsions that did not
2+contain MCTs, including Intralipid, lowered the plateau [Ca ]i,av but had no effect on 
the kinetics of the STZ-induced increase in [Ca2+]i,av. This suggested that emulsions
containing MCT act through PKC to change the kinetics, but not the final height, of
2+the STZ-induced increase in [Ca ]iav. Here we show that the same lipid emulsions,
when added at a clinically relevant concentration of 2.5 mmol/L, also markedly
2+reduce the fMLP-induced increase in [Ca ]iav. Inhibition was not reversed by 
staurosporine, demonstrating that PKC, although activated by LCT/MCT (see above), 
is not primarily involved in the mechanism of action of these emulsions. In contrast, 
this drug readily reversed the inhibitory effect of PMA.
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The data presented show that VLCT and, to a lesser extent, LCT/MCT inhibit 
fMLP-induced neutrophil activation more potently than LCT and LCT-MUFA. Close 
comparison of the fatty acid composition of the triglycerides present in these 
emulsions (see Table 1) reveals that the most potent inhibitor VLCT differs from the 
other three emulsions in that it contains relatively much of the n-3 polyunsaturated 
fatty acids eicosapentaenoic acid (20:5n-3; EPA) and docosahexaenoic acid (22:6n-3; 
DHA). Furthermore, it contains considerably less oleic acid (18:1) than LCT-MUFA. 
Because the latter emulsion is the least potent inhibitor, it can be concluded that the 
DHA and/or EPA containing triglycerides are responsible for the higher potency of 
the VLCT emulsion. The second potent inhibitor LCT/MCT differs from the other 
three emulsions in that it contains relatively much of the MCT caprylic acid (8:0) and 
capric acid (10:0). It contains markedly less oleic acid (18:1) than LCT-MUFA and a 
moderate amount of linoleic acid (18:2) as compared to the second least potent 
inhibitor LCT. This demonstrates that the PUFA containing triglycerides are not 
responsible for the higher potency of the LCT/MCT emulsion. Finally, the second 
least potent inhibitor LCT differs from the least potent inhibitor LCT-MUFA in that it 
contains considerably more linoleic acid (18:2).
Taken together these findings show that triglycerides containing EPA and/or DHA 
inhibit fMLP-induced neutrophil activation more potently than those containing MCT 
and much more potently than those containing linoleic acid or oleic acid. The 
mechanism(s) underlying the prompt inhibitory action of these triglyceride species 
might involve (i) binding of fMLP, thereby decreasing the effective concentration of 
the hormone, (ii) activation of intracellular mechanism(s) resulting in receptor 
desensitisation, or (iii) changes in membrane properties leading to impaired signal 
transduction. In our previous study we showed that LCT and LCT/MCT, when added 
at 2.5 mmol/L, reduced the maximal response to fMLP by 40% and 57%, 
respectively, without changing the half-maximal stimulatory concentration of the 
hormone (EC50 values of 0.79 nmol/L, 0.63 nmol/L and 0.79 nmol/L for untreated 
and LCT- and LCT/MCT-treated cells, respectively). This shows that the lipid 
emulsions do not act by lowering the effective concentration of fMLP. In contrast, 
PMA evoked both a rightward shift of the dose-response curve for the effect of fMLP 
(EC50 of 12.6 nmol/L) and a 50% reduction of the maximal effect of the hormone. 
Here we show that staurosporine readily reversed the inhibitory effect of PMA. This 
indicates that PMA did not act by reducing the effective concentration of fMLP but 
by reducing the sensitivity of the fMLP receptor (rightward shift dose-response 
curve) and the signal transduction efficiency (reduction maximal effect of fMLP). 
Staurosporine did not reverse the inhibitory effect of the lipid emulsions. This 
suggests that the lipid emulsions act by interfering with the signal transduction 
efficiency. Detailed analysis with pure triglycerides may show whether triglycerides 
containing EPA and/or DHA are indeed more potent in inhibiting the fMLP response 
than those containing MCT or linoleic acid.
In summary, this study shows that acute addition of lipid emulsions, at a clinicall 
relevant concentration of 2.5 mmol/L, can significantly reduce hormone-induced
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neutrophil stimulation. On the other hand, when added at a final concentration of 1 
mM, LCT-MUFA and LCT emulsions affect the response to fMLP considerably less 
than VLCT and MCT-containing emulsions. Future studies employing neutrophils that
are obtained from subjects receiving total parenteral nutrition will learn whether and, if2+
so, how fMLP-induced Ca signaling is affected under conditions of long-term 
exposure to nutritional lipid emulsions.
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Figure 1. Dose-response curve for the fMLP-induced peak increase in [Ca2+]i,av in a suspension o f 
human neutrophils.
Wanten et al. Fig 1
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Human neutrophils, loaded with the fluorescent Ca2+ indicator Fura-2, were transferred to a cuvette 
placed in a Shimadzu RF-5301 spectrofluorophotometer equipped with a magnetic stirrer and a 
thermostated (37°C) cuvette holder. The cells were preincubated for 3 min and then stimulated with 
the indicated concentration o f fMLP. The fluorescence emission ratio at 490 nm was monitored as a 
measure o f the average cytosolic free Ca2+ concentration ([Ca2+]i,av) after excitation at 340 and 380 
nm. The peak increase in [Ca2+]i,av obtained with 1 fMLP is set at 100%, to which all other 
values are related. The data presented are from a single experiment.
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Figure 2. Effects o f the nutritional lipid emulsions VLCT (fish oil) and LCT-MUFA (olive oil) on 
the fMLP-induced increase in [Ca2+]i,av in a suspension o f human neutrophils.
Figure 2a. Figure 2b.
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Fura-2-loaded neutrophils were preincubated with either VLCT (0.1 mmol/L; A) or LCT-MUFA 
(0.1 mmol/L; B) in a medium without serum albumin for 3 min and subsequently stimulated with 
fMLP (1 nmol/L). Details on [Ca2+]i,av measurement are given in the legend to Fig. 1.
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Figure 3 a.
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Figure 3. Dose dependence o f the effects o f VLCT (fish oil), LCT-MUFA (olive oil), LCT (soya 
oil) and LCT/MCT (mixture o f coconut oil and soya oil) on the fMLP-induced peak increase in 
[Ca2+]i,av in the absence (A) and presence (B) o f serum albumin.
Neutrophils loaded with Fura-2 were preincubated in the presence o f the indicated concentrations of 
VLCT (closed squares), LCT/MCT (open squares), LCT (closed circles) and LCT-MUFA (open 
circles) in a medium without (A) or with (B) serum albumin for 3 min, after which the cells were 
stimulated with 1 nmol/L fMLP. [Ca2+]i>av was monitored as described in the legend to Fig. 1. The 
peak increase in [Ca2+]i,av obtained in the absence o f lipid emulsion (untreated control) is set at 
100%, to which all other values are related. The data represent means ± SEM of at least four 
measurements. * Significantly different from untreated control (P < 0.01), # Significantly different 
from corresponding LCT-MUFA (P < 0.01), & Significantly different from corresponding LCT (P <
0.01), 5 Significantly different from corresponding LCT/MCT (P < 0.01).
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Figure 4. Effect o f staurosporine on the fMLP-induced peak increase in [Ca2+]i>av in human 
neutrophils pretreated with PM A (A) or LCT/MCT (B).
0.1 u M P M A  10 n M f M L P
t i m e  ( s e c )
Fura-2-loaded neutrophils were preincubated in the absence or presence o f 0.1 ^mol/L PM A (A) or
2.5 mmol/L LCT/MCT (B) for 3 min. W here indicated, 1 ^mol/L staurosporine was added at 30 sec 
after PM A (A) or LCT/MCT (B). After 3 min, the cells were stimulated with 10 nmol/L fMLP. 
Details on [Ca2+]i>av measurement are given in the legend to Fig. 1
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Tocopherol isoforms in parenteral lipid emulsions and neutrophil activation
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Tocopherol isoforms
Abstract
Background & Aims: Tocopherol is a lipid-soluble anti-oxidant that exists in 
several isoforms. Patients on total parenteral nutrition depend on lipid emulsions for 
their tocopherol intake. In the present study we analysed the content of tocopherol 
isoforms in various lipid emulsions. We also tested the hypothesis that immune- 
modulating effects of lipid emulsions could be attributed to different concentrations 
of a-tocopherol (a-toc) or peroxidation products.
Method: a-, P-, y- and 8-toc were measured in emulsions containing long-chain 
triglycerides (LCT), mixed long- and medium-chain triglycerides (LCT/MCT), 
structured lipids (SL), olive-oil (OO) or fish oil (FO). As a measure for cellular 
activation, neutrophil membrane adhesion markers were assessed after exposure to 
two LCT/MCT emulsions that differ only in a-toc content.
Results: Various emulsions differed widely in tocopherol contents, especially with 
respect to the a- isoform. The latter isomer also was subject to considerable 
degradation despite adequate storage conditions. The previously observed activation of 
neutrophils by LCT/MCT was not influenced by the increased concentration of a-toc 
or the decreased concentration of lipid peroxidation products in a new LCT/MCT 
emulsion.
Conclusions: Tocopherol supplementation by parenteral lipid emulsions strongly 
depends on the lipid source and the storage lifetime of the emulsion. The effects of 
LCT/MCT on the immune system are not modulated by a-toc or by lipid peroxidation 
products.
Introduction
Vitamin E (tocopherol) is a chain-breaking, lipid-soluble anti-oxidant that protects 
the integrity of biological membranes by inhibiting lipid peroxidation [1]. Tocopherol 
occurs as a-, P-, y- or 5-isoforms, depending on the number and position of methyl 
groups attached to the chromanol ring. a-Tocopherol (a-toc), the biologically most 
active form, is found in the highest concentration in human plasma and tissues, 
whereas y-toc is present in at least equally high concentrations in the diet [2,3]. The 
biological activities of the P-, y- and 5-isoforms of vitamin E are 0.5, 0.25 and 0.01, 
respectively, compared to a-toc [4,5].
Lipid emulsions, besides providing energy and essential fatty acids, establish the 
major source of vitamin E in patients on total parenteral nutrition (TPN). However, 
often tocopherol requirements are not met by the amounts present in conventional lipid 
emulsions. This is demonstrated by the fact that lipid peroxidation, measurable as the 
increased production of pentane in expired breath, is increased in patients on lipid- 
based TPN and correlates inversely with the a-toc concentration in serum [6,7]. The 
risk for clinical manifestations of tissue damage due to tocopherol deficiency, such as 
hemolysis or neurological problems, therefore is imminent [8-15]. Accordingly, 
addition of tocopherol to a parenteral lipid emulsion has been shown to decrease
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hemolysis [16]. Besides anti-oxidants, also the container materials of TPN bags and 
storage conditions (temperature, light exposure) play a role in the peroxidation 
process [5].
Lipid emulsions have been associated with the increased risk for infectious 
complications that is observed with the use of TPN, and the lipid structure appears to 
be of importance in this respect [17-20]. Intralipid®, the most widely used 
formulation, is a long-chain triglyceride (LCT) emulsion that has shown detrimental 
effects on immune function in some, but not all studies [21-28]. Besides pure LCT, 
also a physical mixture of 50% medium-chain triglycerides (MCT) and 50% LCT 
(LCT/MCT, e.g. Lipofundin®) is used in clinical practice. A third type contains 
structured lipids (SL, e.g. Structolipid®): synthetic triglycerides, with medium- and 
long-chain fatty acids randomly attached to one triglyceride molecule. Previous 
studies indicate that these structurally different emulsions have distinct effects on the 
function and cellular signalling of human neutrophil granulocytes [29-34]. It appears 
that MCT-containing emulsions increase the expression of neutrophil membrane 
surface adhesion and degranulation markers, while LCT and SL, which lack these 
activating effects, are more immune-neutral [35]. The effects of two other emulsion 
types, based on olive oil (e.g. Clinoleic®) and fish oil (e.g. Omegaven®), which have 
been introduced on the market only recently, remain less well characterised.
Besides other emulsion components (lipid, emulsifier, fatty acids), also anti­
oxidants such as tocopherol on the one hand, and lipid peroxidation products on the 
other may contribute to the described effects [36]. Immune-modulating effects of 
tocopherol comprise direct effects on immune competent cells, as well as effects on 
eicosanoid metabolism and key enzymes (phospholipase A2, protein kinase C (PKC)) 
in cellular signalling [1,37-39].
Given the repercussions for supplementation purposes as well as immune function, 
the aim of the present study was to analyse the content of tocopherol isoforms in 
clinically applied and structurally different lipid emulsions. To help unravel the 
mechanism behind previously observed immune-activating effects of MCT- 
containing emulsions, our second goal was to assess the role of a-toc and lipid 
peroxidation products herein. This was enabled by the fact that recently a new 
LCT/MCT formulation (Lipofundin E®, LCT/MCT-E), enriched with a-toc, has 
replaced the original Lipofundin® (LCT/MCT) formulation in The Netherlands. 
Neutrophil activation was assessed by measuring the expression of cellular 
membrane adhesion and degranulation markers, because this has been shown to 
correlate well with other signs of neutrophil activation, such as increased oxygen 
radical production and decreased cellular migration [32,33,35]. Adhesion molecules 
were represented by various members of the p2 integrin subfamily, which comprises 
several aP heterodimeric membrane glycoproteins that share a common p2 unit 
(CD 18). The a  subunits of each of the members, lymphocyte-function-associated 
antigen (LFA)-1, macrophage antigen (Mac)-1, and p150,95 are designated CD11a, - 
b and -c, respectively [40]. Degranulation markers for azurophilic and specific
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granules were CD63 and CD66b, respectively (41,42). Also L-selectin (CD62L) 
expression, which is known to decrease upon cellular adhesion due to shedding, was 
measured.
Materials and Methods
Reagents: Reagents were from Sigma Chemicals (St Louis, MO, USA) unless 
stated otherwise. Hank's balanced salt solution (HBSS) was from Life Technologies 
(Paisley, Scotland). Phosphate-buffered saline (PBS) contained Na+ 163.9 mmol/l, Cl-
140.3 mmol/L, HPO42- 10.9 mmol/L and H2PO4- 1.8 mmol/L (pH 7.4). Isotonic lysis 
solution contained 155 mmol/L NH4Cl, 10 mmol/L KHCO3 and 0.1 mmol/L EDTA 
(pH 7.4). Incubation medium contained HBSS supplemented with 0.5% (wt/vol) 
human serum albumin (HSA, from Behring, Westwood, MA, USA). Pooled human 
serum (PHS), 50% (v/v) in PBS was derived from whole blood of donors at the 
Blood Bank of the University Medical Centre Nijmegen, Nijmegen, The Netherlands. 
Percoll (p 1.129 g/mL at 20°C) was from Pharmacia Biotech AB, Uppsala, Sweden. 
Blood samples were collected in 10 ml Monoject tubes (Sherwood Medical, 
Ballymoney, N. Ireland) with 143 USP units of lithium heparin.
Lipid emulsions: Lipid emulsions (all 20%) were Intralipid® (LCT), Structolipid® 
(SL) and Omegaven® (FO), from Fresenius Kabi AB, Uppsala, Sweden. Lipofundin® 
(LCT/MCT) and Lipofundin E® (LCT/MCT-E) were from B. Braun Melsungen AG, 
Melsungen, Germany. Clinoleic® (OO) was from Baxter Clintec Parenteral SA, 
Maurepas Cedex, France.
Neutrophil isolation: As described previously, neutrophils were isolated from 
whole blood anticoagulated with lithium heparin, obtained from six healthy 
volunteers (3 male, mean age 35 ± 6 years), none of whom was on medication [41]. 
The blood, diluted 1:1 with PBS with 0.4% (wt/vol) trisodium citrate (pH 7.4), was 
placed on Percoll (p 1.076 g/mL) and centrifuged (700 x g, 18 minutes, 25°C). The 
pellet was suspended in 50 ml of ice-cold lysis solution for 10 minutes. After 
centrifugation (5 min, 400 x g, 4°C), the remaining erythrocytes were lysed in fresh 
lysis solution for another 5 minutes. The cells were then washed and resuspended to a 
final concentration of 2 x 106 /mL and were kept at room temperature. Cytospin 
preparations were > 97% pure and > 99% viable as determined by May- 
Grunwald/Giemsa and trypan blue staining, respectively.
Lipid emulsion incubation: Isolated neutrophils (2x106 /mL) were incubated in a 
shaking waterbath (60 min, 37°C) in medium or lipid emulsion (triglyceride 
concentration 2.5 mmol/L). Next, the cells were washed twice and membrane surface 
antigen expression was determined.
Membrane surface antigen expression: Neutrophil surface antigen expression was 
assessed by immune-fluorescent staining and subsequent flowcytometric analysis of 
neutrophils after lipid incubation. Direct monoclonal antibodies (mAb, from DAKO,
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Glostrup, Denmark) were mouse anti-human IgG1 fluorescein (FITC)-conjugated 
anti-CD11a (clone MHM24) and anti-CD11c (clone KB90) and phycoerythrin 
(RPE)-conjugated anti-CD11b (clone 2LPM19c RPE). Indirect mAb anti-CD18 mAb 
AZN-L19 was developed at the dept. of Tumor Immunology, University Medical 
Centre St. Radboud, Nijmegen, The Netherlands. The staining procedure was 
performed on melting ice: 4 x 105 neutrophils were incubated with 100 ^L of PHS for
10 minutes on ice and then transferred to FACS tubes containing saturating doses of 
the mAb and the isotype control. Incubation took place for 30 minutes in the dark at 
4°C, after which the cells were washed with ice-cold medium, resuspended in 200 ^L 
of medium and fixed in 150 ^L of ice-cold 2% paraformaldehyde. In case of indirect 
mAb, after staining with the primary mAb and washing, a second staining step with 
the secondary mAb (FITC-labeled goat-anti-mouse-Ig, 30 minutes in the dark at 4°C) 
was performed prior to fixation. Cell fluorescence measurements were performed on 
a FACScan (Becton and Dickinson & Co., Oxnard, CA, USA).
Analysis o f  tocopherol isoforms: The concentrations of a-, P-, y-, and 5-toc in the 
lipid emulsions were determined immediately after deliverance by the manufacturer 
by high pressure liquid chromatography (HPLC) with fluorescence detection as 
described previously [43]. Fifty ^L of the emulsions were diluted (1:11) with 500 jxL 
of 0.05 mol/l PBS buffer, denatured with 500 ^L of ethanol and centrifuged after the 
addition of the mobile phase (n-hexane: ethanol 99.8:0.2 v/v). For standard 
calibration, a similar procedure to that of the emulsion procedure was used but 
substituting PBS buffer for the emulsion sample and the ethanolic standards for 
ethanol. Stock standards a-, P-, y-, and 5-toc (obtained from Merck Darmstadt, 
Germany) were diluted in ethanol. With spiked emulsions, substituting ethanol for 
ethanolic standards, sample recovery was tested. The extraction recoveries for the 
tocopherol isoforms ranged from 95-109 %.
Lipid peroxidation products: Lipid peroxidation products in LCT/MCT and 
LCT/MCT-E emulsions were assessed by measuring thiobarbituric acid-reactive 
substances (TBARS, in ^mol/L), as described [44]. In this assay, lipid peroxidation 
products, such as malondialdehyde, form adducts (TBARS) with thiobarbituric acid, 
which can be measured by spectrofluorometry, using excitation and emission 
wavelengths of 515 and 553 nm, respectively, and a tetramethoxy-propane standard for 
calibration.
Statistical analysis: Wilcoxon’s signed ranks test (two-tailed) was used for 
analysis of the results. The significance level was set at 0.05. Values are given as 
mean ± SEM.
Results
Structurally different lipid emulsions varied widely in tocopherol content (Table 
1). Especially the concentration of the most active a-form was at least five-fold 
higher in LCT/MCT-E and FO than in the other emulsions. By far SL had the lowest
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a-toc content of all emulsions. ß-toc was not present in significant amounts in any 
emulsion. y-toc, the second-most common isoform in most emulsions, was not 
detected in FO and hardly in OO. The same applies for the biologically least active S 
isoform. Tocopherol contents between different batches of each emulsion were not 
significantly different.
Despite adequate storage conditions, the content of a-toc, in sharp contrast with 
other isoforms, proved to be subject to significant degradation in LCT and LCT/MCT 
(Table 1).
Table 1. a-, ß-, y-, and S-tocopherol isoform concentrations (means, in ^mol/L) in samples from 
three separate batches. All SEM (not shown) were < 2 ^mol/L.
LCT: long-chain trglycerides, derived from soybean oil; LCT/MCT: physical mixture (50/50) of long- 
and medium-chain triglycerides, derived from soybean and coconut oil; LCT/MCT-E: a-tocopherol- 
enriched LCT/MCT; SL: structured lipids; FO: fish-oil; OO: olive oil.
Emulsion name
Intralipid®
Lipofundin®
Lipofundin-E®
Structolipid®
Omegaven®
Clinoleic®
Intralipid®
Lipofundin ®
Triglyceride a-toc ß-toc y-toc 5-toc
LCT 87 14 349 96
LCT/MCT 69 <2 215 73
LCT/MCT 502 <2 215 78
SL 16 <2 123 49
FO 505 <2 <2 <2
OO 75 <2 43 11
in the dark for 6 months
(LCT) 36 15 346 83
(LCT/MCT) 37 <2 199 79
Figure 1 shows that exposure of neutrophils to LCT/MCT and LCT/MCT-E in a 
clinically relevant concentration of 2.5 mmol/L significantly increased the expression 
of membrane adhesion and degranulation markers, when compared with non-lipid- 
exposed cells, irrespective of the different a-toc concentrations of both emulsions. 
Figure 2 shows that the concentration of lipid peroxidation products in LCT/MCT-E 
is significantly lower than in LCT/MCT.
Discussion
The main conclusion to be drawn from the present study is that tocopherol 
supplementation in TPN patients by parenteral lipid emulsions depends strongly on 
both the lipid source and the storage lifetime of the emulsion, especially with regard 
to the concentration of the biologically most active a-isoform. Our findings are in 
accordance with those of previous investigators with regard to LCT and LCT/MCT 
[3,5]. LCT emulsions are made from soybean or safflower oils, which contain 
predominantly y-toc that affords relatively little protection against lipid peroxidation. 
The mentioned studies lack data on SL and FO emulsions, which in the present study 
were found to be relatively poor and rich sources of a-toc, respectively. Although it
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has been suggested that OO would establish a better source of anti-oxidants compared 
with LCT, our results do not support this statement with regard to tocopherol [45].
Figure 1. Membrane surface antigen expression, presented as mean relative fluorescence ± SEM 
compared to incubation in medium, o f isolated neutrophils from volunteers (n=6) after incubation in
2.5 mmol/L lipid emulsions containing a 50%/50% mixture o f long- (LCT) and medium-chain 
(MCT) triglycerides, with (LCT/MCT-E) or without (LCT/MCT) a-tocopherol enrichment.
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Expression o f all shown membrane surface antigens, with the exception o f CD 11 a, was 
significantly influenced by LCT/MCT and LCT/M CT-E incubations compared to lipid-free 
incubation (all P<0.01). Expression o f all membrane markers was not different after incubation in 
LCT/MCT or LCT/MCT-E emulsions.
Cells belonging to the immune system contain high concentrations of tocopherol in 
their membranes, probably to reduce the risk of oxidative damage caused by the high 
content of polyunsaturated fatty acids in the environment. Not surprisingly, adequate 
tocopherol stores are essential for a normal function of all cellular components of the 
immune system [46,47]. Importantly, our results demonstrate that, within the broad 
a-toc concentration ranges of LCT/MCT and LCT/MCT-E, the previously observed 
neutrophil-activating effects of MCT-containing emulsions are not modulated by the 
anti-oxidant a-toc [35]. This lack of effect of a-toc on immune function is in 
accordance with previous findings regarding the effects of lipid emulsions on 
neutrophil migration [32]. The present study, within the indicated concentration 
ranges, also shows that the same applies for lipid peroxidation products. Cellular 
activation therefore necessarily has to be induced by another emulsion component. 
This is strengthened by the observation that tocopherol isoform concentrations of the 
immune-neutral LCT and neutrophil-activating LCT/MCT emulsions are in the same 
range.
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Figure 2. Lipid peroxidation products in 2.5 mmol/L LCT/MCT and LCT/MCT-E emulsions, 
measured as thiobarbituric acid-reactive substances (TBARS, in |imol/L). Results are expressed as 
means ± SEM from three separate experiments.
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The fact that previous investigators found a-toc to protect against upregulation of 
neutrophil adhesion molecules by both the tripeptide N-formyl-methionyl-leucyl- 
phenylalanine and oxidized low-density lipoprotein suggests that the mechanism for 
neutrophil activation by MCT emulsions follows a different signaling pathway [48]. 
a-Toc has shown well-defined inhibitory effects on the respiratory burst of leukocyes,
i.e. inhibition of PKC as well as impaired assembly of the NADPH-oxidase complex 
[49]. However, when we previously compared the effects of LCT/MCT and 
LCT/MCT-E on PKC activity in human neutrophils, we found no alteration of the 
emulsion effect [30].
Finally, in support of the findings of Steger et al., who reported that tocopherol 
isoforms in lipid emulsions are degraded with different kinetics, we found a decrease in 
the concentration of tocopherol isoforms during storage in the order a  > Y > S [5].
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Summary
Background
An adequate nutrient supply is a prerequisite for maintenance of the functional 
integrity of the human body, especially in case of a disease. This is exemplified by 
the increased susceptibility to infections in case of malnutrition. The latter results 
from dysfunction of the immune system that protects us against invasion by 
pathogenic microorganisms. In situations in which the uptake of fluids and nutrients 
by the digestive tract is not adequate, for instance following surgery, intravenous 
administration of a nutritional solution can maintain or improve the nutritional status 
of a patient. This is called Total Parenteral Nutrition (TPN). In clinical practice, many 
patients depend on TPN for a shorter or longer period, and sometimes even 
permanently.
Besides benefits, TPN also has certain disadvantages, such as an increased risk for 
infectious complications. In part this is because microorganisms may invade the body 
at the site of the vascular entrance that is required to administer the TPN solution. 
Another problem is that components of the TPN formulation may inhibit the function 
of immune competent cells. The neutrophilic granulocyte, or neutrophil, is a key cell 
within our innate defense system. It is a white blood cell, or leukocyte, that can ingest 
and kill invading pathogens. The fact that patients on TPN develop wound infections 
and pneumonia relatively often suggests that especially the function of the neutrophil 
may be compromised in this situation.
Previous investigations have indicated that the lipids in TPN formulations are 
responsible for this decreased immune function. Lipids, consisting of a glycerol 
molecule with three fatty acid molecules attached to it, are indispensable as a source 
of fuel calories and (essential) fatty acids. Fatty acids establish structural parts of 
cellular components, such as membranes, and also have a regulatory role in cellular 
metabolism. To be digestible, lipids are administered as a mixture of miniscule fat 
particles in water, a so-called emulsion. Numerous fats exist, which differ with 
respect to the carbonchain-length and number and position of double bonds of the 
involved fatty acids. Fats that only contain fatty acids with a carbonchain-length of 
more that 14 C atoms are called long-chain triglycerides (LCT). Also medium-chain 
triglycerides (MCT) exist, with a carbonchain-length of 6 to12 C atoms. Pure MCT 
are not tolerated by man, but do offer certain metabolic benefits, such as a rapid 
breakdown. Therefore, MCT have been applied in clinical practice since the mid- 
1980’s as a 50/50% physical mixture with LCT.
During the last ten years a third type of lipids has been introduced in which both 
medium- and long-chain fatty acids are attached to the glycerol backbone in a random 
order. These synthetic triglycerides are called ‘structured lipids’ (SL). Currently, 
based on supposedly beneficial effects in epidemiological studies, emulsions 
containing olive and fish oil are being introduced on the market for clinical use.
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Aim o f the investigation
The hypothesis that was tested in this thesis was whether structurally different 
lipids have a distinct modulating, i.e. inhibitory or stimulating, effect on the cells of 
the immune system. Especially, various aspects of the function of the human 
neutrophil were studied in this respect.
Introduction
As an introduction, the functions of the neutrophil are reviewed in more detail 
(Chapter 2). Also, an overview is given of the effects of lipid emulsions on 
components of the immune system that have been reported in previous studies so far 
(Chapter 3).
In vitro studies: incubation o f neutrophils in lipid emulsions in the test tube
We found that in vitro, lipid emulsions display a clear effect on the capacity of 
neutrophils to produce toxic oxygen radicals, which are essential to kill 
microorganisms. In our study, MCT-containing emulsions activated neutrophils in the 
absence of any other stimulus. Importantly, this phenomenon was observed at a 
triglyceride concentration that is clinically relevant. In this respect, LCT/MCT and 
MCT clearly differ from LCT, which displayed no such effect. Also, short-term, 
stimulus-induced oxygen radical production was increased in the presence of MCT, 
whereas LCT en SL showed no effect (Chapter 4).
On the neutrophil outer membrane, adhesion molecules are present that facilitate 
adhesion to other cells and tissues. This feature is essential to enable the neutrophil to 
leave the vascular compartment at the site of an infection, e.g. an abscess. We found 
that LCT/MCT and MCT emulsions, contrary to LCT en SL, increase both the 
expression and function of adhesion molecules, resulting in cell ‘stickiness’, 
indicative for neutrophil activation. In accordance with this notion, under the 
influence of MCT, but not LCT or SL, neutrophils released the contents of 
intracellular organelles into their environment (degranulation) (Chapter 5). To 
perform their functions, neutrophils have to migrate towards a site of infection, 
against the concentration gradient of inflammatory mediators that is released locally. 
Under the influence of LCT/MCT and MCT and to a lesser degree SL, but not with 
LCT, neutrophil migration decreased. This is another indication that MCT-containing 
emulsions activate neutrophils (Chapter 6). Neutrophils eliminate pathogenic 
microorganisms by ingestion and subsequent intracellular killing, by means of toxic 
metabolites such as oxygen radicals. We found that although the capacity of 
neutrophils to ingest particles of the well-known yeast pathogen Candida albicans 
was not affected by any lipid emulsion, exposure to MCT, but not LCT or SL, 
resulted in decreased killing of Candida (Chapter 7). Besides lipids, lipid emulsions 
also contain numerous other components, such as emulsifiers, various anti-oxidants 
en (free) fatty acids. Saturated lipids, i.e. lipids containing fatty acids without double 
bonds, are traditionally regarded as biologically inert substances that only serve as 
source of fuel calories. However, we found that saturated fatty acids and lipids,
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depending on their carbonchain-length, activate neutrophils, resulting in the 
production of oxygen radicals (Chapter 8).
In vivo studies: intravenous administration o f  lipid emulsions to healthy volunteers
Intravenous administration of LCT/MCT, in contrast to pure LCT or placebo 
(saline), resulted within a few hours in increased neutrophil and decreased 
mononuclear cell counts in the venous bloodstream of healthy volunteers (Chapter 
9). Infusion in volunteers of LCT/MCT, but not of LCT, resulted in an altered 
production by mononuclear cells of signalling proteins (cytokines, such as various 
interleukins en y-interferon), in a manner that suggests that the susceptibility for yeast 
infections may be increased. Moreover, cell-free serum samples obtained after 
infusion of LCT/MCT, in contrast to LCT and saline, revealed an increased growth of 
Candida albicans (Chapter 10). Therefore, apart from the described findings in the 
in vitro setting (in the test tube), results of in vivo studies also suggest that 
structurally different lipid emulsions distinctively modulate the function of the 
immune system.
Studies regarding the mechanism behind lipid emulsion effects
‘Membrane fluidity’ is a complex functional characteristic of cellular membranes 
that refers to the freedom of movement of molecules within the membrane. Our 
findings show that incubation of neutrophils in MCT-containing emulsions and to a 
lesser degree with SL, but not with LCT, results in increased membrane fluidity 
(Chapter 11). Because changes in membrane fluidity are involved in cellular 
activation pathways, this observation might explain the effect of MCT emulsions.
To become functional, cells have to translate an extracellular signal into an 
adequate intracellular response. The connection between signal and response is made 
by means of messenger molecules within the cell, the so-called ‘second messengers’, 
such as ionized calcium. We found that lipid emulsions, depending on their lipid 
structure, have a distinct effect on the release of calcium from intracellular stores and 
the activity of the key regulator enzyme protein kinase C (PKC) (Chapter 12). It 
appeared that MCT-containing emulsions sensitize neutrophils for activation by 
serum-treated yeast particles and that LCT, MCT and SL emulsions all inhibit the 
effect of two stimuli (serum-treated yeast particles and a bacterial tripeptide) in a 
non-specific manner. Recently, new lipid emulsions have been developed, based on 
olive- and fish oil. Our results show that LCT and olive oil emulsions inhibit 
bacterial-tripeptide-induced calcium responses of neutrophils at a clinically relevant 
concentration to a considerably lesser degree than LCT/MCT and fish oil emulsions 
(Chapter 13).
The findings in chapters 12 and 13 raise the question how the described lipid 
effects on neutrophil signaling can be related to the lipid effects on various neutrophil 
functions. The induction by MCT of oxygen radical production in unstimulated 
neutrophils, involving the PKC-dependent activation of the NADPH-oxidase 
complex, as well as the upregulation of adhesion molecule expression, point towards
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a PKC-activating or ‘PMA-like’ effect of MCT. That lipids may show such bioactive 
properties is a well-known phenomenon: immune-modulating effects have been 
demonstrated for lipid substances such as platelet-activating factor (PAF) and various 
leukotrienes. The activating effects of MCT, in sharp contrast with the lack of any 
effect of LCT, might be the consequence of the inability of LCT to activate PKC in 
intact cells. This might for instance be due to a decreased LCT uptake in the cell or in 
the cellular membrane, in which the structure of the lipids (carbonchain-length) plays 
a role. Another possibility is that, similar to the effect of PMA, PKC activation by
MCT increases the production of PAF, resulting in a subsequent rise in the
2+intracellular second messenger Ca . Experiments in which PAF production is 
measured, or experiments with the PAF-inhibiting substance WEB 2086 might well 
increase our understanding of the way in which lipid emulsions influence cellular 
signaling. Besides lipids, fat emulsions also contain other constituents that may 
influence the function of the immune system, such as the anti-oxidant tocopherol 
(Vitamine E). Tocopherol exists in several structurally and functionally different 
isoforms, which are known to influence the activity of PKC. We evaluated the 
content of several isoforms in a number of commercially available and structurally 
different emulsions and found that especially the content of the biologically most 
active a-isoform differs widely between emulsions (Chapter 14). Here, we also 
demonstrated that the immunological effects of LCT/MCT, as described in Chapter
5, are not influenced by the increased content of a-tocopherol and decreased content 
of lipid peroxidation products in an otherwise identical, new LCT/MCT formulation.
Summary o f  the results
The results of the investigations presented in this thesis indicate that the hypothesis 
that structurally different lipid emulsions distinctly modulate the function of the 
human immune system is correct. In this respect, the structure and especially the 
carbonchain-length of the lipid component of the emulsion appear to be pivotal. 
MCT-containing emulsions, in contrast with pure LCT or SL, activate neutrophils 
and modulate the function of mononuclear leukocytes. Also, various emulsions 
distinctly influence intracellular leukocyte signal transduction pathways. An 
alteration of membrane fluidity might be one of the mechanisms of the observed lipid 
effects. The question remains whether MCT-induced neutrophil activation has to be 
regarded as beneficial: continuous cell activation (i.e. activation by the ‘improper’ 
stimulus nutrition) eventually might cause depletion of cellular metabolite and/or 
energy stores resulting in decreased responses of immune competent cells. The latter 
is suggested by the decreased killing rates of the yeast pathogen Candida by 
neutrophils after exposure to MCT. It has also to be taken into consideration in this 
respect that the patient category that receives TPN already is immune compromised. 
Clinical studies remain necessary to test the implications of the findings described 
above. Also, the effects of a number of newly developed lipid emulsions remain to be 
characterized.
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Achtergrond
Voor een goed functioneren van het menselijk lichaam is, met name in geval van 
ziekte, een adequate toevoer van voedingsstoffen noodzakelijk. Illustratief hiervoor is 
de toegenomen gevoeligheid voor infecties bij ondervoede patiënten. Dit laatste is 
een gevolg van de afgenomen functie van het afweersysteem dat ons tegen de 
voortdurend dreigende invasie door schadelijke micro-organismen moet beschermen. 
Wanneer het niet mogelijk is om voldoende vocht en voeding via het 
maagdarmkanaal op te nemen, bijvoorbeeld na een darmoperatie, dan kunnen deze 
worden toegediend via de bloedbaan, met behulp van een infuus. Dit wordt Totale 
Parenterale Voeding (TPV) genoemd. In de kliniek wordt een groot aantal patiënten 
gedurende kortere of langere tijd (en soms levenslang) d.m.v. TPV gevoed.
Behalve voordelen heeft TPV echter ook nadelen: patiënten blijken in deze situatie 
namelijk ook vaker infecties te krijgen. Voor een deel komt dit omdat via de 
toegangsweg tot de bloedbaan micro-organismen binnendringen. Daarnaast zouden 
ook bepaalde componenten van de TPV de functie van het afweersysteem kunnen 
doen afnemen. De neutrofiele granulocyt, oftewel neutrofiel, is een belangrijke 
schakel in het afweersysteem. Het is een witte bloedcel (leukocyt) die 
binnendringende ziektekiemen kan opnemen en doden. Het feit dat patiënten die met 
TPV worden behandeld vaker een wondinfectie of een longontsteking ontwikkelen 
pleit ervoor dat met name de functie van dit celtype nadelig wordt beïnvloed.
Eerdere onderzoeken wijzen in de richting van vetten (lipiden), een van de 
componenten van TPV, als oorzaak voor een verminderde functie van het 
afweersysteem. Vetten, bestaande uit een molecule glycerol waaraan drie 
vetzuurmoleculen zijn verankerd, zijn onmisbaar in onze voeding als bron van 
brandstof (calorieën) en vetzuren. Vetzuren zijn een structureel onderdeel van 
celbestanddelen zoals membranen en hebben daarnaast regulerende effecten op de 
celstofwisseling. Om verteerbaar te zijn, worden vetten als een oplossing van 
minuscule vetbolletjes in water, een zogenaamde emulsie, toegediend. Er zijn een 
groot aantal vetten, die verschillen in koolstofketenlengte en het aantal dubbele 
bindingen van de betrokken vetzuren. Zo zijn er vetten die alleen vetzuren met een 
koolstofketen van meer dan 14 koolstof atomen bevatten, de zogenaamde lange-keten 
vetten (long-chain triglycerides of LCT’s). Daarnaast zijn er ook middellange-keten 
vetten (medium-chain triglycerides of MCT’s), met een ketenlengte van 6 tot 12 
koolstof atomen. Omdat MCT’s in zuivere vorm niet worden verdragen door de 
mens, maar deze wel het voordelen hebben van een snelle afbraak, worden ze in de 
klinische praktijk toegediend als een mengsel van 50% LCT en 50% MCT 
(LCT/MCT). Recent werd een derde type, synthetisch bereide, vetten aan het arsenaal 
toegevoegd. Hierbij worden aan een glycerol molecule, in willekeurige volgorde, 
zowel midden- als lange-keten vetzuren gekoppeld: dit zijn de zogenaamde 
‘structured lipids’ (SL). Verder worden op dit moment nieuwe emulsies op basis van 
olijfolie en visolie voor gebruik in TPV in de kliniek geïntroduceerd.
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Vraagstelling
De hypothese die in dit proefschrift wordt getoetst is: structureel verschillende 
vetten hebben een modulerend, d.w.z. een remmend dan wel stimulerend, effect op de 
functie van de cellen van het afweersysteem. Om deze hypothese te toetsen worden 
verschillende immunologisch relevante functies van de neutofiel bestudeerd.
Inleiding
Als eerste worden de functies van de neutrofiele granulocyt, in detail beschreven 
(Hoofdstuk 2). Tevens wordt een overzicht gegeven van wat er bekend is van de 
invloed van vetemulsies op de verschillende componenten van het afweersysteem 
(Hoofdstuk 3).
Studies kunnen zowel in vitro (door in een reageerbuis vetten en cellen samen te 
voegen) als in vivo (door vetten aan mensen toe te dienen) worden uitgevoerd. Omdat 
neutrofielen in de praktijk hun diverse functies pas uitvoeren nadat ze zijn 
geactiveerd, worden de effecten van vetten gemeten in aan- en afwezigheid van 
verschillende stimuli.
In vitro studies: incubatie van neutrofielen en vetemulsies in de reageerbuis
Vetemulsies lieten in ons onderzoek in vitro een uitgesproken effect zien op de 
productie van toxische zuurstofradicalen door neutrofielen. Zuurstofradicalen zijn 
essentieel voor het doden van microorganismen. LCT/MCT en MCT emulsies 
verschillen daarbij duidelijk van LCT en structured lipids (SL): in aanwezigheid van 
MCT bevattende emulsies werden bij een klinisch relevante vetconcentratie de 
neutrofielen geactiveerd door de vetemulsie, terwijl LCT geen effect hadden. Ook de 
radicaalproductie onder invloed van verschillende andere bekende stimuli van 
neutrofielen nam toe in aanwezigheid van MCT bevattende emulsies, terwijl LCT en 
SL geen effect toonden (Hoofdstuk 4).
Op het oppervlak van de neutrofiel zijn adhesiemoleculen aanwezig om het 
mogelijk te maken aan andere cellen te hechten, zoals bijvoorbeeld de bekleding van 
bloedvaten. Zo kan de neutrofiel de bloedbaan verlaten, bijvoorbeeld om een 
infectiehaard elders in het lichaam te bereiken. Ook ten aanzien hiervan lieten 
LCT/MCT en MCT emulsies, in tegenstelling tot LCT en SL, in ons onderzoek een 
duidelijk effect zien: de activiteit van adhesiemoleculen en de mate van adhesie nam 
onder invloed van deze emulsie toe, d.w.z. de cellen gingen ‘plakken’: een teken van 
activatie. Ook bleken de neutrofielen onder invloed van de MCT emulsies de inhoud 
van in de cel gelegen blaasjes met biologisch actieve stoffen (granula) uit te 
storten(degranulatie), een reactie die normaal gesproken alleen optreedt wanneer 
micro-organismen of dode cellen moeten worden opgeruimd (Hoofdstuk 5). 
Neutrofielen moeten zich om hun functie te kunnen vervullen
verplaatsen naar een ontstekingshaard toe. Dit gebeurt door zich tegen de 
concentratiegradiënt van stoffen in te bewegen die vrijkomen bij een ontsteking, de
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ontstekingsmediatoren. In aanwezigheid van MCT, en in geringe mate met SL, maar 
niet met LCT, blijkt het aantal migrerende cellen af te nemen: opnieuw een 
aanwijzing dat MCT emulsies neutrofielen activeren (Hoofdstuk 6). Neutrofielen 
schakelen ziekteverwekkende organismen uit door deze op te eten (fagocyteren) en te 
doden m.b.v. giftige stoffen (o.a. zuurstofradicalen). Een dergelijke ziekteverwekker 
is de gist Candida albicans. Uit ons onderzoek blijkt dat de capaciteit van 
neutrofielen om gistdeeltjes op te nemen niet wordt beïnvloed door vetemulsies, maar 
dat onder invloed van MCT, maar niet van LCT en SL, wel het vermogen om de gist 
te doden afneemt (Hoofdstuk 7). Behalve vetten bevatten vetemulsies een groot 
aantal andere stoffen zoals de emulgator, diverse anti-oxidanten en vrije vetzuren. 
Verzadigde vetten, d.w.z. vetten waarvan de vetzuren geen dubbele bindingen 
bevatten, worden traditioneel als biologisch inerte moleculen beschouwd die louter en 
alleen van belang zijn als bron van calorieën. Wij vonden dat verzadigde 
triglyceriden en vetzuren, afhankelijk van hun koolstofketenlengte, wel degelijk in 
staat zijn neutrofielen te activeren tot de productie van zuurstofradicalen (Hoofdstuk 
8).
In vivo studies: intraveneuze toediening van vetemulsies aan gezonde proefpersonen
In ons lichaam dragen behalve neutrofielen ook verschillende andere soorten witte 
bloedellen bij aan de functie van het afweersysteem. Daarnaast spelen bepaalde 
eiwitmoleculen (cytokinen) een belangrijke rol doordat ze als boodschappers tussen 
de verschillende componenten van het afweersysteem fungeren. Tenslotte zijn 
vetemulsies in het lichaam onderhevig aan afbraak door verschillende 
stofwisselingsprocessen. Om al deze redenen is het belangrijk de eventuele effecten 
van vetten niet alleen in de reageerbuis te bestuderen, maar ook na toediening van 
vetten aan proefpersonen, omdat hierbij de effecten op alle genoemde onderdelen van 
het immuunsysteem worden getest.
Infusie van een LCT/MCT emulsie leidde, in tegenstelling tot een zuivere LCT 
emulsie of fysiologisch zout, binnen enkele uren tot een toename van het aantal 
neutrofielen en een afname van het aantal mononucleaire cellen in de bloedbaan van 
gezonde proefpersonen (Hoofdstuk 9). Infusie van LCT/MCT leidde bij gezonde 
proefpersonen, in tegenstelling tot LCT, ook tot een verandering in de productie door 
mononucleaire cellen van signaaleiwitten (cytokinen, zoals diverse interleukines en y- 
interferon), en wel zodanig dat gesuggereerd wordt dat hierdoor de gevoeligheid voor 
gistinfecties zou kunnen toenemen. Bovendien laten cel vrije serummonsters van 
proefpersonen, afgenomen na infusie van LCT/MCT, in tegenstelling tot LCT en 
fysiologisch zout, een toename zien van de groei van de ziekteverwekkende gist 
Candida albicans (Hoofdstuk 10).
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Studies betreffende mogelijke mechanismen achter de effecten van vetemulsies
We hebben dus aangetoond dat lipiden zowel in de reageerbuis als in de bloedbaan 
effecten hebben op de functie van neutrofielen. De vraag kan dan worden gesteld hoe 
de lipiden deze effecten bewerkstelligen. De activatie van cellen vindt plaats op het 
celoppervlak, gevormd door de celmembraan, waarna de cel via een cascade van 
reacties geactiveerd wordt. Het zou mogelijk zijn dat lipiden een invloed hebben op 
de eigenschappen van de celmembraan en zo aanleiding geven tot de beschreven 
effecten. ‘Membraanvloeibaarheid’ is een complexe variabele waarmee de 
bewegingsvrijheid die moleculen hebben binnen een biologische membraan wordt 
aangegeven. Deze karakteristiek is van groot belang voor de functie van bijvoorbeeld 
de celmembraan. Ons onderzoek laat zien dat incubatie van neutrofielen in MCT 
bevattende emulsies en in geringere mate SL, maar niet met LCT, leidt tot een 
toename van de membraanvloeibaarheid (Hoofdstuk 11). Dit is een belangrijke 
waarneming omdat bekend is dat veranderingen in membraanvloeibaarheid 
aanleiding kunnen geven tot celactivatie en zo een verklaring zouden kunnen vormen 
voor het effect van MCT emulsies.
Om hun functie uit te oefenen moeten cellen een van buiten de cel binnenkomend 
signaal kunnen omzetten in een adequate intracellulaire respons. De verbinding 
tussen signaal en respons komt tot stand met behulp van boodschappermoleculen in 
de cel, zogenaamde ‘second messengers’, zoals geioniseerd calcium. Vetemulsies 
blijken afhankelijk van hun samenstelling een verschillende invloed te hebben op het 
vrijmaken in de cel van calcium en de activiteit van een regulerend enzym dat vele 
processen in de cel stuurt, het proteine kinase C (PKC) (Hoofdstuk 12). Ons 
onderzoek laat zien dat MCT bevattende emulsies neutrofielen gevoeliger maken 
voor activatie door gistdeeltjes en dat LCT, MCT en SL alle het calcium modulerend 
effect van een tweetal stimuli, te weten gistdeeltjes en een bacterieel peptide, op een 
aspecifieke manier remmen. Zeer recent zijn een aantal nieuwe vetemulsies 
ontwikkeld voor gebruik in TPV, op basis van olijfolie en visolie. Ons onderzoek laat 
zien dat LCT en de olijfolie emulsie de calciumrespons van neutrofielen na stimulatie 
door een bacterieel peptide bij een klinisch relevante vetconcentratie aanzienlijk 
minder remmen dan LCT/MCT en de visolie emulsie (Hoofdstuk 13).
De bevindingen in de hoofdstukken 12 en 13 leiden tot de vraag hoe de effecten 
van de diverse vetten op de signaaloverdracht resulteren in de beschreven effecten op 
de diverse functies van de neutrofiele granulocyt. Het feit dat MCT’s 
ongestimuleerde neutrofielen tot zuurstofradicaal produktie kunnen aanzetten, 
waarbij een PKC-afhankelijke activatie van het het NADPH-oxidase complex 
optreedt, evenals de toename van de expressie van adhesiemoleculen onder invloed 
van MCT-bevattende emulsies, duidt op PKC-activatie, oftewel een ‘PMA-achtig’ 
effect van MCT’s. Dat lipiden bio-actieve eigenschappen kunnen hebben is een 
bekend gegeven: immuun modulerende effecten zijn aangetoond voor lipiden zoals 
platelet-activating factor (PAF) en verschillende leukotrienen. Het activerende effect 
van MCT’s, in schril contrast met de afwezigheid van enig effect van LCT’s, zou het 
gevolg kunnen zijn van het feit dat LCT’s niet in staat is PKC te activeren in intacte
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cellen. Dit zou bijvoorbeeld het gevolg kunnen zijn van een afgenomen opname van 
LCT’s in de cel of in de celmembraan, waarbij de vetstructuur (en dan met name de 
koolstofketenlengte) een rol zou kunnen spelen. Een andere mogelijkheid is dat, 
vergelijkbaar met het effect van PMA, PKC activatie door MCT’s leidt tot een 
toegenomen productie van PAF, waardoor vervolgens de concentratie van geioniseerd 
calcium in de cel verhoogd wordt. Experimenten waarbij de PAF productie onder 
invloed van diverse vetten wordt gemeten, of experimenten waarbij een PAF-remmende 
stof zoals WEB 2086 wordt gebruikt, zouden zo onze kennis van de manier waarop 
vetten de signaal-overdracht in de cel beïnvloeden kunnen vergroten.
Behalve vetten zijn er in vetemulsies ook andere componenten aanwezig die de 
functie van het afweersysteem kunnen beïnvloeden. Dit betreft onder meer anti- 
oxidantia zoals tocopherol (Vitamine E). Van tocopherol, waarvan bekend is dat het de 
functie van PKC beïnvloedt, zijn een aantal structureel verschillende varianten 
(isovormen) bekend. Wij hebben het gehalte van deze vitamine E varianten in 
commercieel verkrijgbare vetemulsies in kaart gebracht (Hoofdstuk 14). Tevens laten 
we in dit hoofdstuk zien dat de beschreven immunologische effecten van LCT/MCT niet 
beinvloed worden door een verhoogd gehalte van de biologisch meest actieve tocopherol 
isovorm, het a-tocopherol, in een nieuw soort LCT/MCT emulsie.
Samenvatting van de resultaten
De resultaten van ons onderzoek tonen aan dat de hypothese dat structureel 
verschillende vetemulsies de functie van het afweersysteem op een verschillende wijze 
beïnvloeden juist is. De samenstelling van de vetcomponent van de emulsie lijkt daarbij, 
afhankelijk van de koolstofketenlengte van het betrokken vet, de beslissende factor: 
MCT bevattende emulsies laten, in tegenstelling tot zuivere LCT’s en SL, een duidelijk 
activerend effect op de neutrofiele granulocyt zien en hebben eveneens een modulerend 
effect op de functie van mononucleaire leukocyten. Dit kan onder ander worden 
verklaard door de observatie dat de diverse emulsies de signaaloverdracht in de cel op 
verschillende wijzen beïnvloeden. Een mechanisme achter de effecten van vetten zou 
een verandering van de membraanvloeibaarheid van immuun competente cellen kunnen 
zijn. Het is maar zeer de vraag of de blijkbaar door MCT’s veroorzaakte activatie van 
neutrofielen als een positief gegeven moet worden beschouwd: continue activatie van 
cellen (d.w.z. activatie door de prikkel 'voeding', die eigenlijk niet tot activatie zou 
moeten leiden) zou door uitputting van metabolieten en/of energievoorraden in de cel 
kunnen leiden tot een afgenomen respons op het moment dat de cellen wel in actie 
moeten komen. Vooral de afname in de capaciteit van neutrofielen om Candidacellen te 
doden na blootstelling aan MCT’s wijst in deze richting. Daarbij moet bovendien 
bedacht worden dat de patiëntencategorie die in aanmerking komt voor TPV over het 
algemeen al een verminderde functie van het afweersysteem heeft als gevolg van de 
onderliggende ziekte.
Aanvullende klinische studies zijn noodzakelijk om de bovenstaande bevindingen 
in de klinische praktijk te toetsen. Verder moeten ook de effecten van een aantal 
recentelijk ontwikkelde vetemulsies verder in kaart worden gebracht.
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Dankwoord
De titelpagina van een proefschrift is natuurlijk bedoeld om na te gaan of het de 
moeite waard is om het boekje open te slaan, maar vooral toch ook om het ego van de 
promovendus (De Auteur) te strelen. Pas in de sectie ‘Dankwoord’ valt hij of zij door 
de mand en blijkt de klus geklaard te zijn met hulp van een groot aantal personen. Zo 
ook nu.
Eind 1996, kort na mijn komst naar Nijmegen voor het academische deel van mijn 
opleiding tot internist, vond ik een briefje in mijn postvak.
“H ebje interesse in voedingsonderzoek, kom dan eenspraten”
Ton Naber, MDL
Kort tevoren was ik begonnen om een infectiologisch onderzoek bij dialyse patienten 
van de grond te krijgen. Helaas bleek het achterliggende idee minder uniek dan 
gehoopt en door anderen al te zijn uitgewerkt in een -in  uitvoering zijnde- Europese 
multi-center trial. Alhoewel ik geen bijzondere associaties had met voeding ben ik 
daarom maar eens gaan praten met dokter Naber. Voor U ligt het gevolg van dit 
gesprek.
Beste Ton, met de affiniteit met voeding -en dan vooral met de vetten daarin- is het 
de afgelopen jaren wel goed gekomen. Ik kijk vooral door jouw inbreng terug op een 
plezierige en vruchtbare Willie Wortelperiode op het lab, waarbij ik kon 
voortborduren op hetgeen Joanna Kruimel al aan dit onderzoek had gedaan. Dank 
vooral voor de vrijheid van handelen die ik kreeg en voor het feit dat je me op een 
onderbezette afdeling uit de klauwen van de kliniek hield, voor zover ik dat zelf 
wilde. Ik hou er ernstig rekening mee dat we de komende tijd een mooi vervolg aan 
dit project kunnen geven.
Prof. Dr. Jan Jansen, jou dank ik onder andere voor de mogelijkheid op de afdeling 
Maag-, Darm- en Leverziekten dit onderzoek te kunnen doen, voor je collegialiteit en 
je humor.
Prof. Dr. Dirk Roos (CLB, Amsterdam, een kei in ‘streepjes’) en Dr. Peter Willems 
(Biochemie, een kei in calcium) noem ik in een adem omdat ze een vergelijkbare, 
cruciale rol hebben gespeeld in dit project. Jullie beiden waren voor mij van 
onschatbare waarde, zowel op praktisch als theoretisch gebied en daarnaast altijd 
bereikbaar voor overleg en kritische correcties. Ook Dr. Anton Tool (CLB, 
Amsterdam), Sjenet van Emst (Biochemie), Dr. Theo Geijtenbeek (Tumor­
Immunologie), Dr. Reinier Raymakers (Haematologie), Dr. Peter van Lent
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(Rheumatologie), Janet Beunk en Dr. Dorien Swinkels (Klinische Chemie) bedank ik 
hierbij.
Het in vivo onderzoek werd in samenwerking verricht met de afdeling Interne 
Geneeskunde. Met name wil ik hierbij Dr. Mihai Netea, Liesbeth Jacobs, Trees 
Verver, Dr. Bart-Jan Kullberg, Dr. Berry van Tits, Magda Hectors en Dr. Pierre 
Demacker bedanken voor hun bijdrage op meerdere vlakken. Marij Hendriks en Arie 
Pennnings (Haematologie) hielpen mij op weg op de flowcytometer. Wilma Kraak en 
Dr. Jo Curfs (Medische Microbiologie) leverden een bijdrage aan de Candida­
experimenten.
Beste medewerkers van het lab en de kliniek. Jullie vormden voor mij in deze periode 
de habitat waarbinnen ik mijn niche vond. Mijn interesse als bioloog in het gedrag 
van al wat groeit en bloeit werd vooral gevoed tijdens de observatie van de tussen-de- 
middag-even-rikken-sessies. In niet geheel willekeurige volgorde bedank ik Wilbert 
Peters (‘als het zo moet gaan’), Annie van Schaik (‘toedeledokie, met 
ooievaarskuitenvet sluiten die doppen wel’), Hennie Roelofs (‘de mu, de pi en de 
theta doen het weer !!’), PCRené te Morsche, Albert Tangerman (‘hufters aller 
tijden’), Wim Hopman (‘wat was er ook alweer troef?’), Maarten Raaijmakers en 
Claudia van de Braak voor hulp en humor. Daarbij zij aangetekend dat deze populatie 
(vaak op vrijwillige basis), naast enkele professionele proefpersonen, in de meeste 
gevallen ook de leverancier van de neutrofielen was, waarvoor dank.
Als student-stagiaires hebben Frank Jansen, Heidi Fransen, Angelique Rops, Suzanne 
Heemskerk, Anneke Kusters, Marja Molag en Lydia Schipper hun bijdrage geleverd. 
Alhoewel de eerste stappen op een lab lang niet altijd de eenvoudigste zijn hoop ik 
dat ook jullie onze samenwerking als plezierig hebben ervaren.
Lieve mam, pap en Thea. Ik heb dit werk alleen maar kunnen doen door de 
mogelijkheden die jullie me hebben geboden en ik ben er trots op dat jullie deze 
gebeurtenis mee kunnen maken.
En dan ben ik nu aangekomen op de plaats waar normaal gesproken ontboezemingen 
volgen over doorwaakte nachten, verwaarloosde partners en verweesde kinderen. 
Echter, niets van dit alles (mede dank zij de hulp van de eerder genoemde personen) . 
En daarom, lest best, lieve Yvonne. We hebben elkaar pas leren kennen, ieder met 
een rugzak aan ervaringen, toen dit onderzoek al voor een deel verricht was. En 
alhoewel het leven van een gastroenteroloog met een chirurg de nodige haken en 
knopen kent heb ik er het volste vertrouwen in dat we samen van de komende periode 
met grote veranderingen iets heel moois zullen maken.
Geert.
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Curriculum vitae
Geert Wanten werd op 25 januari 1962 te Tegelen geboren. Na de middelbare school 
(Gymnasium-P, Bisschoppelijk College te Roermond) studeerde hij vanaf 1980 
Biologie aan de Katholieke Universiteit Nijmegen (kandidaatsexamen B1 geologie 
1983). In 1987 studeerde hij af met als bijvakken Algemene Botanie en Keel-neus- 
oorheelkunde en als hoofdvak Microbiologie. Tevens studeerde hij vanaf 1983 aan 
deze universiteit Geneeskunde (doctoraalexamen 1988). In 1991 werd het artsexamen 
behaald, waarna hij als arts-assistent niet in opleiding (AGNIO) op de afdeling 
Medische Oncologie van het Academisch Ziekenhuis Nijmegen werkte (hoofd: 
Prof.Dr.Th.Wagener). Nadien was hij als AGNIO werkzaam op de afdeling Interne 
Geneeskunde van het Bosch Medicentrum, alwaar tussen 1993 en 1996 een begin 
werd gemaakt met de opleiding tot internist (Opleider: Dr. J.Th.M. Burghouts). Na 
voortzetting in het Academisch Ziekenhuis Nijmegen (Opleider: Prof.Dr. J.W.M. van 
der Meer) werd deze opleiding in 1997 onderbroken om op de afdeling Maag-, Darm­
en Leverziekten (Hoofd: Prof.dr. J.B.M.J. Jansen), met behulp van een subsidie van 
de Nederlandse Organisatie voor Wetenschappelijk Onderzoek, het onderzoek te 
verrichten dat resulteerde in dit proefschrift. Sinds 1 oktober 2000 is hij geregistreerd 
als internist en in opleiding tot gastro-enteroloog. Hij is nog steeds niet getrouwd met 
Yvonne Paquay. Samen hebben ze twee katten, Ronnie (± 9) en Mimi (± 7).
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Abbreviatons
Abbreviations
AA: arachidonic acid
ADCC: antibody-dependent cellular cytotoxicity 
BCECF: bis-carboxyethyl-carboxyfluorescein
BCECF-AM: bis-carboxyethyl-carboxyfluorescein pentaacetoxymethylester
DAG: diacylglycerol
DHA: docosahexaenoic acid
DPH: diphenyl-hexatriene
DTH: delayed-type hypersensitivity
EFA: essential fatty acid
EPA: eicosapentaenoic acid
FA : fatty acid
fMLP: N-formyl methionyl-leucyl-phenylalanine
GEF: guanine-nucleotide-exchange factor
HBSS: Hank's balanced salt solution
InsP3: inositol (1,4,5)-trisphosphate
ITAM: immunoreceptor tyrosine-based activation m otif
LAK cells: lymphokine-activated killer cells
LCT: long-chain triglyceride
LCFA: long-chain fatty acid
LP: lymphocyte proliferation
MCT: medium-chain triglyceride
MCFA: medium-chain fatty acid
MP: macrophage
MPS: mononuclear phagocyte system
NK cells: natural killer cells
NOS: nitric oxide synthase
PBMC: peripheral blood mononuclear cell
PBS: phosphate-buffered saline
PDK: 3'OH-phosphoinositide-dependent kinase 1
PI 3-K: phosphoinositide 3-kinase
PKB/C: protein kinase B/C
PLC: phospholipase C
PMA: phorbol 12-myristate 13-acetate
PtdInsP2: phosphatidylinositol (4,5)-bisphosphate
PtdInsP3: phosphatidylinositol (1,4,5)-trisphosphate
PTK: protein tyrosine kinase
PUFA: polyunsaturated fatty acid
RES: reticulo-endothelial system
SH2: src-homology 2
SL: structured lipids
STZ: serum-treated zymosan
Th: T helper cell
Ts: T suppressor cell
TMA-DPH: trimethylammonium-diphenyl-hexatriene 
TPN: total parenteral nutrition
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Stellingen
behorend bij het proefschrift
Immune modulation by nutritional lipid emulsions:
with emphasis on human neutrophil function
Geert Wanten, oktober 2002
1. ‘Het’ effect van vetten op het afweersysteem bestaat niet.
- Dit proefschrift -
2. Parenterale vetemulsies moduleren verschillende functionele aspecten van 
het afweersysteem afhankelijk van de chemische structuur van de 
aanwezige lipiden.
- Dit proefschrift -
3. Immuunmodulatie door vetemulsies treedt zowel in vitro (in de 
reageerbuis) als in vivo (na toediening van vetten via een infuus) op.
- Dit proefschrift -
4. MCT’s (medium-chain triglycerides) hebben, in tegenstelling tot LCT’s 
(long-chain triglycerides), een activerend effect op de neutrofiele 
granulocyt.
- Dit proefschrift -
5. De verschillen in effect op het afweersysteem tussen vetemulsies kunnen 
niet verklaard worden door verschillen in vitamine-E gehalte.
- Dit proefschrift -
6. Een direct effect van vetten op de signaal-transductie in 
immuuncompetente cellen zou kunnen resulteren in de beschreven 
immuunmodulerende effecten van de diverse emulsies.
- Dit proefschrift -
7. Gebruik van een verkeerde lipidenemulsie kan leiden tot vette pech.
8. Twee dokters op een kussen, daar ligt een telefoon tussen.
9. Zowel melkzuurmoleculen als politici kennen links- en rechtsdraaiende 
varianten.
